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Abstract 
BACKGROUND:  Breast cancer patients typically present with unhealthy body composition 
(high fat mass and low muscularity) near diagnosis.  These body composition characteristics 
often worsen during treatment and ultimately contribute to the development of secondary 
diseases like diabetes and cardiovascular disease in survivorship.  Inflammation in overweight 
or obese individuals is associated with impaired glucose metabolism; the presence of the 
tumour may lead to greater impairments in glucose metabolism in breast cancer patients.  
OBJECTIVES AND HYPOTHESES:  The objectives of this study were to: 1) evaluate breast 
cancer patients near the onset of treatment for metabolic measures including an oral glucose 
tolerance test (OGTT), cytokine profiles, as well as body composition, nutritional status and 
fitness and, 2) make comparisons between breast cancer patients, age- and BMI-matched 
females (HM females), and a group of young, non-malignant females with healthy BMIs (HY 
females) on these measures.  We hypothesized that breast cancer patients would demonstrate 
impaired glucose metabolism relative to HM females, and that this would be attributed to 
systemic inflammation.  We also hypothesized that both breast cancer patients and HM females 
would present with unhealthy body composition, impaired glucose and lipid metabolism, 
systemic inflammation, poor fitness and greater caloric intake compared to HY females.   
METHODS:  We evaluated body composition using % body fat (skinfold callipers) and waist 
circumference.  Following collection of fasting blood samples, an OGTT was conducted to 
assess glucose, insulin, c-peptide and glucagon dynamics.  Fasting blood samples were 
analysed for lipids and pro- and anti-inflammatory cytokines.  Incremental exercise tests were 
conducted to assess VO2peak, and estimated 1-RM tests assessed strength of the biceps, triceps 
and quadriceps muscles.  Baecke and CHAMPS questionnaires provided an indication of 
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habitual physical activity.  A 3-day food record was used to analyze daily caloric intake and 
macronutrient distribution.  Breast cancer patients and HM females were compared using 
paired t-tests. Patients and HM females were compared to HY females using t-tests.  Statistical 
significance was accepted at p < 0.05.   
RESULTS:  Overall, breast cancer patients were overweight (BMI: 28.8 ± 6.0 kg/m2) and 
presented with abdominal obesity (waist circumference: 94.6 ± 14.0 cm) and dyslipidemia 
(TAG: 1.84 ± 1.17 mM and HDL-c: 1.08 ± 0.23 mM), indicating risk for metabolic syndrome.  
Although fasting glucose concentrations did not differ between the 3 groups, breast cancer 
patients demonstrated higher glucose concentrations at 30 min during an OGTT.  Similar to 
glucose, fasting insulin concentrations did not differ between the 3 groups, but patients 
demonstrated higher insulin at 150 min during an OGTT.  Breast cancer patients had elevated 
fasting serum c-peptide (2.6 ± 1.2 ng/mL vs. 1.9 ± 0.8 ng/mL, p = 0.005).  C-peptide remained 
elevated in patients compared to non-malignant females during the last hour of the OGTT, 
indicating that insulin secretion was sustained in breast cancer patients.  We observed no 
difference in serum cytokines between patients and HM females or between patients and HY 
females.  VO2peak, although lower compared to HY females, was similar in patients and HM 
females.  There were no differences in habitual physical activity or nutrition measures between 
any groups.   
DISCUSSION AND CONCLUSIONS:  Breast cancer patients presented with poorer glucose 
features during an OGTT compared to HM and HY females.  However, systemic 
inflammation, body composition, energy expenditure and energy intake were similar in breast 
cancer patients and HM females.  Thus, these impairments may be tumour-related.  Future 
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1.0  Overview  
Although breast cancer is the most commonly diagnosed form of cancer in females, 
patients have an 89% chance of achieving 5-year survival (Canadian Cancer Society 2011).  
These statistics are encouraging, however once patients enter into survivorship (here defined as 
the time post-treatment (Feuerstein 2007)), they are prone to developing secondary conditions 
such as diabetes, cardiovascular disease and even cancer recurrence.  High fat mass, and 
perhaps low lean tissue, is associated with the development of breast cancer (Freedman 2004; 
Demark-Wahnefried et al. 2001; Rock and Demark-Wahnefried 2002).  As breast cancer 
patients progress through treatment, and later as they enter into survivorship, they tend to 
experience further fat gains and lean tissue losses.   
In non-malignant populations, obesity and sarcopenia (the term used to describe 
individuals with lower than normal muscularity) have been shown to contribute to the 
development of diabetes, cardiovascular disease and other metabolic complications (Choi 
2010; Lee 2011).  In breast cancer patients, obesity and sarcopenia at diagnosis, followed by 
fat gains and lean tissue losses during treatment and in survivorship, may have the same or 
exacerbated negative metabolic implications compared to non-malignant populations.  Thus, it 
is important to understand the consequences of unhealthy body composition in breast cancer 
patients near the onset of treatment to develop future interventions that might attenuate the 
deleterious changes that occur during the disease trajectory and in survivorship. 
In non-malignant populations, high fat mass and low lean tissue are associated with 
various metabolic complications including inflammation, glucose intolerance and dyslipidemia 
(Medalie et al. 1975).  Increased serum concentrations of pro-inflammatory cytokines (i.e. 
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interleukin 6 (IL-6) and tumour necrosis factor-alpha (TNF-α)) (Park 2005) and decreased 
serum concentrations of anti-inflammatory cytokines (Matsubara 2002) accompany increases 
in fat mass and decreases in lean tissue mass.  The increased concentrations of IL-6 and TNF-α 
that accompany high fat mass activate signal transduction pathways that may reduce insulin 
sensitivity and increase lipolysis (Plomgaard et al. 2005; Uysal et al. 1997; Kim et al. 2004).  
The resulting impairment in glucose metabolism and dyslipidemia have been shown in some 
cases to lead to an increased risk of developing serious metabolic diseases such as diabetes and 
cardiovascular disease in obese, non-malignant populations (Medalie et al. 1975).  In obese, 
non-malignant populations, unhealthy body composition profiles (i.e. high fat mass and low 
levels of lean tissue) can be explained by energy imbalance.  When energy expenditure is 
reduced (i.e. sedentarism (Weiss et al. 2006)) and energy intake increased (i.e. increased 
caloric intake (Racette et al. 2006)), the excess energy is stored as fat in adipose tissue, skeletal 
muscle and liver.  Fat deposition may result in dysregulation of glucose and lipid metabolism 
in these tissues (Kelley et al. 2003; Kern et al. 2001; Corcoran et al. 2007). 	  
Despite that high fat mass and low lean tissue have been characterized in breast cancer 
patients at different stages of the disease trajectory (Amaral et al. 2010; Demark-Wahnefried et 
al. 1997; Irwin et al. 2005), this unhealthy body composition profile may not necessarily lead 
to the same metabolic consequences as observed in non-malignant populations.  Due to their 
underlying disease state, breast cancer patients may experience a greater degree of 
inflammation (Dehqanzada et al. 2007; Muraro et al. 2011).  The combined effects of 
inflammation due to the tumour and high fat mass may result in a greater predisposition for the 
development of insulin resistance and dyslipidemia (Figure 1). 
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This thesis examines the body composition, metabolic characteristics, exercise and 
nutrition of a group of breast cancer patients at the onset of treatment.  It is important to 
evaluate the patients before or at the early stages of chemotherapy, which can alter fat mass 
and inflammation (Demark-Wahnefried et al. 2001; Mills et al. 2005).  We expected that 
patients would present with greater inflammation than can be explained due to their high fat 
mass.  Inflammation would be associated with worse glucose and lipid metabolism compared 
to age and BMI-matched, non-malignant controls.  Based on these concepts and results, this 
thesis provides a framework to design future exercise and nutrition interventions that will aim 










Figure 1 Obesity and the tumour may increase systemic inflammation in breast cancer 
patients.  A model indicating the potential role of inflammation to the development of 
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2.0  Unhealthy body composition develops during treatment and in survivorship for 
breast cancer patients 
Unlike other forms of cancer that are associated with pronounced weight loss (Di 
Sebastiano et al. 2012; Murphy et al. 2010), breast cancer is associated with weight gain over 
the disease trajectory and in survivorship (Goodwin et al. 1988; Goodwin et al. 1999).  At 
diagnosis, patients tend to be overweight or obese with a large waist circumference and a high 
percentage body fat.  Yaw et al. (2010) observed that at the time of diagnosis 42.4% of breast 
cancer patients were overweight or obese.  In a large proportion of studies, newly diagnosed 
breast cancer patients are, on average, overweight or obese (Healy et al. 2010; Goodwin et al. 
2009; Yaw et al. 2010) with BMI’s reaching as high as 54.8 kg/m2 (Goodwin et al. 2009).  
Interestingly, based on waist circumference, patients are also centrally obese (Healy et al. 
2010; Goodwin et al. 2009) with values as high as 123.5 cm.  Amaral et al. (2010) further 
investigated the tendency towards abdominal adiposity in breast cancer by comparing patients’ 
waist circumferences to the International Diabetes Federation (IDF) cut-point for metabolic 
syndrome (a waist circumference > 88 cm (Alberti et al. 2006)).  Metabolic syndrome is a set 
of risk factors that increase an individual’s risk of developing cardiovascular disease and type 
II diabetes (Alberti et al. 2006).  Amaral et al. (2010) observed that 62% of patients in their 
study had a waist circumference > 88 cm, and thus were at a higher risk of developing 
metabolic syndrome (Amaral et al. 2010).  Furthermore, 89% of patients had a percentage body 
fat > 30%.  
 Unhealthy body composition profiles persist over the course of treatment for breast 
cancer (Prado et al. 2009; Van Londen et al. 2011), indicating the importance of potential 
interventions during treatment to attenuate these negative changes in body composition.  In 
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addition to being characterized as overweight or obese during treatment, patients actually 
experience significant weight gain during this time.  Demark-Wahnefried et al. (1993 and 
1997) estimated that 50-96% of patients gained 2.5-6.2 kg over the course of treatment and 
Lankester et al. (2002) reported that 64% of patients experienced gains of at least 2 kg during 6 
cycles of chemotherapy.  It is noteworthy that the pattern of weight gain over the course of 
treatment for breast cancer is not the same as the pattern of weight gain in non-malignant 
females.  Fat gains in non-malignant females are generally accompanied by gains in lean 
tissue, provided the individual is mobile (Forbes et al. 1986; Forbes 1987).  Weight gain in 
breast cancer, on the other hand, is generally restricted to fat mass (Harvie et al. 2004; Demark-
Wahnefried et al. 2001).  In fact, patients may even lose lean tissue mass over the course of 
treatment.  Dual energy x-ray absorptiometry (DXA) demonstrated that patients gained fat and 
lost muscle during a treatment regimen of 12 weeks of chemotherapy and radiation treatments 
in one study (Kutynec et al. 1999) and after a 6 month regimen of chemotherapy in another 
study (Cheney and Mahloch 1997).  Prado et al. (2009) used computed tomography (CT) 
images to quantify muscle mass in patients undergoing treatment.  They determined that 25.5% 
of patients were sarcopenic, with an average lean tissue mass of 34 ± 3.3 kg (average age of the 
patients was 54.8 ± 10.4 years) (Prado et al. 2009).  As a comparison, a healthy lean tissue 
mass for females aged 50-59 years is 40.3 ± 4.0 kg (Tankó et al. 2002).  Interestingly, loss of 
lean tissue is most pronounced in the lower limbs (Cheney and Mahloch 1997).  This finding 
might suggest that breast cancer patients are performing less weight-bearing exercise and 
possibly becoming more inactive over treatment.  
In survivorship, patients continue to gain weight. Irwin et al. (2005) observed that 68% 
of breast cancer survivors gained an average of 3.8 kg in the 3 years after completing 
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treatment, while Demark-Wahnefried et al. (2001) noted that breast cancer survivors gained an 
average of 2.1 kg in the 12 months after completing treatment.  Weight gain in survivorship 
follows a pattern similar to weight gain during treatment: fat gain is accompanied by lean 
tissue loss.  Demark-Wahnefried et al. (2001) demonstrated, using DXA, that patients gained 
fat mass (from 24.0 ± 1.6 kg to 26.3 ± 1.8 kg, p=0.04) and lost lean mass (from 45.4 ± 0.8 kg 
to 45.0 ± 0.8 kg, p=0.02) from the time they finished treatment to 12 months post-treatment.  
Not only is weight gain in survivorship significant, it is also progressive.  When Makari-Judson 
et al. (2007) examined breast cancer survivors 1, 2 and 3 years post-treatment, they discovered 
that survivors gained 1.5 kg after 1 year, 2.7 kg after 2 years and 2.8 kg after 3 years.  
It is clear that high fat mass and low lean tissue are associated with breast cancer at 
multiple points over the disease trajectory.  This pattern of unhealthy body composition has 
negative metabolic implications in non-malignant populations, notably decreased insulin 
sensitivity and increased chronic inflammation (Goodpaster et al. 2005; Shoelson et al. 2007).  
Adipose tissue is not an inert storage depot, as it was previously thought to be.  Rather, it is an 
active endocrine organ.  When fat mass is high, there is an increase in secretion of pro-
inflammatory cytokines into circulation (Mohamed-Ali et al. 1997; Fried et al. 1998), which 
may lead to impaired glucose tolerance and dyslipidemia (Wisse 2004).  
It is possible that high fat mass has similar, if not more detrimental, metabolic 
consequences in breast cancer patients.  Breast cancer patients have increased concentrations of 
circulating pro-inflammatory cytokines (Dehqanzada et al. 2007; Lyon et al. 2008), which have 
been shown to negatively alter aspects of glucose and lipid metabolism (Figure 1).  A better 
understanding of unhealthy body composition and the associated metabolic perturbations at the 
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onset of treatment will advance our understanding of the underlying higher risk for secondary 
metabolic diseases in breast cancer survivorship.  
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3.0  High fat mass can develop from an imbalance of energy intake and energy 
expenditure in non-malignant populations  
3.1 Reduced energy expenditure 
Sedentarism, or low physical activity, reduces energy expenditure and is associated 
with increased risk of obesity (Hill and Peters 1998; Prentice and Jebbs 1995).  The Centers for 
Disease Control and Prevention (1996) determined, from a sample of 25 164 overweight 
females, that 41% of overweight American females reported engaging in no physical activity 
during their leisure time.  Further, the percentage of females not partaking in physical activity 
increased along with their degree of overweight.  Body mass index (BMI), an indicator of 
obesity, was significantly and inversely correlated with physical activity, as measured in 
metabolic equivalent (MET) hours (MET-hr and BMI: r = -0.11, p < 0.05; MET-hr) (Fung et 
al. 2000).  In a study of American indigenous peoples it was observed that Pima Indians who 
expend significantly more energy per day (3156 ± 415 kcal/day versus 2805 ± 415 kcal/day, 
p<0.04) have a lower percentage body fat compared to Pima Indians whose energy expenditure 
is reduced (29 ± 10% versus 41 ± 10%, p<0.0001) (Esparza et al. 2000).  
 These correlations between obesity and energy expenditure are supported by detraining 
studies.  One such study, conducted by Liu et al. (2008), examined the effect of 1 month of 
detraining on elite level kayakers.  Prior to initiation of the study, participants trained 18 hours 
per week.  Their average maximal oxygen uptake (VO2max) and BMI were 58.5 ± 1.77 
mL/kg/min and 23.74 ± 0.54 kg/m2, respectively.  For 1 month, half of the kayakers (n=8) 
ceased all training; the remaining half of the kayakers (n=8) reduced their training volume by 
50%.  At the end of 1 month, waist circumference had significantly increased in both groups 
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(Liu et al. 2008).  Liu et al. (2008) did not assess or control for caloric intake, which may also 
have contributed to the observed increases in waist circumference.  
  
3.2 Increased energy intake 
Overnutrition, or excess caloric intake, contributes to the development of obesity.  
Energy intake has traditionally been difficult to assess: food records, food frequency 
questionnaires and 24-hour diet recalls are commonly used but often provide underestimates of 
daily caloric intake (Trabulsi and Schoeller 2001).  The doubly labelled water technique 
provides perhaps the most accurate assessment of energy expenditure: by measuring the 
clearance rates of water labeled with stable isotopes 2H and 18O over several days, total energy 
expenditure is calculated.  In a weight stable individual, energy expenditure is equal to habitual 
caloric intake.  Using this principle, doubly labelled water can provide an estimate of caloric 
intake.  Park et al. (2011) used doubly labelled water to assess caloric intake in Japanese 
females across a spectrum of BMI’s.  They determined that females with higher BMI’s had 
significantly higher caloric intakes compared to females with lower BMI’s.  Participants with 
BMI’s between 24.7 – 40.0 kg/m2 consumed on average 2373 ± 363 kcal/day.  Their energy 
intake was significantly higher than participants with BMI’s between 20.5 – 22.1 kg/m2 (2038 
± 210 kcal/day, p < 0.01) and participants with BMI’s between 22.3 – 24.7 kg/m2 (2229 ± 297 
kcal/day, p < 0.05) (Park et al. 2011).  No difference in physical activity levels, measured using 
hip-mounted accelerometers, was observed between groups of females.  Other researchers have 
used doubly labelled water to estimate energy intake in females with BMI’s greater than 30 
kg/m2: females with BMI’s of 32.9 ± 4.6 kg/m2 consumed an average of 2445 ± 108 kcal/day 
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(Prentice et al. 1986), and females with BMI’s of 37.4 ± 8.1 kg/m2 consumed an average of 
3708 ± 367 kcal/day (Platte et al. 1995).  Participants in the latter study were selected only if 
they reported engaging in < 5 hours of physical activity per week.  
 High amounts of dietary fat may also contribute to the development of obesity.  Using 3 
and 7 day food records, both Miller et al. (1990) and Tucker and Kano (1992) found that obese 
females consume a significantly higher proportion of dietary fat versus lean females (Miller: 
36.3 ± 1.5% for obese and 28.6 ± 1.5% for lean, p<0.05; Tucker and Kano: 42.58 ± 10.7% for 
obese and 37.64 ± 8.1% for lean, p<0.05).  Although these findings support high fat diets being 
associated with obesity, given the challenges of recording dietary intake, they should be 
interpreted with caution.  
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4.0  Metabolic perturbations like glucose and lipid dysregulation develop as a result of 
unhealthy body composition in non-malignant populations 
Glucose metabolism is a tightly controlled process in the healthy individual.  In a fasted 
state or between meals, the liver releases glucose for use by other tissues (Stumvoll et al. 1998) 
and insulin secretion from the beta cells of the pancreas slows.  As well, lipolysis occurs in the 
adipose tissue to provide non-esterified fatty acids (NEFAs) as an alternative fuel source to 
glucose (Jensen et al. 1987).  When a meal is ingested, exogenous glucose enters the 
bloodstream, triggering increased secretion of insulin.  Insulin suppresses glucose release from 
the liver and lipolysis in the adipose tissue (Korenblat et al. 2008).  Insulin also facilitates 
glucose uptake in skeletal muscle (Korenblat et al. 2008): insulin binds to receptors on the 
sarcolemma and initiates an intracellular signalling cascade that results in the translocation of 
additional glucose transporter type 4 (GLUT4) transporters to the cell surface (Czech 1995).  
This process allows more glucose molecules to enter the muscle cell and become metabolized 
to fuel cellular functions.  In an obese individual, high fat mass can disrupt this process and 
contribute to glucose intolerance and dyslipidemia in the following ways: 1) fat storage in 
tissues other than adipose tissue (like liver and skeletal muscle) (Goodpaster et al. 2005); 2) 
increasing lipolysis (Björntorp et al. 1969); and 3) decreasing glucose uptake by skeletal 
muscle (Bonen 2004).   
 
4.1 Fat Storage in liver and skeletal muscle 
Fat mass can contribute to metabolic dysregulation, particularly when it accumulates in 
visceral or ectopic depots.  Body fat can be stored subcutaneously (beneath the skin), viscerally 
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(around the tissues of the abdomen, deep to the abdominal and paraspinal muscles) or 
ectopically (within and around organs not designed to harbour fat, like the liver, skeletal 
muscle, heart and blood vessels) (Goodpaster et al. 2005).  Subcutaneous fat storage, 
particularly in the gluteal region is preferred to visceral or ectopic storage (Osama et al. 2006).  
Visceral adiposity is more strongly correlated with an increased risk of diabetes (Kapoor et al. 
2007; Lebovitz and Banerji 2005), although the physiological mechanisms behind this 
correlation are unclear.  It is possible that since visceral adipose tissue has direct access to 
portal circulation, the NEFAs and pro-inflammatory cytokines produced by visceral adipose 
tissue may be removed by and accumulate in the liver (Shoelson 2007).  Accumulation of 
NEFAs and pro-inflammatory cytokines in hepatocytes increases liver inflammation and 
stimulates hepatic insulin resistance (Shoelson 2007).  
Ectopic fat storage is positively associated with the incidence of cardiovascular disease: 
when excess fat accumulates around the heart and blood vessels, it impairs organ function, 
leading to vascular stiffness and hypertension (Montani et al. 2004).  As well, intrahepatic fat 
and intramuscular fat are both associated with insulin resistance, a characteristic that 
predisposes one to diabetes: high intrahepatic fat content impairs insulin’s ability to suppress 
glucose release from the liver (Samuel et al. 2004) and intramuscular fat impairs insulin’s 
ability to stimulate glucose uptake in skeletal muscle (Perseghin et al. 1999).   
 
4.2 Increased lipolysis 
High fat mass can also influence metabolic dysregulation by increasing lipolysis 
(Jensen et al. 1989; Björntorp et al. 1969).  Fat mass has a strong positive correlation with 
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lipolytic rates, meaning that circulating NEFA concentrations are elevated in obese compared 
to lean individuals (Horowitz et al. 1999; Gordon 1960).  Obese individuals also have 
increased amounts of plasma membrane fatty acid transporters, which work to escort NEFAs 
into cells (Bonen 2004).   
Once inside the cell, NEFAs compete with glucose as an energy substrate in muscle and 
adipose tissue (Fanelli et al. 1993), and inhibit insulin-stimulated glucose uptake.  NEFAs may 
inhibit glucose uptake by disrupting GLUT4 synthesis, vesicle trafficking, budding and fusion 
(Roden et al. 1996).  Griffin et al. (1999) reported that increased circulating NEFA 
concentrations may also inhibit insulin signalling within the muscle cell.  When these 
circulating lipids accumulate within the cell they stimulate protein kinase C theta (PKCθ), a 
molecule with an inhibitory effect on phosphoinositide 3-kinase (PI3 kinase) (Griffin et al. 
1999).  As seen in Figure 2, PI3 kinase is directly involved in the cascade that leads to GLUT4 
translocation to the cell membrane (Zierath et al. 2000).  Stimulation of PKCθ therefore 




Figure 2  Insulin-stimulated glucose uptake in skeletal muscle.  Insulin binds to its receptor, 
initiating a signal transduction pathway that increases GLUT4 translocation to the plasma 
membrane. Increased GLUT4 at the plasma membrane facilitates glucose uptake from the 
blood stream. 
 
Increased lipolysis impacts cardiovascular health in addition to whole body glucose 
metabolism.  High circulating levels of NEFAs can induce insulin resistance in cardiac muscle 
(Ferrannini and Iozzo 2006; Yanai et al. 2008).  Reduced glucose uptake in cardiovascular 
tissue can impair cardiac function (Ferrannini and Iozzo 2006) and contribute to cardiovascular 
disease.  Additionally, increased NEFA concentrations also stimulate endothelial nitric oxide 
production, which impairs endothelium-dependent vasodilation and leads to hypertension 
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4.3 Decreased glucose uptake by skeletal muscle 
High fat mass is associated with decreased glucose uptake in skeletal muscle and this 
negatively impacts metabolic health.  Skeletal muscle sarcolemma of both obese and diabetic 
individuals contains high amounts of the fatty acid transporter/cluster of differentiation 36 
(FAT/CD36) compared to lean controls (Bonen 2004).  Bonen et al. (2004) noted that this 
increased amount of fatty acid transporter not only served to increase intramyocellular 
triglyceride content but was also associated with a reduced amount of GLUT4 at the plasma 
membrane, limiting the amount of glucose that can be removed from circulation.  In this study, 
localization of FAT/CD36 at the plasma membrane was increased 40% in obese individuals 
and 76% in diabetic individuals compared to a lean group. 
It is generally accepted that high fat mass contributes to impaired glucose tolerance and 
dyslipidemia in various ways, for instance accumulating in the liver and muscle (Kelley et al. 
2003), stimulating lipolysis (Björntorp et al. 1969; Jensen et al. 1989) and reducing glucose 
uptake in skeletal muscle (Bonen 2004).  However, the emergence of adipose tissue as a 
potential new endocrine organ has stimulated further investigation into the mechanisms 
relating obesity and metabolic dysregulation.  Researchers are beginning to uncover the role of 
inflammatory mediators in the development of glucose intolerance and cardiovascular disease.  
High amounts of adipose tissue are associated with elevated pro-inflammatory cytokine 
concentrations (Wisse 2004).  Pro-inflammatory cytokines like IL-6 and TNF- α may interfere 
with insulin signalling pathways and facilitate the development of insulin resistance 
(Plomgaard et al. 2005; Uysal et al. 1997; Kim et al. 2004).  
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5.0  Inflammation may develop with unhealthy body composition, and may contribute 
to glucose and lipid dysregulation in non-malignant populations 
Inflammation is a proposed link between obesity and metabolic diseases like 
cardiovascular disease and diabetes in non-malignant populations.  In obese individuals, 
adipose tissue is a source of pro-inflammatory cytokines such as TNF-α, IL-6 and IL-8 (Xu et 
al. 2003).  When adipocytes hypertrophy, monocyte-derived macrophages infiltrate the adipose 
tissue.  Once inside the adipose tissue, macrophages release TNF-α, IL-6 and IL-8 (Weisberg 
et al. 2003).  High circulating concentrations of these pro-inflammatory cytokines have been 
observed in obese compared to lean individuals (Ziccardi 2002; Xu et al. 2003; Visser et al. 
1999).  
TNF-α and IL-6 are associated with metabolic complications.  Van Hall et al. (2003) 
noted an increase in lipolysis along with increasing serum concentrations of IL-6.  Moreover, a 
positive correlation has been observed between serum concentrations of IL-6 and insulin 
resistance (Kern et al. 2001; Klover et al. 2003).  TNF-α is also positively correlated with 
increased adipose tissue lipolysis and insulin resistance (Kern et al. 2001; Hotamisligil and 
Spiegelman 1994).  TNF-α and IL-6 are products of the nuclear factor- κB (NF-κB) pathway 
(Shoelson et al. 2003), however they can also act as stimuli for the same pathway and in doing 
so, induce insulin resistance (Cifuentes et al. 2010).  IKK-β, a serine kinase that is another 
product of the NF-κB pathway, promotes tyrosine phosphorylation and prevents serine 
phosphorylation of insulin receptor substrate 1 (IRS-1) when TNF- α or IL-6 activate the NF-
κB pathway (Shoelson et al. 2003).  Serine phosphorylation of IRS-1 is required for GLUT4 
translocation; when tyrosine phosphorylation results from increased IKK-β, insulin resistance 
occurs (Yuan et al. 2001) (Figure 2).  TNF-α and IL-6 also stimulate the c-Jun N-terminal 
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kinase (JNK) pathway; increased circulating JNK inhibits the activation of IRS-1 in the insulin 
signalling cascade, preventing the translocation of GLUT4 vesicles to the cell surface (Lee et 
al. 2003).  This can also result in insulin resistance. IL-1β and c-reactive protein (CRP) are 
increased in obesity as well (Visser et al. 1999; De Lorenzo et al. 2007), and it has been shown 
that IL-10, an anti-inflammatory cytokine, is depressed in obesity (Gotoh et al. 2012).  Fewer 
studies have examined the effects of obesity on other anti-inflammatory cytokines, although 
IL-4 is reportedly depressed in breast cancer patients compared to controls (Dehqanzada et al. 
2007).  It is possible that reduced circulating concentrations of anti-inflammatory cytokines, 
like IL-4 and IL-10, are associated with the low-grade chronic inflammation characteristic of 
obesity as well as the increased inflammation observed in breast cancer.  Pro-inflammatory 
cytokine levels are reportedly elevated in breast cancer patients compared to non-malignant 




6.0  Investigation into the metabolic consequences of unhealthy body composition in 
breast cancer is limited 
Unhealthy body composition (high fat mass in particular, as well as low muscularity) 
has been characterized and documented in breast cancer patients (Demark-Wahnefried et al. 
1993; Demark-Wahnefried et al. 1997; Demark-Wahnefried et al. 2001).  While metabolic 
consequences attributed to high fat mass and low lean tissue (i.e. inflammation, glucose 
intolerance and dyslipidemia) in non-malignant individuals have been well-described (Kern et 
al. 2001; Modan et al. 1985; Howard et al. 2003; Klover et al. 2003), these effects have been 
minimally explored in breast cancer.  Studies have reported that breast cancer patients have 
increased chronic inflammation due to their underlying disease state (Kozlowski et al. 2003; 
Zhang and Adachi 1999; Tessitore et al. 2000), which may exacerbate the metabolic 
consequences anticipated due to high fat mass.  Kozlowski et al. (2003) noted that breast 
cancer patients had increased serum concentrations of IL-6 compared to non-malignant 
controls.  Kozlowski and colleagues (2003) also observed that the serum concentrations of this 
cytokine correlated positively with clinical disease stage.  Zhang et al. (1999) confirmed a 
strong positive correlation between tumour progression and cytokine concentrations, and also 
observed that CRP is elevated in the serum of breast cancer patients.  Serum TNF- α has also 
been documented to be significantly higher in breast cancer patients compared to non-
malignant controls (Tessitore et al. 2003).  It is possible that the combined effects of the 
tumour and high fat mass may result in higher concentrations of circulating pro-inflammatory 
cytokines, and thus a worse degree of glucose intolerance and dyslipidemia, than would be 
expected of a non-malignant female of a similar percentage body fat (Figure 1).  To date, 
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however, no studies have examined the association between inflammation, glucose tolerance 
and serum lipids in breast cancer patients.  
Despite that IL-6 and TNF- α are known to hinder insulin sensitivity in non-malignant 
individuals (Kern et al. 2001; Klover et al. 2003; Hotamisligil and Spiegelman 1994), 
investigation of the effects of these cytokines on impairing glucose and lipid metabolism in 
breast cancer patients remains extremely limited.  The majority of studies on metabolism in 
breast cancer have focused on evaluating risk of cancer development in association with 
various metabolic disorders such as diabetes (Bjørge et al. 2010; Lipscombe et al. 2006; Mink 
2002).  However, understanding the links between body composition and metabolism as a 
mechanism to potentially explain these increased risks in breast cancer patients is unclear or 
lacking.  
The vast majority of studies that have examined the metabolic disorders associated with 
breast cancer are large-scale population-based risk assessment studies.  Bjørge et al. (2010) 
collected blood samples and anthropomorphic measurements from 290 000 European females 
between 1974 and 2005.  Of these females, 4862 developed breast cancer.  By comparing the 
cases and controls, Bjørge showed that post-menopausal females who demonstrated symptoms 
of metabolic syndrome such as impaired fasting and 2-hr glucose, abdominal obesity, high 
TAG concentrations and low high density lipoprotein (HDL) cholesterol concentrations were 
more likely to develop breast cancer.  With similar study designs high fasting glucose, high 
fasting insulin and insulin resistance were confirmed as other risk factors for breast cancer 
(Muti et al. 2002; Mink et al. 2002; Goodwin et al. 1988).  Diabetes is another risk factor for 
breast cancer.  Using Ontario health databases, Lipscombe et al. (2006) determined that the 
chance of a diabetic female developing breast cancer is 2.97/1000, compared the chance of a 
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non-diabetic female developing breast cancer, which is 2.75/1000 (p=0.021).  These findings 
were further supported by Mink et al. (2002) who demonstrated that breast cancer incidence is 
60% higher in diabetic females compared to females with a healthy fasting glucose (< 5.6 
mM).  Dyslipidemia is also prevalent in breast cancer patients (Kökoğlu et al. 1994).  Goodwin 
et al. (1997) examined fasting lipids in females who underwent breast biopsies.  They 
discovered that plasma TAG concentrations were significantly higher in breast cancer patients 
compared to patients whose biopsies were negative for proliferative disease (0.94 ± 1.04 mg/ml 
vs 0.83 ± 1.04 mg/ml, p=0.03) (Goodwin et al. 1997).  
 These risk assessment studies have established a relationship between breast cancer 
incidence and metabolic disorders.  However, no studies to date have quantified fasting glucose 
or 2-hr glucose during an oral glucose tolerance test (OGTT), fasting lipids or markers of 
inflammation like CRP, IL-6 or TNF-α in recently diagnosed breast cancer patients.  During an 
OGTT a standard 75g load of glucose is administered orally to a fasted individual and blood is 
drawn at regular intervals for 2-3 hours.  OGTTs crudely assess whether an individual is 
glucose tolerant, insulin resistant or diabetic based on their fasting and 2 hour serum glucose 
concentrations.  A handful of studies have performed OGTTs in breast cancer patients to 
evaluate the effects of treatment (Chala et al. 2006; Polushina et al. 2002; Elefsiniotis et al. 
2004).  Chala et al. (2006) and Elefsiniotis et al. (2004) did not include a non-malignant female 
group for comparison.  Polushina et al. (2002) evaluated breast cancer patients relative to a 
non-malignant female group, however they did not indicate whether measures were taken prior 
to or during chemotherapy. 
The aforementioned studies on breast cancer have not examined metabolism, exercise 
capacity and nutrition in association with breast cancer.  The majority of these studies 
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examined metabolism, exercise capacity or nutrition independently.  Due to the 
interrelationships between body composition, metabolism, nutrition and exercise, it is 
methodologically important to take an integrative approach and study these topics together in a 
single group of breast cancer patients.  It is also important to examine these patients near 
diagnosis before further gains in fat and losses in muscle occur over treatment and in 
survivorship.  With the data from this thesis, we can further understand the metabolic disorders 
that may develop in treatment and survivorship, and design effective exercise and nutrition 
interventions to prevent or counter co-morbidities.  
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7.0  Rationale 
Eighty-nine percent of breast cancer patients achieve 5-year survival and this number 
increases each year (Canadian Cancer Society 2011). As such, it is increasingly important to 
address the secondary diseases like diabetes and cardiovascular disease that develop once 
patients enter into survivorship. It is known that breast cancer patients have high fat mass and 
low muscle mass upon diagnosis (Amaral et al. 2010; Healy et al. 2010; Yaw et al. 2010) and 
that these profiles worsen as patients progress through treatment and enter into survivorship 
(Demark-Wahnefried et al. 2001; Demark-Wahnefried et al. 1993; Demark-Wahnefried et al. 
1997).  In non-malignant populations, similar unhealthy body composition profiles are 
associated with a variety of metabolic complications, like chronic inflammation, glucose 
intolerance and dyslipidemia, all of which increase the risk of diabetes and cardiovascular 
disease. It is well supported that obesity in non-malignant populations can be attributed to 
reduced energy expenditure and increased energy intake.  
The metabolic consequences of high fat mass and low lean tissue in breast cancer 
patients are not well known, as they are in non-malignant populations.  It is possible that 
inflammation resulting from lingering effects of the recently excised tumour combined with 
inflammation due to high fat mass may cause patients to present with a greater degree of 
impaired glucose tolerance and dyslipidemia at diagnosis compared to non-malignant controls 
of a similar age and BMI.  The increased concentrations of circulating pro-inflammatory 
cytokines may explain patients’ predisposition to the development of secondary diseases in 
survivorship.  
Before we can begin countering the development of diabetes and cardiovascular disease 
in survivorship, we need to examine the extent of metabolic complications such as 
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inflammation, glucose intolerance and dyslipidemia at baseline. The onset of chemotherapy is 
an important baseline to avoid the confounding effects of body composition changes as a result 
of treatment and treatment-associated fatigue.  Once we understand how patients differ from 
non-malignant controls, we can begin designing effective and targeted nutrition and exercise 
interventions over treatment that will counter the development of diabetes, cardiovascular 
disease and cancer recurrence in survivorship.  For instance, we may determine that breast 
cancer patients have a significantly higher fat mass compared to age/BMI-matched controls, 
and that this excess fat mass is associated with reduced glucose tolerance. With exercise data 
from patients we can start to identify potential population specific exercise prescriptions for 




8.0  Objectives 
1. To independently evaluate the body composition, glucose/lipid metabolism, 
inflammation, exercise capacity and nutrition of breast cancer patients near diagnosis 
and compare these parameters to IDF cutpoints for metabolic syndrome. A healthy 
group of non-malignant females who were matched to breast cancer patients by age and 
BMI (HM) as well as young healthy non-malignant females (HY) will also be 
compared to IDF cutpoints for metabolic syndrome. 
	  
2. To compare metabolic parameters of breast cancer patients to HM females to determine 
whether breast cancer patients are associated with a greater degree of metabolic 
dysregulation and inflammation.  
 
3. To compare metabolic parameters of breast cancer patients and HM females with a 




9.0  Hypotheses  
1. Breast cancer patients will present with: 
a. BMI’s in the overweight or obese categories, which will be supported by a high 
percentage body fat and a large waist circumference relative to IDF cutpoints 
for metabolic syndrome.  
 
b. TAG, HDL cholesterol and fasting glucose concentrations that are outside the 
IDF cut-points and indicate risk for metabolic syndrome.  The breast cancer 
patients will also demonstrate unfavourable partitioning of other serum lipids: 
high fasting total cholesterol, low-density lipoprotein (LDL) cholesterol and 
TAG concentrations. 
 
c. High fasting and 2-hr blood glucose concentrations during an OGTT, and 
elevated insulin and c-peptide responses during an OGTT compared with HM 
females.  
 
d. High circulating concentrations of TNF-α, IL-6, IL-8 and CRP; low circulating 
concentrations of IL-4 and IL-10, compared to HM females. 
 




f. Low energy expenditure and high caloric intake compared to HM females. This 
will be associated with their high percentage body fat.  
 
2. Both breast cancer patients and HM females will have similar circulating 
concentrations of pro-inflammatory cytokines, lower circulating concentrations of anti-
inflammatory cytokines and impairments in glucose metabolism and dyslipidemia; 
however, these metabolic parameters will be exaggerated in breast cancer patients 
compared to HM females.  Although there will be impairments to glucose and lipid 
metabolism, overall HM females will not present with metabolic syndrome. 
 
3. Compared to the HY females, both the breast cancer patients and the HM females will 
have a higher BMI, a higher percentage fat mass, a greater waist circumference, 
elevated circulating concentrations of pro-inflammatory cytokines, depressed 
circulating concentrations of anti-inflammatory cytokines, impaired glucose 
metabolism, dyslipidemia, poor relative VO2peak and strength measures, low energy 
expenditure and high energy intake. HY females will not present with any factors that 
indicate risk of metabolic syndrome. 
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10.0  Methods 
10.1  General Study Design 
This study involved 26 participants: 8 breast cancer patients, 8 HM females and 10 HY 
females.  All participants received 4 evaluations within a 1 week period: 1) body composition 
using skinfolds and circumference measurements; 2) blood sampling after an overnight fast 
and during an OGTT to measure aspects of glucose and lipid metabolism, as well as 
inflammation; 3) exercise capacity using a cardiovascular test, a strength test, and physical 
activity questionnaires (PAQs); and 4) nutrition using a 3 day food diary.  This study was 
reviewed and received ethics clearance by the University of Waterloo Office of Research 
Ethics (for all participants) and by the Tri-Hospital Research Ethics Board (for breast cancer 
patients).  Copies of the forms indicating ethics clearance was received have been included in 
Appendix I.   
 
10.2  Participants  
 
Eligibility criteria for the breast cancer patients, HM and HY females are presented in 
Table 1.  All participants completed a Health Questionnaire (Appendix II) to assess whether 
they were free from metabolic disease (i.e. cardiovascular disease and diabetes) and free of any 






Table 1.  Eligibility criteria for breast cancer patients, HM females and HY females 
Breast Cancer Patients HM HY 
Inclusion Criteria 
• Females ≥ 18 years • Age within ± 3 year of matched patient • Females 18-25 years 
• Recent diagnosis of 
breast cancer and up to 
4 weeks following first 
cycle of chemotherapy 
• BMI within ± 2 kg/m2 
of matched patient 
• BMI between 18.5-24.9 
kg/m2 
• Clinical stages I-II   
 
• Use/no use of hormonal 
contraception matched 
to patient 
• Not currently using 
hormonal contraceptives 
and have not used 
hormonal contraceptives 
within the past 6 months 
 • Menopausal status 
matched to patient 
 
  • Recreationally active 3-
5 days per week 
• Fasting glucose <7.0 
mM 
• Fasting glucose <7.0 
mM 
• Fasting glucose <6.0 
mM 
Exclusion Criteria 
• Previous diagnosis of cancer in the last 5 years (other than carcinoma in situ) 
• Cardiovascular disease or thyroid disease that is not currently managed with 
medication 
• Diabetes or HIV 
• Injuries or health conditions that prevent participants’ safe participation in exercise 
 
 
10.3  Recruitment 
Breast cancer patients were recruited from the Grand River Regional Cancer Center 
(GRRCC) in Kitchener.  Oncologists and the Clinical Trials Department from GRRCC 
completed a Hospital Screening Form detailing the eligibility requirements listed in Table 1 for 
each newly diagnosed breast cancer patient.  Completed screening forms were forwarded to the 
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Nutrition and Metabolism Laboratory and our laboratory contacted eligible patients with 
details about the study.  
HM females were recruited from the city of Kitchener-Waterloo through recruitment 
posters displayed in community centers, grocery stores, fitness centers and online bulletins.  
HY females were recruited from the University of Waterloo through announcements made in 
undergraduate classes and recruitment posters that were placed around campus.  Additional 




Potential participants were screened for eligibility before beginning their assessments, 
using the eligibility criteria outlined in Table 1.  Interested individuals who consented arrived 
at the laboratory after an overnight fast (no food or drink except water after midnight the night 
before) and received a finger-prick test (Aviva Accu-Check; Roche Diagnostics) to confirm 
that blood glucose was < 7.0 mM for patients and HM females, and < 6.0 mM for HY females.  
Potential participants were also weighed and measured to determine BMI, and completed a 
Health Status Screening Form to determine if they had any prior cancer or metabolic disease 
that would have excluded them from participating in the study.  All screening sessions took 
place between 8:30am and 9:00am so that all potential participants were fasted for 8-12 hours. 
  
10.5  Data Collection 
Eligible participants received the following 4 assessments within a 1-week period: 1) 
body composition; 2) blood sampling; 3) cardiovascular and strength assessments, as well as 
physical activity questionnaires; and 4) nutrition.  
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10.5.1  Body Composition  
Skinfold caliper (Harpenden Skinfold Caliper; Burgess Hill, West Sussex) and 
circumference measurements were taken by an exercise physiologist at the UW-WELLFIT 
center to minimize variation between measurements.  Skinfold measurements were taken on 
the triceps, suprailiac region and thighs (2-3 trials per site) using the method described by 
Jackson and Pollock (1985).  Sites were located using boney landmarks on the right side of the 
body while the participant was standing with their feet hip width apart.  The triceps skinfold 
site was marked midway between the acromion process and the tip of the olecranon process 
while the forearm was supinated and flexed at 90°.  The triceps skinfold measurement was 
taken with the arm returned to a neutral position at the side of the body.  The suprailiac 
skinfold site was marked along the anterior superior iliac spine and taken while the 
participant’s right arm was abducted to 90° with the fingertips of their right hand resting on 
their right shoulder.  The thigh skinfold site was marked midway between the base of the 
patella and the inguinal crease.  All skinfold measurements were taken once in the order in 
which they have been described, and then repeated in the same order once the subcutaneous 
adipose tissue has had approximately 30 seconds to relax.  If the difference between 
measurements at any site was greater than 0.4 mm, the measurement was taken a third time.  
We used the average of the closest 2 trials as the final measurement for each site.  Body fat 
percentage was estimated from the skinfold measurements taken at the triceps, suprailiac 
region and thigh.  The skinfold measurements was entered into the Jackson 3-Site Equation for 
body density: 
Body density = 1.0994921 – (0.0009929 x [sum of 3 skinfolds in mm]) + 




The body density value was then converted to percentage body fat using the Siri Equation: 
% body fat = (495/body density) - 450 
 
Circumferences were measured using a tape measure.  Landmarking and measuring for 
the mid-humerus circumferences were done using the same positioning as the triceps skinfolds.  
The waist circumference was taken at the top of the iliac crests, in accordance with the 
American College of Sports Medicine (ACSM 2009).  The mid-thigh circumference was 
landmarked with the participant’s right leg bent at 90°.  This positioning causes the midpoint 
between the base of the patella and the inguinal crease to shift distally, so the midpoint was re-
marked for the circumference measurement.  Circumference measurements were taken once at 
each site, on the participant’s right side. 
One breast cancer patient, as well as all HM and HY females received a full-body DXA 
scan (Hologic QDR Series, Discovery W S/N 84474; Bedford, MA) for additional 
quantification of % body fat and lean tissue mass.  Scans were completed by the same certified 
medical radiation technologist on the same day as the anthropomorphic body composition 
measurements.  All participants wore a cotton hospital gown during the scan, removed all 
jewellery and lay in a supine position with their legs extended but separated by at least 2 cm, 
and feet turned in (toes touching).  Their upper limbs lay at their sides, leaving 2 cm gap 
between torso and limb, with the forearms in a supinated position, and their neck and spine in a 
neutral position.  This positioning allowed for easier separation of individual body 
compartments during analysis of the scan (i.e. upper limbs, lower limbs and pelvic region).  
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The remaining 7 breast cancer patients did not receive DXA scans since they were recruited 
and assessed before this lab acquired the DXA equipment.  Percent body fat was determined 
using the skinfold calipers and was compared between all participants.  
We estimated lean tissue mass in the breast cancer patients without DXAs indirectly 
from their skinfold caliper measurements:  
 
Estimated lean tissue = (100 - % body fat)% * weight 
 
To determine whether indirect calculations of lean tissue using skinfold measurements 
were comparable to measurements from DXA, we compared estimated and measured lean 
tissue in all participants who received DXA scans (n=19) using a paired t-test (Appendix IV).  
Lean tissue was calculated from skinfold measurements by multiplying % body fat by body 
weight to attain fat mass and, subsequently, subtracting fat mass from body weight.  On 
average, our calculations using skinfolds provided an overestimation of lean tissue compared to 
DXA for the majority (14/19) of participants (mean ± SD for lean tissue measured by skinfold 
and DXA: 42.8 ± 5.5 kg vs. 40.4 ± 5.0 kg, respectively, p = 0.018); the average difference 
between estimate and measurement was 2.5 ± 4.1 kg.  Considering the average difference 
between estimated and measured lean tissue was consistent and relatively small (2.5 kg 
represents < 6.5% of the lean tissue in a 70 kg adult) we used estimated lean tissue mass for 





10.5.2  Blood Sampling  
Participants arrived at the University of Waterloo after an overnight fast (8-12 hours 
with no food or drink except for water) for an OGTT (see Figure 3).  A sterile catheter was 
inserted into the antecubital vein of the participant’s preferred arm and 25 mL of blood was 
drawn.  Thirty minutes later a second fasting sample of 5 mL was drawn.  Immediately after 
the second fasting sample, participants were instructed to consume a 75 g glucose drink (Trutol 
Glucose Tolerance Beverage, Thermo Fisher Scientific; East Providence, RI).  All participants 
consumed the glucose drink within 10 min.  Fifteen minutes after participants consumed the 
glucose drink, 5 mL of blood was drawn.  Blood was also drawn at 30, 45 and 60 minutes post-
glucose drink.  After 60 minutes post-glucose drink, blood was drawn every 30 minutes for a 




Figure 3  Timing of events during the 3 hour OGTT protocol.  The thin black arrows 
indicate when blood was sampled.  Participants were fasted and ingested a 75g bolus of 
glucose after the 0 min blood draw.   
 
Blood collected during the first blood draw (i.e. at -30 minutes) was analyzed for the 
parameters listed in Table 2.  Blood samples collected at all timepoints during the OGTT were 







assessed for glucose, insulin, c-peptide and glucagon.  We assessed insulin sensitivity using the 
homeostatic model assessment of insulin resistance (HOMA-IR), which considers fasting 
values only, and the Matsuda Index (Matsuda and Defronzo 1999), which takes into account 
glucose and insulin values during a 75g OGTT.  The Matsuda index has been validated against 
the euglycemic insulin clamp. 
 




Matsuda Index = !"  !!!
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The molar ratio of glucagon to insulin provides an indication of whether 
gluconeogenesis and insulin action are balanced.  To calculate this ratio we divided plasma 
glucagon by serum insulin (both in pM).  We multiplied insulin concentrations by 6.945 to 
convert them from µIU/mL to pM; we multiplied glucagon concentrations by 3.485 to convert 




Table 2.  Metabolic parameters assessed using blood collected at the -30 min timepoint 
Glucose metabolism Fasting lipids Inflammatory 
mediators 
Glucose Total cholesterol IL-6 
Insulin LDL-cholesterol TNF-α 
C-peptide HDL-cholesterol IL-8 
Glucagon TAG IL-4 
 NEFA IL-10 
 Glycerol CRP 
 
 
10.5.3  Cardiovascular and Strength Assessments, and Physical Activity Questionnaires   
All exercise testing took place in the UW WELL-FIT Center.  Predictive VO2peak tests 
were conducted on a cycle ergometer (Ergometrics er800s; Ergoline, Bitz, Germany) using the 
Vmax breath-by-breath system (Vmax; SensorMedics, Yorba Linda, CA) as an indicator of 
cardiovascular fitness.  Predictive VO2peak tests were used instead of VO2max tests since most 
exercise tests on clinical populations are symptom limited and VO2max is generally not 
achieved.  All participants wore a Hans Rudolph facemask (7400 Vmask Series Oro-Nasal 
MASK) during the test.  The mouthpiece was not used since many patients experience dry 
mouth and mouth sores as a result of chemotherapy; the facemask is a valid, and more 
comfortable, alternative (Evans and Potteiger 1995; Bell et al. 2012).  Heart rate was monitored 
throughout the test using an electrocardiogram (EK10 Spacelabs Burdick Inc.; Deerfield, WI).  
  Participants rested in a seated position for 5-10 minutes on the cycle ergometer while 
the set-up was completed.  We then collected 2 minutes of resting values with the participant 
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seated on the cycle ergometer, after which time instructed the participant to begin pedaling at a 
resistance of 25 W.  Participants maintained a cadence of 50 – 70 rpm throughout the test.  
Blood pressure, using a manual sphygmomanometer, and rating of perceived exertion were 
recorded every 2 minutes.  Resistance was increased between 10 – 50 W depending on the 
participant’s rating of perceived exertion in the previous increment.  Tests were terminated 
when participants reach 85% of their age-predicted maximal heart rate (HR), when they were 
no longer able to maintain a cadence of 50 – 70 rpm or requested to stop.  VO2peak was 
extrapolated using HR and VO2 data for each stage. VO2 and HR are linearly correlated (Darby 
and Yaekle 2000).  It is therefore possible to predict VO2peak using a participant’s maximal HR. 
VO2 is plotted against HR at the end of each exercise increment, and a linear trend line is 
created.  VO2peak is then extrapolated using the participant’s age-predicted maximal HR and the 
equation of the trend line. 
Strength was assessed using predictive repetition maximum (1RM) tests for biceps curl, 
triceps extension and leg extension.  Bench press is conventionally used to assess upper body 
strength, however many breast cancer patients may endure surgery during the treatment time-
course, which may lead to lymphedema or tightening of the tendons and ligaments (‘cording’) 
on one side of their body.  This often results in strength differences. Biceps curls and triceps 
extensions can be assessed unilaterally and allows for the accurate measurement of muscle 
strength for each side of the body.  A squat is used by convention to measure lower body 
strength.  However, this compound exercise is difficult to instruct to participants who have 
limited exercise experience.  We chose to assess leg extension since it can be measured using a 
weight machine, which restricts extraneous movement.  Biceps and triceps were assessed 
unilaterally using a cable machine and stacked weights; quadriceps were assessed bilaterally.  
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For each exercise, following a demonstration on proper technique, participants 
performed 10 repetitions at 40-60% of their 1RM as a warm-up (estimated using data from the 
Institute for Aerobics Research based on the weight of the participant).  After 1-3 minutes of 
rest, the weight was increased to the participant’s estimated 60-80% and participants completed 
up to 10 repetitions with proper technique.  If participants reached 10 repetitions during this 
first stage, after 3-5 minutes of rest the weight was increased to the participant’s estimated 80-
95% 1RM.  They completed as many repetitions as possible using proper technique and the 
first stage was then discounted.  1RM was predicted using the O’Connor Equation (O'Connor 
et al. 1989): 
1RM = !"#$!!  !"#$%&
!"#"$%$%&'(




Habitual physical activity was assessed using the Baecke PAQ (Baecke, Burema, and 
Frijters 1982) and the CHAMPS Activities Questionnaire for Older Adults (Stewart et al. 
2001).  These questionnaires provide information regarding the participant’s habitual patterns 
of physical activity that may not necessarily be represented by their cardiovascular and strength 
test results.  The Baecke PAQ provides 3 quantitative indices of physical activity that can be 
compared across participants: the Work Index, which evaluates occupational physical activity; 
the Sport Index, which evaluates voluntary exercise during leisure time; and the Leisure Index 
which accounts for other types of physical activity during leisure time.  The CHAMPS 
Activities Questionnaire for Older Adults provides an estimate of exercise-related caloric 
expenditure per week.  The Baecke questionnaire has been validated for use in adults aged 20-
70 (Pols et al. 1995); the CHAMPS questionnaire has been validated for use in older adults, 
clinical populations as well as in individuals of different ethnic backgrounds (Feldman et al. 
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2009; Resnicow et al. 2003).  The use of both of these questionnaires captured a wide range of 
ages for this study. 
Caloric expenditure per week was estimated using the CHAMPS Activities 
Questionnaire for Older Adults using the equation described by the ACSM.  The participant 
provided an indication of the duration of each activity described in the questionnaire.  Each 
activity is assigned a metabolic equivalent of task (MET) value; a MET is a physiological 
measure that expresses the energy required for various physical activities.  One MET is 
generally considered to reflect resting energy expenditure (Ainsworth et al. 1993).  Caloric 
expenditure per activity per week was determined using the following:  
kcal/activity/week = duration(hours/week)*METs(/minute)*3.5*60*(weight in kg/200) 
Caloric expenditure per week was estimated by summing the expenditure of each activity. 
 Resting energy expenditure was calculated using the equation described by Ainsworth 
et al. (1993): 
1 MET = weight in kg * 1 kcal * 24 hours 
 
 Total energy expenditure (TEE) per day was estimated using the following equation 
(Brooks et al. 2004): 
 
TEE = 354 – (6.91 * age) + PA [(9.36 * weight in kg) + (726 * height in m)] 
 
Physical activity level (PAL) scores between 1.2 – 2.0 were assigned to participants depending 
on their CHAMPS and Baecke scores, and PAL was used to calculate the physical activity 
coefficient (PA).  
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10.5.4 Nutrition  
Participants completed a 3-day food record, as described by Thompson and Byers 
(1994), over the course of 2 weekdays and 1 weekend day during the same week of the body 
composition, metabolic and exercise capacity evaluations (Appendix V).  We chose the 3-day 
food record over other methods of dietary assessment such as the 24-hr diet recall and food 
frequency questionnaire because it has shown a stronger correlation when compared to the gold 
standard of measurement for energy intake, doubly labeled water (Trabulsi and Schoeller 
2001). The 3-day food record is also advantageous because of its prospective nature and ability 
to provide quantitative information about dietary intake (Thompson and Byers 1994).  Previous 
studies that have evaluated energy intake in cancer patients who are undergoing chemotherapy 
have employed 3-day food records (Kutynec et al. 1999; Ovesen et al. 1993).   
We determined daily caloric intake and macronutrient breakdown (% fat, % 
carbohydrate and % protein) from these records using ESHA Food Processor software.  The 
Canadian Nutrient File was primarily used during data analysis with ESHA, however data from 
the USDA National Nutrient Database for Standard Reference was used when Canadian 
information was not available.  At the end of each day, participants were instructed to indicate 
whether they consumed more, the same or less than they usually did, as well as record any 
supplements or vitamins taken.  Participants also rated their appetite and level of tiredness on a 
scale of 0 – 10 at the end of each day, where 0 indicated their best appetite and no feelings of 
tiredness, and 10 indicated their worst appetite and worst feelings of tiredness.  In addition, 
breast cancer patients rated their level of nausea on a scale of 0 – 10 at the end of each day, 
where 0 indicated no feelings of nausea and 10 indicated their worst feelings of nausea.  At the 
end of the 3-day period, patients completed a short questionnaire where they indicated any self-
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reported weight change or symptoms of chemotherapy that might have affected their eating 
habits (i.e. mouth sores, changes in taste of certain foods) in the past 2 weeks, and whether 
their food intake and activities levels had changed in the past month.  
 
10.6 Analyses 
10.6.1 Blood Analyses   
Serum was collected for glucose, insulin, c-peptide, lactate, glycerol, NEFAs, TNF-α, 
IL-6, IL-4, IL-8, IL-10 and CRP.  Whole blood was given 30 minutes to clot at room 
temperature in borosilicate glass tubes.  The blood was then be centrifuged at 2500 rpm for 10 
minutes at room temperature. For the analysis of total cholesterol, LDL cholesterol, HDL 
cholesterol and TAGs, 2 mL of whole blood from the -30 minute time-point was added to a 
gold-capped serum-separting tube (SST) provided by Lifelabs Medical Laboratory Services.  
These tubes contained clot activators and a serum separating gel, and yielded serum.  The 
blood in the SSTs were also centrifuged at 2500 rpm for 10 minutes at room temperature.  
 Plasma samples for glucagon were prepared by adding 2.0 mL of whole blood to test 
tubes containing 50 µL of a solution of combined EDTA and aprotinin ([EDTA] = 40 mg/mL 
saline; [aprotinin] = 0.4 mg/mL saline).  Heparin and EDTA are anticoagulants.  Aprotinin is 
an antiproteolytic protein, which prevents the breakdown of rapidly degraded proteins like 
glucagon.  These tubes were kept on ice for the duration of the OGTT and then centrifuged at 
2800 rpm at 4° C for 15 minutes.  
After centrifugation, the serum and plasma were then extracted from the borosilicate 
glass tubes and SSTs, aliquoted into separate eppendorf tubes to avoid multiple thaw/re-freeze 
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cycles, and stored at -80° C for subsequent analysis.  Plasma samples for glucagon analysis 
were stored in borosilicate glass test tubes because of glucagon’s tendency to adhere to plastic.  
 
 
10.6.2  Serum Glucose 
Serum glucose was measured using a spectrophotometer (Shimadzu UV160U UV-
Visible Recording Spectrophotometer; Columbia, MD) and peroxidase/glucose oxidase 
enzymatic reaction.  Test tubes were filled in triplicate with 10 µL distilled water (blank), 
glucose standard or serum sample.  We added 2.5 mL of a reagent solution containing 
peroxidase, glucose oxidase and o-dianisidine dihydrochloride to each tube.  Tubes were then 
vortexed and incubated at 37° C for 30 minutes.  During the incubation period, glucose in the 
blanks, standards and samples reacted with glucose oxidase, releasing hydrogen peroxide.  
Peroxidase then catalyzed a reaction between the liberated hydrogen peroxide and o-
dianisidine dihydrochloride, forming oxidized o-dianisidine.  Oxidized o-dianisidine produces 
a colour that was read at 450 nm by the spectrophotometer.  The intensity of the colour in the 
samples in comparison to the intensity of the colour in the standards provides an indication of 
glucose concentration.  
 
 
10.6.3  Serum Insulin 
Serum insulin was measured in duplicate using a Coat-A-Count Insulin 
Radioimmunoassay kit (Siemans Healthcare Diagnostics; Deerfield, IL).  We added 200 µL of 
blank, standard or sample to polypropylene tubes pre-coated with insulin antibody.  To all 
tubes we added 1.0 mL of 125I-labeled insulin.  Tubes were then vortexed and incubated at 
room temperature for 24 hours.  During the incubation period, 125I-labeled insulin competes 
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with insulin in the sample or standard for binding sites on the insulin antibody molecules, 
which are fixed to the polypropylene tube walls.  After 24 hours the supernatant was aspirated 
and tubes were counted for 1 minute using a gamma counter (Wallac Wizard 1470 Automatic 
Gamma Counter; PerkinElmer Life and Analytical Sciences; Woodbridge, ON).  Samples or 
standards with high concentrations of insulin would bind less 125I-labeled insulin and be less 
radioactive.  
 
10.6.4  Serum C-Peptide 
Serum c-peptide was assessed in duplicate using a C-Peptide Double Antibody 
Radioimmunoassay kit (Siemans Healthcare Diagnostics; Deerfield, IL).  During the assay, 25 
µL of standard or serum was combined with 100 µL 125I-labeled c-peptide and 100 µL c-
peptide antibody in polypropylene tubes.  The tubes were vortexed and incubated for 4 hours at 
room temperature.  During the incubation, c-peptide in the standard and sample competes with 
125I-labeled c-peptide for binding sites on the c-peptide antibody.  After the 4 hour incubation, 
1.0 mL of cold (4° C) precipitating solution was added to each tube.  The tubes were vortexed 
and then centrifuged at 3000g for 15 minutes.  After centrifugation, the supernatant was 
aspirated and the tubes were counted for 1 minute in a gamma counter.  Radioactivity is 
inversely correlated with c-peptide concentration.  Concentration of c-peptide was determined 
by interpolating samples from a graph of known c-peptide concentrations.  
 
10.6.5  Plasma Glucagon 
Plasma glucagon was assayed in duplicate using a Glucagon Double Antibody 
Radioimmunoassay kit (Siemans Healthcare Diagnostics; Deerfield, IL).  200 µL of plasma 
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sample or standard was added to a borosilicate glass test tube, along with 100 µL of glucagon 
antibody.  The tubes were vortexed and incubated at 4° C for 24 hours.  After the first 
incubation period, 100 µL of 125I-labeled glucagon was added to all tubes.  The tubes were 
vortexed and incubated at 4° C for 24 hours again.  After the second incubation period 1.0 mL 
of cold (4° C) precipitating solution was added to each tube.  The tubes were vortexed once 
more and centrifuged at 1500g for 15 minutes.  When centrifugation was complete, the 
supernatant was aspirated and the tubes were counted for 1 minute in a gamma counter.  Over 
the course of the 2 incubation periods, glucagon in the standards and samples competes with 
125I-labeled glucagon for binding sites on the glucagon antibodies.  Thus, radioactivity of the 
samples is inversely related to glucagon concentration.  Plotting the radioactivity (counts per 
minute) of the standards (known concentrations of glucagon) generates a standard curve from 
which concentrations of the samples were interpolated.   
 
 
10.6.6  Perchloric Acid (PCA) Extraction for Glycerol Samples 
Serum contains extraneous proteins that interfere with the true reading of certain 
metabolites like glycerol.  To remove this extra protein, a solution of 0.6 M perchloric acid was 
prepared by combining perchloric acid stock solution and water.  500 µL of this solution was 
combined with 100 µL serum in an eppendorf tube.  All tubes and solutions were kept on ice 
throughout the procedure.  Tubes were vortexed and centrifuged at 4° C at 15 000g for 2 
minutes.  After centrifugation, 250 µL of 1.25 M potassium bicarbonate was added to each 
tube.  After tubes were allowed to sit for 10 minutes, centrifugation was repeated and the 
supernatant was extracted, transferred to new eppendorf tubes and stored at -80 °C.  A dilution 
 45 
factor of 8.5 is introduced with the PCA extraction; the dilution factor was taken into account 





10.6.7  Serum Glycerol 
Serum glycerol was measured in triplicate using a glycerol kinase-based enzymatic 
reaction and a spectrofluorophotometer.  A dilute reagent of hydrazine, glycine, NAD+, ATP, 
MgCl2, Cysteine and 3-GPDH was prepared.  The first 6 reagents were combined, the solution 
was adjusted to the desired volume using distilled water and then the pH was adjusted to 9.2 
(for enzyme stability).  3-GPDH was added after the pH was adjusted.  50 µL of standard or 
sample was added to each test tube and combined with 1.0 mL dilute reagent and vortexed.  
The test tubes were then read on the spectrofluorophotometer at 365 – 455 nm (baseline).  A 
solution of 20 µL glycerol kinase and 1.0 mL dilute reagent was then prepared.  10 µL of the 
glycerol kinase solution was added to each test tube.  Tubes were incubated at room 
temperature in the dark for 60 min and then re-read.  During the incubation, glycerol kinase 
catalyzes the reaction of glycerol in the samples and standards with ATP.  This reaction forms 
glycerol-3-P which then reacts with NAD+ in a reaction catalyzed by 3-GPDH.  This second 
reaction forms NADH, which fluoresces in direct proportion to glycerol in the sample or 
standard.   
 
 
10.6.8  Serum Non-Esterified Fatty Acids 
NEFAs were measured in quadruplicate using the Wako NEFA-HR(2) Microtiter 
Procedure (Wako Diagnostics; Richmond, VA).  5 µL of blank, standard or sample were added 
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to separate wells in a 96 well microplate.  200 µL of Colour Reagent A (acyl-coenzyme A 
synthase, coenzyme A, ATP and 4-aminoantipyrine) were added to each well and the 
microplate was then incubated at 37° C for 5 minutes inside the spectrophotometer 
(Spectramax Plus 384; Molecular Devices; Sunnyvale, PA).  The absorbance was read at 550 
nm (baseline) and then 100 µL of Color Reagent B (acyl-coenzyme A oxidase and peroxidase) 
was added to each well.  The microplate was incubated again and read a second time.  During 
the first incubation, serum NEFAs react with Color Reagent A to produce acyl-COA and 
several byproducts.  In the second incubation, acyl-COA is oxidized to produced hydrogen 
peroxide.  Hydrogen peroxide then catalyzes the reaction of 4-aminoantipyrine, whose produce 
fluoresces in direct proportion to the concentration of NEFAs in each sample or standard.  
Concentrations were determined from the equation provided in the Wako Diagnostics kit.  
NEFA concentrations were determined using the following equation provided by Wako 
Diagnostics: 





10.6.9  Serum Triacylglycerol, Total Cholesterol, LDL Cholesterol and HDL 
Cholesterol 
 
Total cholesterol, LDL cholesterol, HDL cholesterol and TAGs were analyzed by 





10.6.10 Serum TNF-α, IL-6, IL-4, IL-8, IL-10 
Serum cytokines were analyzed using the BD Cytometric Bead Array Human Soluble 
Protein Master Buffer Kit and BD FACSCalibur flow cytometer (BD Biosciences; 
Mississauga, ON).  The kit provides 6 types of capture beads coated with an antibody specific 
to TNF-α, IL-6, IL-4, IL-8 or IL-10.  Each bead has a matching detection reagent that 
fluoresces at a specific activity.  Prior to beginning the assay, all beads were combined into a 
single tube labelled ‘Mixed Capture Beads’ and vortexed.  All detection reagents were 
combined into single tube labelled ‘Mixed Detection Reagents’.  
During the assay, 50 µL of each standard or sample was added to appropriately labelled 
tubes. 50 µL of the Mixed Capture Beads was then added to each tube: tubes were then 
vortexed and incubated at room temperature for 1 hour.  During the incubation, the beads form 
complexes with the cytokines matching their antibodies.  After 1 hour, 50 µL of Mixed 
Detection Reagents was added to each tube, tubes were vortexed and then incubated for 2 
hours at room temperature.  During the 2 hour incubation, the detection reagent specific to each 
bead associates with the bead/cytokine complex, forming a sandwich structure.  After 2 hours, 
1 mL of wash buffer was added to all tubes.  Tubes were vortexed and centrifuged at 200g for 
5 minutes, after which time the supernatant was aspirated.  Each pellet was then resuspended 
with 300 µL wash buffer and acquired on the flow cytometer.  Each of the 6 
bead/cytokine/detection reagent complexes is reflected as a different population.  
Concentrations were determined by comparing the mean fluorescence of the population to the 
standard curve for each cytokine.  Due to difficulty detecting TNF-α in several samples, we 
verified TNF- α concentrations in all samples using a Quantikine HS ELISA Human TNF-α 
Immunoassay (R&D Systems Inc.; Minneapolis, MN; Appendix VI). 
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10.6.11  Serum CRP 
Serum CRP was measured using an enzyme-linked immunosorbant assay (ELISA) 
(ALPCO Immunoassays; Salem, NH).  Wells of the ELISA plate were pre-coated with rabbit 
polyclonal antibody specific for human CRP.  After washing each well thoroughly with dilute 
wash buffer, 100 µL of standard or sample (diluted 100-fold) was added and the plate was 
incubated at room temperature for 1 hour.  During the incubation period, CRP in the standards 
or samples became bound to the antibody coated microwells.  Following the incubation, the 
plate was washed to remove all unbound substances and 100 µL of immunoconjugate 
(peroxidase-labeled rabbit anti-CRP) was added to each well and the plate was incubated for 
another hour.  During the second incubation period, the immunoconjugate became bound to the 
CRP-antibody complex affixed to the wells.  Following the second incubation, the plate was 
washed again and 100 µL of tetramethylbenzidine (TMB, a peroxidase substrate) was added to 
each well.  The plate was incubated in the dark at room temperature for 20 minutes, during 
which time a blue colour developed as the TMB reacted with peroxidase.  The reaction was 
stopped, and the colour turned yellow, when 50 µL of 0.45 M sulphuric acid was added to each 
well.  The absorbance of each well was read at 450 nm.  The amount of colour is directly 
proportional to the concentration of CRP in the sample.   
 
10.7  Statistical analysis and calculations 
Values are presented as mean ± SD.  Area under curve (AUC) calculations were 
completed using Sigma Plot ® version 11.2 (Systat Software Inc.; San Jose, CA); t-tests and 
paired t-tests were completed using Microsoft Excel.  Areas under the curves (AUC) for 
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glucose, insulin, c-peptide and glucagon were calculated using the incremental area method 
(Allison et al. 1995).  For all analyses, statistical significance was accepted at p < 0.05.  Trends 
were identified as p < 0.10.  Values > ± 2 SD were excluded as outliers. 
As described in the following sections, 2-tailed student t-tests and paired t-tests were 
used in place of 2-way ANOVA (time vs. participant group) for the OGTT data and in place of 
1-way ANOVA (participant group) for the fasting serum data (i.e. lipids, cytokines etc.).  Our 
consulting biostatistician (Dr. Joel Dubin) had suggested that time should be considered a 
continuous variable and therefore should not be used as a treatment in 2-way ANOVA. T-tests 
were therefore used for these comparisons instead.  1-way ANOVA was inappropriate for the 
fasting data since paired t-tests, and not student t-tests, were conducted between breast cancer 
patients and HM females. 
 
10.7.1 Comparison of breast cancer patients and HM females 
We used paired t-tests and 95% confidence intervals (CI) to compare body 
composition, fasting metabolites, OGTT measurements and AUC, exercise and nutrition 
measurements between breast cancer patients and HM females.  In all comparisons between 
breast cancer patients and HM females, paired t-tests and 95% CI analyses agreed.  The p-
values reported in 11.0 Results refer to the paired t-tests.   
 
10.7.2 Comparison of breast cancer patients and HM females to HY females 
Two-tailed two-sample t-tests were used to compare breast cancer patients to HY 
females, and HM females to HY females.  
 
 50 
10.7.3 Comparison between fasting and OGTT values for glucose, insulin, c-peptide and 
glucagon 
Two-tailed two-sample t-tests were used to compare average fasting glucose, insulin, c-
peptide and glucagon to values obtained 15, 30, 45, 60, 90, 120, 150 and 180 min post-glucose 




11.1 Clinical description of breast cancer patients 
The breast cancer patient group was fairly homogeneous based on clinical criteria, 
despite our small sample size.  All patients were Stage I or II, indicating that the disease was 
confined to the breast tissue or the surrounding lymph nodes.  The primary tumour mass was 
either < 5 cm with metastases to surrounding lymph nodes or > 5 cm with no metastases to 
surrounding lymph nodes (National Cancer Institute 2012).  Patients had no metastases to other 
areas of the body.  All patients had undergone either tumour resection or mastectomy prior to 
participating in the present study.  The length of time between surgery and the initiation of 
chemotherapy was not reported in most cases.  However, no more than 4 months elapsed 
between diagnosis and the first cycle of chemotherapy for all patients.  Chemotherapy 
regimens prescribed to patients were AC (doxorubicin + cyclophosphamide), ACT 
(doxorubicin + cyclophosphamide + paclitaxel) or TC (docetaxel + cyclophosphamide).  All 
patients had received 1-2 cycles of chemotherapy prior to data collection.   
 
11.2 Breast cancer patients were overweight and exhibited similar body composition compared 
to HM females 
On average at the time of data collection, breast cancer patients were 46 ± 10 years of 
age and overweight (BMI: 28.8 ± 6.0 kg/m2; Table 3); 2 patients had BMIs in the normal 
weight category (18.5 – 24.9 kg/m2), 4 patients were overweight (25 – 30 kg/m2) and 2 were 
obese (> 30 kg/m2).  Breast cancer patients were individually matched to HM females for age 
and BMI, so it follows that we did not observe any significant differences in these parameters 
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between patients and HM females (age: 46 ± 10 yrs vs. 47 ± 10 yrs respectively, p = 0.160; 
BMI: 28.8 ± 6.0 kg/m2 vs. 28.9 ± 6.4 kg/m2 respectively, p = 0.892).  Percent body fat and 
waist circumference were not controlled for during HM recruitment however we found that 
these parameters were not different between patients and HM females (body fat: 41.3 ± 10.9% 
vs. 43.9 ± 12.7% respectively, p = 0.524; waist circumference: 94.6 ± 14.0 cm vs. 97.4 ± 18.5 
cm respectively, p = 0.507).  On average HY females were younger (21 ± 2 yrs), had a normal 
BMI (22.0 ± 2.4 kg/m2), lower percentage body fat (26.4 ± 4.7%) and a smaller waist 
circumference (75.1 ± 5.5 cm) compared to patients and HM females.  
 Using skin-fold measurements, calculated lean tissue mass in patients was on average 
43.7 ± 5.4 kg.  We observed no difference between this estimate of lean tissue in breast cancer 
patients and the estimates of lean tissue HM and HY groups (HM: 42.7 ± 6.2 kg, p = 0.877, 
HY: 42.7 ± 5.4 kg, p = 0.690).  Further, the estimate of lean tissue in breast cancer patients was 
not different from the more precise measurements of lean tissue using DXA in HM females 
and HY females (HM: 42.6 ± 4.3 kg, p = 0.633, HY: 38.6 ± 5.3, p = 0.062).	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Table 3. Physical characteristics and body composition of all participant groups 
 Breast cancer patients HM females HY females 
Age (years) 46 ± 10# 47 ± 10# 21 ± 2 
BMI (kg/m2) 28.8 ± 6.0# 28.9 ± 6.4# 22.0 ± 2.4 
Weight (kg) 76.8 ± 17.8# 75.9 ± 17.8# 59.0 ± 9.3 
Height (m) 1.63 ± 0.05 1.64 ± 0.06 1.63 ± 0.07 
Waist circumference (cm) 94.6 ± 14.0# 97.4 ± 18.5# 75.1 ± 5.5 
Body fat (%) 41.3 ± 10.9# 43.9 ± 12.7# 26.4 ± 4.7 
Estimate of lean tissue mass (kg) 43.7 ± 5.4 42.6 ± 6.1 42.7 ± 5.4 
Data are presented as mean ± SD.  * denotes significant difference from HM females; # denotes significant difference from HY 
females.  Statistical significance was accepted at p < 0.05.  
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11.3 Overall, breast cancer patients presented with symptoms of metabolic syndrome 
attributed to dyslipidemia and abdominal obesity 
Individuals with abdominal obesity (a waist circumference > 88 cm) along with any 2 
of the following criteria were characterized as having metabolic syndrome according to IDF 
guidelines: fasting serum glucose ≥ 5.6 mM, fasting TAG ≥ 1.7 mM, fasting HDL-cholesterol 
≤ 1.3 mM or high blood pressure (systolic blood pressure ≥ 130 mmHg or diastolic blood 
pressure ≥ 85 mmHg).  When considered individually, 2 patients presented with metabolic 
syndrome.  Overall, patients had a waist circumference of 94.6 ± 14.0 cm (6 of 8 patients were 
centrally obese; Table 4), fasting TAG of 1.84 ± 1.17 mM, and HDL-cholesterol of 1.08 ± 0.23 
mM.  On average, these parameters were in line with the ranges of metabolic syndrome in 
breast cancer patients.  HM females demonstrated central obesity (average waist 
circumference: 97.4 ± 18.5 cm; 6 of 8 participants were centrally obese) similar to breast 
cancer patients, which was expected considering patients and HM females were matched for 
BMI.  Unlike the patient group, however, average fasting TAG (0.93 ± 0.27 mM), HDL-
cholesterol (1.58 ± 0.42 mM) for the HM females were within the IDF cutpoints, indicating 
that HM females were not at risk for metabolic syndrome.  Average fasting serum glucose and 
blood pressure were also within IDF cutpoints for the HM group (Table 4).  When considered 
individually, 1 participant in the HM group was identified as having metabolic syndrome.  As 
expected, HY females did not demonstrate central obesity (average waist circumference: 75.1 ± 
5.5 cm) and all other criteria for metabolic syndrome were within IDF cutpoints (Table 4).  
None of the HY females was identified as having metabolic syndrome.	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Table 4.  Description of breast cancer patients, HM females and HY females relative to IDF cutpoints for metabolic syndrome. 
 IDF cutpoint Breast cancer patients HM females HY females 
Waist circumference (cm) ≥ 88 94.6 ± 14.0 
(6 of 8) 
97.4 ± 18.5 
(6 of 8) 
75.1 ± 5.5 
(0 of 10) 
Fasting serum glucose (mM) ≥ 5.6 5.11 ± 1.17 
(2 of 8) 
4.58 ± 1.01 
(1 of 8) 
4.29 ± 1.09 
(1 of 10) 
TAG (mM) ≥ 1.7 1.84 ± 1.17 
(2 of 8) 
0.93 ± 0.27 
(0 of 8) 
0.74 ± 0.33 
(0 of 10) 
HDL-cholesterol (mM) < 1.3 1.08 ± 0.23 
(5 of 8) 
1.58 ± 0.42 
(2 of 8) 
1.31 ± 0.20 
(5 of 10) 
SBP (mmHg) ≥ 130 126 ± 16 
(3 of 8)  
120 ± 7 
(1 of 8) 
114 ± 5 
(0 of 10) 
DBP (mmHg) ≥ 85 77 ± 11 
(3 of 8) 
77 ± 6 
(0 of 8) 
73 ± 8 
(0 of 10) 
Data are presented as mean ± SD.  Number of participants in each group outside the IDF cutpoints supporting the presence of 
metabolic syndrome is indicated in brackets.  * denotes significant difference from HM females; # denotes significant difference from 
HY females.  Statistical significance was accepted at p < 0.05.  
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We did not observe any significant differences between breast cancer patients and HM 
females in fasting total cholesterol, LDL-cholesterol, NEFA, glycerol or TAG, however there 
was a trend towards lower HDL-cholesterol in patients compared to HM females (1.08 ± 0.23 
mM vs. 1.58 ± 0.42 mM, p = 0.083; Table 5).  Breast cancer patients demonstrated lower 
fasting HDL-cholesterol, higher fasting glycerol and higher fasting TAG, relative to HY 
females whereas HM females demonstrated higher fasting total cholesterol and glycerol 
compared to HY females.  Overall, these data suggest that breast cancer patients may be at 
increased risk for developing type 2 diabetes (Canadian Diabetes Association 2012) and 
cardiovascular disease (Heart and Stroke Foundation 2012) due to their central obesity and the 
presence of dyslipidemia, which are independent risk factors for both of these conditions.   
 
11.4 Breast cancer patients demonstrated elevated serum glucose, insulin and c-peptide during 
an OGTT compared to HM and HY females 
Fasting serum glucose was not different between the 3 groups (Table 4).  Serum 
glucose was significantly elevated at 15 min post-ingestion of the carbohydrate drink compared 
to fasting concentrations in all 3 groups (Figure 4). Interestingly, serum glucose concentrations 
returned to <6.0mM at 150 min, 120 min and 60 min post-ingestion in breast cancer patients, 
HM females and HY females, respectively.  As we hypothesized, this suggests that breast 
cancer patients are less adept at clearing glucose following an oral carbohydrate challenge 
compared to HM females, and that both patients and HM females are less adept at clearing 
glucose compared to HY females, despite that average fasting serum glucose was not different 
between the 3 groups.  
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Table 5. Fasting lipids in breast cancer patients, HM females and HY females 
 Breast cancer patients HM females HY females 
Total cholesterol (mM) 4.12 ± 0.75 4.47 ± 0.79# 3.74 ± 0.37 
HDL-C (mM) 1.08 ± 0.23# 1.58 ± 0.42 1.31 ± 0.20 
LDL-C (mM) 2.20 ± 0.36 2.47 ± 0.57 2.09 ± 0.45 
NEFA (mM) 0.574 ± 0.220  0.708 ± 0.288 0.462 ± 0.214 
Glycerol (µM) 115.7 ± 59.2# 167.1 ± 95.3# 55.7 ± 23.0 
TAG (mM) 1.84 ± 1.17# 0.93 ± 0.27 0.74 ± 0.33 
Data are presented as mean ± SD.  * denotes significant difference from HM females; # denotes significant difference from HY 
females.  Statistical significance was accepted at p < 0.05.  
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Figure 4 Serum glucose during an OGTT for all participant groups.  Error bars represent standard deviation.  * denotes 
significant difference from HM females; # denotes significant difference from HY females; a denotes significant difference from 
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Breast cancer patients     HM females    HY females 
Figure 5 Serum glucose AUC during an OGTT across all participant groups.  Black diamonds, squares and triangles represent 
individual data points for breast cancer patients, HM females and HY females, respectively. No significant differences were 
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Figure 6 Serum insulin during an OGTT for all participant groups.  Error bars represent standard deviation.  * denotes 
significant difference from HM females; a denotes significant difference from fasting values within group.  Statistical significance 
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Figure 7 Serum insulin AUC during an OGTT across all participant groups.  Black diamonds, squares and triangles represent 
individual data points for breast cancer patients, HM females and HY females, respectively.  No significant differences were observed 
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When we examined differences in glucose concentrations between groups at individual 
time-points during the OGTT, breast cancer patients demonstrated higher serum glucose at 30 
min compared to HM females (8.62 ± 2.28 mM vs. 7.26 ± 1.94 mM, respectively, p = 0.010; 
Figure 4A), and higher serum glucose at 45 and 60 min compared to HY females.  There was 
no significant difference in serum glucose between HM females and HY females at any time-
point during the OGTT.  Glucose AUC between patients, HM and HY groups did not differ 
(400 ± 359 mM*min vs. 237 ± 179 mM*min vs. 175 ± 124 mM*min; Figure 5).  
We observed no difference in fasting insulin concentrations between any of the groups.  
However, similar to glucose, serum insulin was significantly elevated at 15 min post-ingestion 
of the carbohydrate drink compared to fasting concentrations for all groups (Figure 6).  
Interestingly, insulin remained elevated for the duration of the OGTT for the breast cancer 
patients and until 150 min for the HM and HY groups.  When we compared serum insulin 
concentrations between groups at individual time-points during the OGTT, we observed that 
patients demonstrated almost double the concentrations of serum insulin compared to HM 
females at 150 min (37.8 ± 26.5 µIU/mL vs. 21.6 ± 15.7 µIU/mL, p = 0.025). Although serum 
insulin concentrations tended to be higher in breast cancer patients compared to HY females at 
120 and 150 min, these differences were not significant. We also observed a trend towards 
higher insulin AUC in the breast cancer patients compared to HM females (10170 ± 6193 
µIU/mL*min vs. 7257 ± 3530 µIU/mL*min, p = 0.051; Figure 7).  
Fasting serum c-peptide was significantly elevated in breast cancer patients compared 
to HM and HY females (2.6 ± 1.2 ng/mL, 1.9 ± 0.8 ng/mL and 1.5 ± 0.6 ng/mL, respectively; p 
= 0.005 in patients vs. HM; p = 0.015 in patients vs. HY; Figure 8).  Serum c-peptide followed 
a similar pattern to serum glucose and insulin and was elevated at 15 min post-ingestion of the	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Figure 8 Serum c-peptide during an OGTT for all participant groups.  Error bars represent standard deviation.  * denotes 
significant difference from HM females; # denotes significant difference from HY females; a denotes significant difference from 
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Figure 9 Serum c-peptide AUC during an OGTT across all participant groups.  E Black diamonds, squares and triangles 
represent individual data points for breast cancer patients, HM females and HY females, respectively.  No significant differences 
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Figure 10 Plasma glucagon during an OGTT for all groups. Error bars represent standard deviation.  No significant differences 
from fasting concentrations were observed within groups.  When individual time-points were compared across groups, no significant 
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     Breast cancer patients             HM females      HY females 
Figure 11 Plasma glucagon AUC during an OGTT across all participant groups.  Black diamonds, squares and triangles represent 
individual data points for breast cancer patients, HM females and HY females, respectively.  No significant differences were observed 
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carbohydrate drink compared to fasting values for breast cancer patients, HM females and HY 
females, and remained elevated in all 3 groups until 180 min.  When we compared the 3 groups 
at individual time-points throughout the OGTT we observed that c-peptide concentrations in 
breast cancer patients remained elevated relative to both non-malignant groups until 120 
(breast cancer patients), 150 (HM group) and 180 (HY group) min, indicating that there was 
continued insulin secretion later in the OGTT protocol for breast cancer patients compared to 
the non-malignant groups.  This is in line with the elevated insulin concentrations observed in 
patients compared to the non-malignant females.  We observed no significant differences in 
serum c-peptide between HM and HY females.  However, similar to the insulin results, we 
observed a trend towards greater c-peptide AUC in the breast cancer patients compared to HM 
females (1236 ± 499 ng/mL*min vs. 921 ± 336 ng/mL*min, p = 0.051; Figure 9).  
Plasma glucagon was not elevated post-ingestion of carbohydrate compared to fasting 
values for any of the groups (Figure 10), and we did not observe any significant differences in 
plasma glucagon between any of the 3 groups at any time point during the OGTT. Further, 
there were no differences in plasma glucagon AUC between breast cancer patients (Figure 11; 
1224 ± 2076 pg/mL), HM females (1286 ± 1786 pg/mL) and HY females (1374 ± 2612 
pg/mL).  
Glucagon-to-insulin ratios decreased 15 min post-ingestion of the carbohydrate drink 
relative to fasting values for the breast cancer patients (Table 6; 0.05 ± 0.03 vs. 0.38 ± 0.21, p = 
0.004), HM females (0.05 ± 0.03 vs. 0.29 ± 0.27, p = 0.026) and HY females (0.07 ± 0.05 vs. 
0.43 ± 0.24, p < 0.001), and this depression was maintained for all groups until 120 min.  We 
observed no difference in the glucagon-to-insulin ratio between any groups at any time point 
during the OGTT, suggesting that the balance between gluconeogenesis and insulin action is	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Table 6. Glucagon-to-insulin ratio during the OGTT and insulin sensitivity indices for all participant groups 
 Breast cancer patients HM females HY females 
Glucagon:Insulin 
Average Fasting 0.38 ± 0.21 0.29 ± 0.27 0.43 ± 0.24 
15 min 0.05 ± 0.03a 0.05 ± 0.03a 0.07 ± 0.05a 
30 min 0.04 ± 0.01a 0.04 ± 0.03a 0.05 ± 0.02a 
45 min 0.03 ± 0.01a 0.03 ± 0.02a 0.04 ± 0.02a 
60 min 0.04 ± 0.03a 0.04 ± 0.02a 0.05 ± 0.05a 
90 min 0.05 ± 0.04a 0.03 ± 0.02a 0.06 ± 0.05a 
120 min 0.06 ± 0.04a 0.05 ± 0.03a 0.08 ± 0.06a 
150 min 0.16 ± 0.19 0.17 ± 0.19 0.21 ± 0.23 
180 min 0.29 ± 0.31 0.22 ± 0.22 0.31 ± 0.23 
Insulin sensitivity 
HOMA-IR 1.63 ± 1.53 1.91 ± 1.69 1.14 ± 0.60 
Matsuda Index 7.98 ± 7.37 7.66 ± 4.83 7.68 ± 4.06 
Data are presented as mean ± SD.  * denotes significant difference from HM females; # denotes significant difference from HY 
females; a denotes difference from average fasting value within group.  Statistical significance was accepted at p < 0.05.  
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similar between patients, HM females and HY females. As shown in Table 6, there appeared to 
be no difference in insulin sensitivity between the 3 groups, as assessed by HOMA-IR (breast 
cancer patients: 1.63 ± 1.53; HM females: 1.91 ± 1.69; HY females: 1.14 ± 0.60) and Matsuda 
Index (breast cancer patients: 7.98 ± 7.37; HM females: 7.66 ± 4.83; HY females: 7.68 ± 4.06).  
 
11.5 Inflammation was not elevated in breast cancer patients compared to HM and HY 
females.  
Although we did not observe a difference in serum CRP between breast cancer patients 
and HM females (Table 7; 7.84 ± 10.97 pg/mL in patients vs. 1.44 ± 1.50 pg/mL in HM 
females, p = 0.193), CRP in the HM females was elevated relative to HY females (0.13 ± 0.09 
pg/mL, p = 0.019).  Additionally, we observed a trend towards elevated CRP in the breast 
cancer patients relative to the HY females (p = 0.051).  Despite that serum CRP concentrations 
tended to be greater in patients and HM females relative to HY females, HY females 
demonstrated similar values to breast cancer patients and HM females for TNF-α, IL-8, IL-4 
and IL-10.  There was no difference between breast cancer patients and HM females for serum 
TNF-α, IL-6, IL-8, IL-4 or IL-10.  Serum IL-6 was elevated in HM females relative to HY 
females (10.84 ± 2.72 pg/mL vs. 7.98 ± 1.69 pg/mL respectively, p = 0.017; Table 7), and there 
was a trend towards elevated IL-6 in patients relative to HY females (10.04 ± 2.41 pg/mL vs. 
7.98 ± 1.69 pg/mL respectively, p = 0.055).  
 It is important to note that TNF-α, IL-6, IL-4 and IL-10 were not detectable in all 
samples (Table 7). In particular, TNF-α was undetectable in 4/8 breast cancer patient samples, 
6/8 HM females samples and 6/10 HY female samples.  TNF-α results should therefore be	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Table 7.  Pro- and anti-inflammatory cytokine concentrations for all participant groups 
 Breast cancer patients HM females HY females 
Pro-inflammatory 
TNF-α (pg/mL) 8.94 ± 3.06 (n=4) 
range: 6.39 – 12.49 
10.04 ± 3.97 (n=2) 
range: 7.23 – 12.85 
7.63 ± 1.15 (n=4) 
range: 6.39 – 9.17 
IL-6 (pg/mL) 10.04 ± 2.41 (n=7) 
range: 7.33 – 13.76 
10.84 ± 2.72# (n=7) 
range: 7.02 – 15.23 
7.98 ± 1.69 (n=10) 
range: 5.22 – 9.93 
IL-8 (pg/mL) 18.26 ± 4.40 (n=8) 
range: 13.48 – 26.14 
16.49 ± 2.85 (n=8) 
range: 11.67 – 19.46  
19.54 ± 9.79 (n=10) 
range: 11.67 – 23.51 
CRP (mg/L) 7.84 ± 10.97 (n=8) 
range: 0.17 – 26.82 
1.44 ± 1.50# (n=7) 
range: 0.08 – 3.92 
0.13 ± 0.09 (n=9) 
range: 0.05 – 0.31 
Anti-inflammatory 
IL-4 (pg/mL) 8.81 ± 1.04 (n=7) 
range: 7.37 – 10.80 
8.65 ± 1.16 (n=8) 
range: 6.56 – 10.29 
8.19 ± 1.49 (n=8) 
range: 6.56 – 11.05 
IL-10 (pg/mL) 8.83 ± 1.38 (n=8) 
range: 7.14 – 10.96 
9.14 ± 2.36 (n=8) 
range: 6.73 – 12.95 
7.98 ± 1.14 (n=9) 
range: 5.64 – 9.23 
All cytokines were not detectable in every participant.  Data are presented as mean ± SD for detected values, along with number of 
participants who had detectable values in brackets. The range of values that were detected is also provided.  * denotes significant 
difference from HM females; # denotes significant difference from HY females.  Statistical significance was accepted at p < 0.05. 	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interpreted with caution, however the values we observed in the present study are similar to 
what has been observed in other studies on breast cancer patients (Appendix VII) and healthy 
overweight and lean females (Appendix VIII).  Additionally, other studies that assessed serum 
cytokines using bead array analysis have reported undetectable TNF-α levels (Appendix IX).  
 
11.6 Cardiovascular fitness and habitual physical activity was poor in breast cancer patients 
and HM females 
Breast cancer patients and HM females achieved similar VO2peak measurements during an 
incremental exercise test (27.33 ± 10.90 mL/kg/min vs. 30.61 ± 10.86 mL/kg/min respectively, 
p = 0.207; Table 8), however both patients and HM females’ VO2peak was significantly lower 
than HY females (43.41 ± 9.95 mL/kg/min).  According to the American College of Sports 
Medicine (ACSM 2009), a ‘good’ VO2max for females aged 40 – 49 yrs is 35 – 38 mL/kg/min 
(Appendix X).  Breast cancer patients and HM females fall into the ‘poor’ category of aerobic 
fitness (VO2max ≤ 31 mL/kg/min), indicating that both groups are unfit.  By comparison, HY 
females fall into the ‘good’ category of aerobic fitness for females aged 20 – 29 yrs, which is 
40 – 43 mL/kg/min.  This is not surprising since the eligibility criteria for females in this group 
included a normal BMI and engaging in recreational physical activity 3-5 times per week.  
Interestingly, 1RM for leg extension was greater in patients (59 ± 19 lbs; Table 8) and HM 
females (45 ± 8 lbs) compared to HY females (32 ± 9 lbs), suggesting that quadriceps strength 
was greater in heavier participants. We observed no differences in 1RM for forearm flexion or 
extension.	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Table 8.  Exercise assessment results (cardiovascular and strength) for all participant groups 
 Breast cancer patients HM females HY females 
Cardiovascular fitness 
VO2peak (mL/kg/min) 27.33 ± 10.90# 30.61 ± 10.86# 43.41 ± 9.95 
Strength (1RM) 
L Forearm flexion (lbs) 31 ± 5 32 ± 6 31 ± 8  
R Forearm flexion (lbs) 31 ± 6 33 ± 6 32 ± 8 
L Forearm extension (lbs) 33 ± 7 33 ± 8 28 ± 7 
R Forearm extension (lbs) 33 ± 7 34 ± 7 29 ± 7 
Leg extension (lbs) 59 ± 19# 45 ± 8# 32 ± 9 
Data are presented as mean ± SD.  * denotes significant difference from HM females; # denotes significant difference from HY 
females.  Statistical significance was accepted at p < 0.05.  
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Table 9. Comparison of subjective measures of habitual physical activity between participant groups 
 Breast cancer patients HM females HY females 
Baecke Questionnaire 
Work Index 2.03 ± 0.47 2.76 ± 1.00 2.29 ± 0.48 
Sport Index 2.81 ± 1.16 3.06 ± 0.79 3.23 ± 0.79 
Leisure Index 3.00 ± 0.63 2.92 ± 0.72 3.45 ± 0.55 
CHAMPS Questionnaire 
All exercise-related activity      
kcal/d 489 ± 290 569 ± 272 504 ± 313 
frequency/d 4 ± 1 3 ± 2 3 ± 1 
Moderate-intensity activity    
kcal/d 299 ± 245 344 ± 210 420 ± 272 
frequency/d 1 ± 1 1 ± 1 2 ± 1 
Total Energy Expenditure 
(kcal/d) 2351 ± 490 2564 ± 429 2171 ± 570 
Data are presented as mean ± SD.  Each activity on the CHAMPS questionnaire was assigned a MET value.  Kcal/d for all exercise 
related activity was calculated by summing energy expended on all activities with a MET value ≥ 2.0, for each participant; kcal/d for 
moderate-intensity activity was calculated by summing energy expended on activities with a MET value ≥ 3.0, for each participant. 
Frequency/d was calculated by dividing the number of times per week participants reported engaging in an activity by 7.  * denotes 
significant difference from HM females; # denotes significant difference from HY females.  Statistical significance was accepted at p 
< 0.05.  
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Using weight and physical activity level (PAL), we estimated that the average TEE for 
the breast cancer patients was 2351 ± 490 kcal/d.  Although we observed a trend towards lower 
TEE in the breast cancer patients compared to HM females (2351 ± 490 kcal/d vs. 2564 ± 429 
kcal/d, p = 0.053; Table 9), no significant differences in TEE existed between groups.  We 
used 2 physical activity questionnaires to assess habitual physical activity due to the wide 
range in age of all participants in the study. Using the Baecke questionnaire, breast cancer 
patients achieved a work index of 2.03 ± 0.47 (Table 9), a sport index of 2.81 ± 1.16 and a 
leisure index of 3.00 ± 0.63.  These indices represent physical activity level during work, sport 
and leisure time, with higher numbers (> 2.9, > 2.4 and > 3.1, respectively) indicating 
relatively high levels of physical activity and lower numbers (< 2.9, < 2.4 and < 3.1, 
respectively) indicating relatively low levels of physical activity (Baecke et al. 1982).  We did 
not observe any differences in any of the Baecke indices between breast cancer patients, HM or 
HY females.  Furthermore, the CHAMPS questionnaire revealed no differences between 
groups for estimates of all exercise-related energy expenditure and moderate-intensity energy 
expenditure.  Although it appears that habitual physical activity levels are similar across all 
groups, our methods of assessment were crude and subjective; the questionnaires may not have 
been sensitive or objective enough tools to discern differences in activity levels, particularly 
when compared to the VO2peak results.  
 
11.7 Energy intake did not differ between breast cancer patients, HM females and HY females 
The 3-day food record revealed that daily caloric intake was similar between breast cancer 
patients (1857 ± 422 kcal/d; Figure 8), HM females (1829 ± 431 kcal/d) and HY females (1830 
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± 409 kcal/d).  The average macronutrient distribution was similar between groups and ranged 
from 47 – 54% for carbohydrate, 30 – 33% for fat and 16 – 19% for protein.  Alcohol intake 
did not differ across groups.  When we examined the Scored Patient-Generated Subjective 
Global Assessments, 3 patients indicated a self-reported decrease in weight in the 2 weeks 
prior to completing the food diary, and 5 patients reported experiencing symptoms of 
chemotherapy relating to loss of appetite (i.e. ‘foods taste funny’, ‘mouth sores’, ‘feeling full 
quickly’).  Despite these reports, the average nausea rating for patients during the 3 days they 
recorded their food intake was minimal (0.6 ± 1.0 out of 10), and appetite and tiredness rating 
did not differ between patients and control groups.  We examined the 3-day variation in caloric 
intake, macronutrient distribution and appetite and tiredness ratings between breast cancer 
patients, HM females and HY females, to explore whether breast cancer patients demonstrated 
greater inconsistency in their diets.  However variation across days was similar for all 
parameters for all groups.	  
	   76 
 
    Breast Cancer Patients      HM females        HY females 
 
 
Figure 12 Daily caloric intake and macronutrient distribution for all participant groups.  Error bars represent standard deviation.  
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12.0 Discussion  
In the present study, we successfully matched the breast cancer patients to HM females 
for age and BMI.  Patients and HM females were overweight according to BMI and 
demonstrated similarities in other aspects of body composition, including a high percent body 
fat (>30%) and abdominal adiposity.  Furthermore, both of these groups differed significantly 
from the HY females, who were younger, with a normal BMI.  Thus, we were successful in 
establishing our proposed model (Figure 1): a comparison of metabolic parameters, exercise 
and nutrition a) between breast cancer patients and non-malignant females of similar age and 
body composition, and b) between non-malignant, young females with a normal BMI and the 
two aforementioned groups.   
Both breast cancer patients and HM females exhibited abdominal obesity, which is an 
independent risk factor for secondary diseases like diabetes and cardiovascular disease. 
Overall, patients also presented with metabolic syndrome and dyslipidemia.  During an OGTT, 
serum glucose concentrations were greater at early time points and took longer to reach 
<6.0mM in breast cancer patients compared to HM and HY females.  Further, breast cancer 
patients demonstrated insulin and c-peptide concentrations that remained elevated throughout 
the entire OGTT compared with the HM and HY females, indicating continued insulin 
secretion compared to the non-malignant females.  These metabolic characteristics are of 
particular concern given that breast cancer patients are expected to gain weight in the form of 
adipose tissue over the course of treatment.  Further deleterious changes in body composition 
may worsen glucose handling, further increase insulin secretion and, ultimately, increase risk 
of secondary disease in survivorship.  We observed no differences in markers of inflammation 
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between breast cancer patients and HM females, suggesting that the differences in glucose 
metabolism between these two groups may not be attributed to systemic inflammation.  
Based on our results, neither reduced energy expenditure nor increased caloric intake 
explained the differences in glucose metabolism between breast cancer patients and HM 
females.  Both groups demonstrated similar VO2peak and strength measurements, and we 
observed no differences in habitual physical activity, as assessed by the Baecke and CHAMPS 
questionnaires.  Caloric intake, macronutrient distribution, appetite, tiredness and variation 
between days did not differ between groups.  It is possible that other factors, independent of 
physical activity level, nutrition or inflammation, are responsible for the difference in glucose 
metabolism between breast cancer patients and HM females.   
 
12.1 Breast cancer patients on average presented with poor indicators of metabolic health 
including abdominal obesity, dyslipidemia and metabolic syndrome 
Few studies have evaluated the metabolic health of patients at diagnosis, and to our 
knowledge, this is the first study to examine patients near the onset of treatment for symptoms 
of metabolic syndrome.  Despite that not all patients could be described as having metabolic 
syndrome – only 2 patients were considered to have metabolic syndrome – it is apparent that 
this group was not healthy. On average, patients were dyslipidemic in 2 elements of the lipid 
profile and 6 out of 8 patients demonstrated abdominal obesity.  Dyslipidemia and abdominal 
obesity are both strong, independent risk factors for cardiovascular disease and diabetes (Sattar 
2003).   HM females were also centrally obese, and as such, may have an increased risk of 
diabetes or cardiovascular disease. Since, on average, HM females did not present with 
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metabolic syndrome and presented with fewer indicators of metabolic disease compared to 
breast cancer patients, the risk of diabetes or cardiovascular disease is likely lower in HM 
females compared to patients. 
Based on the similarities in body composition between our patient population and the 
patients examined in other studies, our patient characteristics reflect those of a typical 
population of recently diagnosed breast cancer patients.  Patients generally presented with 
BMIs in the overweight category, as did patients in studies by Healy et al. (2010), Goodwin et 
al. (2009) and Yaw et al. (2010).  The proportion of patients in our study with a waist 
circumference > 88cm (6/8 patients or 75%) and > 30% body fat (7/8 patients or 88%) was 
similar to the proportion of patients in a study by Amaral et al. (2010) who demonstrated that 
62% of patients (or 44/71 patients) had a waist circumference of > 88cm, and 89% of patients 
(or 63/71 patients) had >30% body fat.  
The present study has revealed that breast cancer patients have unhealthy metabolic 
characteristics that accompany their breast cancer diagnosis, and that they are at risk for 
secondary disease.  Patients examined in the present study were Stage I and II; it is unknown 
whether later stage patients have worse body composition or display a higher prevalence of 
metabolic syndrome.  Advanced stage breast cancer patients tend to exhibit muscle and fat 
wasting (Prado et al. 2009; Hortobagyi et al. 1983).  Further, patients in the present study are 
likely representative of the general population of breast cancer patients based on the 
comparisons of the existing literature; however, larger scale studies are still needed.  It is 
important to bear in mind that individuals with metabolic syndrome are 5-times more likely to 
develop diabetes compared to individuals without metabolic syndrome (Stern et al. 2004).  
Furthermore, the risk of experiencing or dying from a heart attack or stroke is 3-fold and 2-fold 
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greater respectively in individuals with metabolic syndrome (Alberti et al. 2006).  Breast 
cancer patients tend to gain weight over the course of treatment, which contributes to the 
development of secondary disease in survivorship (Demark-Wahnefried et al. 2001; Demark-
Wahnefried et al. 1997; Demark-Wahnefried et al. 1993).  The findings of the present study 
underscore the importance of exercise and nutrition interventions to prevent patients from 
developing further deleterious metabolic perturbations during treatment trajectory.   
 
12.2 Breast cancer patients demonstrated impaired glucose metabolism compared to HM and 
HY females 
We are the first group to conduct OGTTs on breast cancer patients near the onset of 
treatment and compare the patients to an age- and BMI-matched non-malignant control group.  
By conducting an OGTT we were able to reveal differences in glucose metabolism between 
breast cancer patients and non-malignant females that would not have been apparent by 
examination of fasting values only.  Fasting serum glucose and fasting serum insulin were the 
same across all three groups, however during the OGTT, serum glucose concentrations took 
longer to return to <6.0 mM in patients compared to both groups of non-malignant females, 
and in HM females compared to HY females.  Interestingly, the OGTT also revealed that 
fasting insulin secretion, measured by c-peptide, was elevated in breast cancer patients relative 
to both non-malignant groups.  Moreover, breast cancer patients continued to secrete insulin 
during an OGTT for a longer period of time than HM and HY females, contributing to the 
relatively elevated insulin concentrations during the OGTT in breast cancer patients.  Despite 
that there were no differences in the insulin sensitivity indices that were calculated amongst the 
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different groups, the results of the OGTT demonstrated that glucose metabolism in patients 
may be dysregulated.   
Although patients in the present study were measured at the onset of chemotherapy, all 
patients had recently undergone surgical resection to remove the primary tumour mass.  
Despite tumour resection, it is possible that the impairments in glucose metabolism relative to 
non-malignant females that we observed resulted from lingering effects of the tumour.  
Previous studies have reported that impairments in glucose metabolism can persist in cancer 
patients post-tumour resection for 6 months (Litwin et al. 2008) to 1 year in some cases (Rex 
and Duckworth 1984), and as long as 3 years in other cases (Fogar et al. 1994).  If this is the 
case, we expect that the breast cancer patients in the present study would have exhibited a 
greater degree of glucose dysregulation had we measured them prior to tumour resection.  
However, since no studies to date have compared glucose metabolism pre- and post-tumour 
resection in breast cancer patients, we cannot be certain.    
 
12.3 Inflammation may not explain differences in glucose metabolism between breast cancer 
patients and HM females 
 No differences in serum cytokines were observed between breast cancer patients and 
HM females.  IL-6 and CRP concentrations were significantly elevated in HM females 
compared to HY females.  Breast cancer patients and HM females demonstrated similar 
unhealthy body composition, whereas HY females were normal weight according to BMI and 
demonstrated a low percentage body fat.  Previous studies have shown that serum 
concentrations of IL-6 and CRP increase along with BMI and percentage body fat (Visser et al. 
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1999; Bastard et al. 2000).  Therefore, high BMI and high percentage body fat in the breast 
cancer patients and HM females compared to the HY females is a possible explanation for the 
differences in IL-6 and CRP.  No differences in other pro- or anti-inflammatory cytokines were 
apparent between the matched participants and the HY females.  This is not altogether 
surprising, given that cytokines are distinct molecules with integrated, yet unique, roles in 
human physiology (Coppack 2007).  
Previous studies have reported significantly increased systemic concentrations of pro-
inflammatory cytokines, and significantly decreased systemic concentrations of anti-
inflammatory cytokines, in breast cancer patients compared to non-malignant females 
(Dehqanzada et al. 2007; Kozlowski et al. 2003; Tessitore et al. 2000).  There is a vast range in 
the magnitude of these differences: for example, Kozlowski et al. (2003) reported a 10-fold 
increase in IL-6, whereas Dehqanzada et al. (2007) reported a mere 1.5-fold decrease in IL-4, 
in patients versus non-malignant females.   
Obesity is also associated with increased systemic inflammation (Weisberg et al. 2003), 
likely because adipose tissue has been observed to be a source of pro-inflammatory cytokines 
such as TNF-α, IL-6 and IL-8 (Xu et al. 2003).  Further, TNF-α and IL-6 have been shown to 
interact with the insulin signaling pathway (Uysal et al. 1997; Plomgaard et al. 2005; Kim et al. 
2004), preventing GLUT4 translocation to the sarcolemma and thereby contributing to reduced 
overall glucose uptake (Lee et al. 2003; Shoelson et al. 2003; Yuan et al. 2001).  In light of the 
evidence supporting increased systemic inflammation in breast cancer patients, as well as the 
high prevalence of obesity in this population, we were led to hypothesize: firstly, that patients 
would demonstrate impairments in glucose metabolism compared to non-malignant females of 
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the same age and BMI; and secondly, that increased concentrations of pro-inflammatory 
cytokines may be responsible for this difference.  
Elevated systemic pro-inflammatory cytokines have not been consistently reported in 
breast cancer patients: Sheen-Chen et al. (1997) observed average TNF-α concentrations of 
1.47 ± 0.58 pg/mL in patients with invasive breast cancer, which is lower than the average 
TNF-α concentrations observed in non-malignant females in the present study (HM females: 
10.04 ± 3.97 pg/mL; HY females: 7.63 ± 1.15 pg/mL).  Other studies have reported similarly 
low concentrations for IL-6 and IL-8 in breast cancer (Pusztai et al. 2004; Dehqanzada et al. 
2007).  Additionally, high concentrations of pro-inflammatory cytokines have been observed in 
normal-weight non-malignant females (De Lorenzo et al. 2007; Ferguson et al. 2004).  Kim et 
al. (2006) observed IL-8 concentrations as high as 120 pg/mL in a relatively young group of 
non-malignant females (age: 37 ± 6 yrs).  Discrepancies regarding concentrations of pro-
inflammatory cytokines in patients and non-malignant individuals may have arisen due to 
different methods of measurement (i.e. ELISA vs. bead array), staging of patients or timing of 
testing patients.  Not all studies stratified their patients into clinical or tumour stage, which 
may have had an effect on systemic inflammation.  As well, it was unclear whether these 
studies controlled for cycles of chemotherapy; concentrations of pro-inflammatory cytokines 
might have varied depending on whether patients were tested immediately prior to or 
immediately post a dose of chemotherapy.   
In light of the ambiguous evidence regarding systemic inflammation, it is possible that 
some other factor(s) is(are) responsible for the difference in glucose metabolism between 
breast cancer patients and HM females in the present study.  This unknown factor may be 
tumour-related since the present study observed no differences in other factors that might play 
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a role in impairments in glucose metabolism, such as unhealthy body composition, excess 
energy intake and reduced energy expenditure.  Patients in the present study had previously 
undergone tumour resection, however previous studies have shown that impairments in glucose 
metabolism can persist for months following tumour resection in cancer patients (Fogar et al. 
1994; Litwin et al. 2008).   
 
12.3.1 Body composition, activity levels and nutrition may not explain differences in glucose 
metabolism between breast cancer patients and HM females 
Body composition (adiposity and lean tissue mass) (Kohrt and Holloszy 1995; 
Shoelson et al. 2007), activity levels (Karelis et al. 2008) and nutrition (Park et al. 2011) have 
been well established as factors that can influence glucose metabolism.  However, we observed 
no differences in any of these parameters between breast cancer patients and HM females.  
Excess adiposity contributes to glucose dysregulation in several ways.  Increased rates of 
lipolysis allow fatty acids to accumulate in the liver, where they inhibit the suppression of 
glucose release (Shoelson et al. 2007), and in skeletal muscle where they interfere with insulin 
signaling and glucose uptake (Griffin et al. 1999; Perseghin et al. 1999).  When NEFAs 
accumulate in muscle cells they compete with glucose as an energy substrate (Fanelli 1993).  
Additionally, NEFAs have been shown to stimulate PKCθ, an inhibitor of PI3 kinase (Griffin 
et al. 1999).  PI3 kinase is an integral component of the insulin signaling pathways that leads to 
translocation of GLUT4 to the sarcolemma for glucose uptake.  Skeletal muscle of individuals 
with greater adiposity also contains more fatty acid transporters (FAT/CD36), at the expense of 
GLUT4 transporters (Bonen 2004).  This reduces the amount of glucose that can be taken up 
	   85 
by skeletal muscle.  As such, individuals with greater adiposity often demonstrate glucose 
dysregulation.   
Similarly, individuals with reduced lean tissue mass also tend to demonstrate glucose 
dysregulation.  Lean mass, or more specifically skeletal muscle mass, is a major site for 
glucose uptake during an OGTT (Katz et al. 1983; Ferrannini et al. 1985).  Kalyani et al. 
(2012) performed lower-limb CT scans and 2-hr OGTTs on 587 non-diabetic adults aged 26-95 
years.  Kalyani et al. (2012) found that at 2 hours during the OGTT, serum glucose was greater 
in participants with muscle cross-sectional area (CSA) in the lowest quartile compared to 
participants with muscle CSA in the highest quartile (Q1: 6.69 ± 1.72 mM vs. Q4: 5.81 ± 1.64 
mM, p < 0.001).  Muscle CSA was also inversely correlated with fasting glucose, fasting 
insulin, glucose and insulin AUC, and insulin resistance.  Similarly, Srikanthan et al. (2010) 
observed a positive association between sarcopenia and insulin resistance in 9892 middle-aged 
non-obese and obese adults.  We observed no difference in percent body fat or waist 
circumference in breast cancer patients compared to HM females in the present study.  
Although we did not measure lean tissue, our lean tissue estimates (based on skin-fold 
measures) in breast cancer patients were similar to the lean tissue estimates and measurements 
in HM females.  Without DXA measurements for the breast cancer patient group we cannot be 
certain that no differences in lean tissue mass exist between patients and HM females.  
However, based on our results adiposity and lean tissue likely do not account for differences in 
glucose metabolism.  
Active, normal weight females typically exhibit healthier glucose metabolism 
compared to sedentary females of similar body composition (Karelis et al. 2008), and this 
distinction has also been demonstrated in overweight and obesity.  In an observational study, 
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Ekelund (2007) assessed physical activity energy expenditure (PAEE), % body fat, fasting 
glucose and 2-hr glucose in 217 overweight females at baseline and after 5.6 years.  After 5.6 
years, females who had increased their PAEE of their own volition had also exhibited 
improvements in fasting and 2-hr glucose despite no change in body fat or VO2max.  In the 
present study, both breast cancer patients and HM females achieved an average VO2peak 
significantly lower than HY females; HY females achieved a ‘good’ cardiovascular fitness 
level for their age.  The discrepancy in VO2peak between breast cancer patients and HM females 
compared to the HY females alludes to an increased level of physical activity in the HY 
females.  This increased physical activity is likely a contributing factor to the improvements in 
glucose metabolism in HY females compared to the 2 older groups.  We observed no 
difference in objective measures of physical fitness (VO2peak, strength) or subjective measures 
of habitual physical activity (Baecke and CHAMPS questionnaire scores) between patients and 
HM females.  Activity levels therefore may not explain the observed differences in glucose 
metabolism between breast cancer patients and HM females.  
Excess energy intake, or overnutrition, may contribute to glucose dysregulation (Mott 
et al. 1986).  When an individual is in positive energy balance the body stores excess calories 
as adipose tissue.  Excess adipose tissue is associated with increased lipolysis and glucose 
dysregulation.  We did not observe any differences in daily caloric intake, macronutrient 
distribution, tiredness, appetite or variation in diet between groups when we examined the 3-
day food records.  Similar dietary intake across breast cancer patients, HM females and HY 
females does not support our hypotheses, and is not consistent with the literature regarding 
breast cancer and dietary habits. This suggests that overnutrition may not be a contributing 
factor to impaired glucose metabolism in the patient group.   
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It is important to bear in mind that daily caloric intakes reported by participants in the 
present study are likely underestimates.  We estimated, using 3-day food records, that breast 
cancer patients and HM females consumed 1857 ± 422 kcal/d and 1829 ± 431 kcal/d 
respectively.  Park et al. (2011) observed using doubly labeled water that healthy Japanese 
females of a similar age and BMI (mean age: 52.4 ± 9.4 years, BMI: 24.7 – 40.0 kg/m2) 
consumed 2373 ± 363, which is roughly 30% greater than the estimates for breast cancer 
patients and HM females.  Underestimates of daily caloric intake were observed in the HY 
control group as well: females of normal BMI in the study by Park et al. (2011) consumed 
roughly 22% more per day compared to HY females (2229 ± 297 kcal/d vs. 1830 ± 409 kcal/d, 
respectively).  Studies validating 3, 7 and 14-day food records against doubly labeled water 
have observed under-reporting in food records by 32% (Prentice et al. 1986), 46% (Platte et al. 
1995) and 58% (Trabulsi and Schoeller 2001).  It is not surprising that participants in the 
present study under-reported because the act of completing a food diary can both consciously 
and unconsciously cause participants to alter their eating habits.  Further, under-reporting is 
more prevalent among overweight and obese individuals.  A more objective measurement of 
nutrition might have revealed differences in caloric intake or macronutrient distribution 
between groups. 
Chemotherapy may have an effect on glucose metabolism, however investigation into 
this hypothesis is limited.  The development of diabetes and glucose intolerance has been 
observed in patients with acute lymphocytic leukemia (Weiser et al. 2004) and colorectal 
cancer (Feng et al. 2012) who were treated with chemotherapy and who were non-diabetic 
prior to treatment.  Only one study to date has examined the effects of chemotherapy on 
glucose metabolism in breast cancer patients: Hickish et al. (2001) observed that fasting blood 
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glucose was increased following the completion of all cycles of chemotherapy relative to 
diagnosis in non-diabetic patients.  Patients in the studies by Weiser et al. (2004), Feng et al. 
(2012) and Hickish et al. (2001) had all received 5-fluorouracil-based chemotherapy, and it 
may be that this particular chemotherapy regimen is responsible for the observed impairments 
in glucose metabolism.  In the present study, no patients received 5-fluorouracil-based 
chemotherapy.  Furthermore, the study by Hickish et al. (2001) suggests that the effects of 
chemotherapy on glucose metabolism may only become apparent in later cycles, towards the 
completion of treatment, and patients in the present study had received only 1 or 2 cycles of 
chemotherapy at the time of assessment.  Therefore chemotherapy likely is not responsible for 
the impairments in glucose metabolism observed in the present study.  However, investigation 
into the effects of AC, ACT and TC chemotherapy on glucose metabolism is necessary before 
these regimens can be discounted as contributors to impairments in glucose metabolism. 
The differences in glucose metabolism between breast cancer patients and HM females 
align with our hypotheses; however, in contrast to our hypotheses, pro-inflammatory cytokines 
may not have contributed to this glucose dysregulation.  Systemic concentrations of pro-
inflammatory cytokines were not elevated in patients compared to HM controls.  It is possible 
that the tumour is still responsible for the impairment in glucose metabolism in breast cancer 
patients but not in the capacity we hypothesized.  Glucose is the preferred energy substrate for 
tumour tissue (Reitzer et al. 1979) and it is well documented that tumours metabolize glucose 
at a high rate (Warburg 1956; Cori and Cori 1925; Gullino et al. 1967).  Alterations to glucose 
metabolism in patients has been observed in various types of cancer (Norton et al. 1984; Carter 
et al. 1975; Yoshikawa et al. 2001; Muscogiuri et al. 2011).  While the mechanism is unknown, 
it is possible that the tumour may reduce glucose uptake in the host to increase glucose 
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available for the tumour itself.  Increased insulin secretion, as indicated by elevated c-peptide 
concentrations, might be a compensatory effect of reduced glucose uptake in peripheral tissues; 
if skeletal muscle glucose uptake is somehow inhibited, one might expect that more insulin 
would be secreted in an attempt to promote glucose uptake. 
 
12.4 The tumour might be responsible for differences in glucose metabolism between breast 
cancer patients and HM females 
 Impaired glucose metabolism in cancer patients is not a new finding.  In 1885, Freund 
first reported that patients with various types of cancer demonstrated alterations in glucose 
handling.  These results were confirmed in 1888 by Tuffier and again in 1919 by Rohdenburg 
and Edwards, who used crude OGTTs to compare glucose handling between cancer patients 
and normal controls.  In 1975, Carter et al. used a 100g 6-hr OGTT to compare breast cancer 
patients to normal controls, and reported results similar to results of the present study.  Patients 
demonstrated normal fasting glucose and insulin concentrations that were not significantly 
different from normal controls, however serum glucose took longer to return to < 6.0 mM in 
patients compared to controls (roughly 240 min vs. 150 min, respectively).  Patients and 
controls were of a similar age (mean[range]: 51[40 – 60] vs. 48[21-65]) however average BMI 
was in the normal range for the breast cancer patients and in the overweight range for the 
control group.  Given that overweight individuals are more likely to experience impaired 
glucose metabolism compared to normal weight individuals (Shoelson et al. 2007), the 
difference in BMI between patients and controls in the Carter et al. (1975) study supports the 
tumour as a potential explanation for impaired glucose metabolism in these patients.   
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More recently, Yoshikawa (2001) used euglycemic hyperinsulinemic clamps to assess 
glucose dynamics in a group of stomach, colorectal and lung cancer patients and in a group of 
non-malignant controls.  His results support previous studies that employed OGTTs: cancer 
patients demonstrated similar fasting and 120 min glucose and insulin concentrations compared 
to non-malignant controls, however overall glucose uptake in peripheral tissues was reduced in 
all cancer patients compared to non-malignant controls.  Anabolic resistance and eventual 
wasting of skeletal muscle in stomach and lung cancer patients is a common characteristic of 
advanced disease, and may be a potential explanation for the impaired glucose metabolism 
observed in the study by Yoshikawa et al. (2001).  Anabolic resistance is a state in which the 
rate of skeletal muscle protein synthesis is reduced, despite adequate supply of nutrients (Breen 
and Phillips 2011).  However, since patients were weight stable and resting energy 
expenditure, measured using indirect calorimetry, was similar in patients and controls in the 
Yoshikawa et al. (2001) study, it is unlikely that anabolic resistance was responsible.  
Yoshikawa et al. (2001) postulated that reduced glucose uptake in cancer was tumour-driven.  
If this is the case, lingering impairments in glucose metabolism might persist in patients who 
have undergone tumour resection (Litwin et al. 2008).  
 Tumour size is positively correlated with degree of glucose impairment.  Muscogiuri et 
al. (2011) used euglycemic hyperinsulinemic clamps to assess glucose dynamics in adrenal 
incidentaloma patients and non-malignant controls, and CT imaging to assess size of the 
tumour.  Muscogiuri et al. (2011) observed that glucose uptake in peripheral tissues was lower 
in patients compared to non-malignant controls (25.4 ± 10.0 µmol/kg/min vs. 32.5 ± 13.3 
µmol/kg/min, p < 0.05).  There was no statistical difference in BMI, fat mass or lean tissue 
mass (measured using DXA) observed between patients and controls.  Further, tumour mass 
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was inversely correlated with insulin sensitivity (R = - 0.57, p = 0.04).  Muscogiuri et al. 
(2011) hypothesized that the relationship between tumour size and degree of glucose 
intolerance in cancer patients might be explained by the high glucose requirement of tumours.  
They suggested that the tumour might secrete some unknown factor to increase glucose 
availability or prevent glucose uptake by the host’s peripheral tissues.  If the hypothesis put 
forth by Muscogiuri et al. (2011) is correct, removal of the tumour should improve glucose 
metabolism in the patient, at least to a certain extent.  It is unlikely that the patient’s tissues 
will resume a metabolic state equivalent to that of a non-malignant individual immediately 
post-surgery.   
 Surgical removal of tumours is associated with improved glucose handling in cancer 
patients.  Saruc et al. (2009) examined glucose tolerance of pancreatic cancer patients pre- and 
post-surgery: pre-tumour resection 12/18 patients exhibited impaired glucose tolerance and 6 
weeks post-tumour resection only 5/18 patients exhibited impaired glucose tolerance.  Similar 
improvements in glucose handling post-tumour resection were observed by Permert et al. 
(1993) and Ohtsuka et al. (2009).  Other studies have suggested that while improvements in 
glucose handling following tumour-resection do occur, there is likely a lingering impairment in 
glucose handling that persists for an unidentified length of time.  For example, Litwin et al. 
(2008) observed that the percentage of patients with normal glucose tolerance improved 
following tumour-resection for pancreatic cancer, and continued to improve for at least 6 
months post-tumour resection (proportion of patients with normal glucose tolerance: 15% pre-
tumour resection, 39% 2 months post-tumour resection and 45% 6 months post-tumour 
resection).  Cancer patients in a study by Fogar et al. (1994) showed improvements in glucose 
tolerance following tumour resection, however these improvements were observed as early as 2 
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months in some patients and as late as 40 months (3.3 years) in other patients.  Patients in the 
present study underwent tumour resection prior to the OGTT, however we still observed 
impairments in glucose metabolism at the time of evaluation that cannot be attributed to 
adiposity, physical activity levels or nutrition.   
It is important to bear in mind that although Permert et al. (1993), Fogar et al. (1994), 
Litwin et al. (2008) and Midorikawa et al. (2001) observed improvements in glucose 
metabolism following tumour-resection, none of these studies compared glucose metabolism in 
patients to a non-malignant control group.  Furthermore, none of these studies reported glucose 
or insulin values during the OGTTs conducted in their studies, nor did they present the glucose 
or insulin curves.  They only reported whether the status of patients had changed from diabetic 
to impaired glucose tolerance or normal glucose tolerance, or from impaired glucose tolerance 
to normal glucose tolerance.  Importantly, although glucose metabolism may improve 
following tumour resection in cancer patients, patients may still be impaired relative to non-
malignant individuals.  Post-tumour resection in the study by Midorikawa et al. (2001), steady-
state plasma glucose (SSPG; a measure of glucose metabolism) improved to approximately 7.5 
mM.  However, Suzuki et al. (1999) has previously reported that SSPG in normal glucose 
tolerant, non-malignant females was 4.72 ± 0.28 mM.  We have seen in the present study that 
although breast cancer patients are considered to have normal glucose tolerance (fasting 
glucose < 5.6 mM and 120 min glucose < 7.8 mM), glucose concentrations take longer to 
return to < 6.0 mM compared to HM females.  Thus, although breast cancer patients in the 
present study were considered to have normal glucose tolerance, their glucose handling was 
impaired compared to HM females.  
	   93 
Impairments in glucose metabolism have been observed in numerous studies on various 
types of cancer (Norton et al. 1984; Rohdenburg et al. 1919; Freund 1885).  Further, the 
impairments observed in these studies were similar to the impairments observed in the present 
study (i.e. normal fasting glucose but reduced glucose clearance compared to non-malignant 
controls during an OGTT) (Carter et al. 1975; Norton et al. 1984; Yoshikawa et al. 2001).  
Considering that the degree of glucose impairment is correlated with tumour size (Muscogiuri 
et al. 2011), and that surgical resection of the tumour may improve glucose metabolism to a 
certain degree (Saruc et al. 2009), it is possible that impairments in glucose metabolism 
observed in breast cancer patients in the present study may have been worse if we had 
collected the data pre-tumour resection.  Therefore the pattern of glucose, insulin and c-peptide 
that we observed during the OGTT post-tumour resection may in fact be relative improvements 
compared to pre-tumour resection.   
Cell culture work has been conducted to elucidate the mechanism responsible for 
impaired glucose metabolism in cancer.  Isaksson et al. (2003) observed that skeletal muscle 
isolated from pancreatic patients was less responsive to physiological concentrations of insulin 
compared to non-malignant controls.  Further, they observed that the impairments in insulin 
signaling were specific to glucose transport across the sarcolemma and PI3K activity.  
Decreased glycogen synthase activity was also observed in skeletal muscle of humans and 
rodents with pancreatic cancer compared to controls.  Basso et al. (2002) attempted to identify 
the postulated factor secreted by tumours that may impair glucose metabolism in cancer 
patients by fractionating tumour-conditioned media into portions of separate molecular 
weights.  They then observed that impairments in glucose metabolism in rat hepatocytes were 
induced by fractions of the media comprised of proteins with molecular weights as low as 10 
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kDa.  Most cytokines have molecular weights greater than 20 – 30 kDa, suggesting that the 
factor responsible for impaired glucose metabolism in patient tissues may not be a pro-
inflammatory cytokine.  It is important to note that Isaksson et al. (2003) and Basso et al. 
(2002) both conducted their experiments using tissues from humans and animals with 
pancreatic cancer.  Due to the location of the tumour, inherent alterations to glucose 
metabolism may be expected, and it difficult to know whether these alterations would be 
present in tissues from breast cancer patients.  Nonetheless, further investigation into this 
unidentified protein is warranted, and should be the focus of future studies.   
 
12.5 Methodological Limitations 
This study was underpowered owing to its small sample size (power calculations are 
provided in Appendix XI).  We observed many trends that might have reached significance had 
we had more participants (for example, differences in insulin and glucose AUC between 
groups).  A larger sample size would have reduced the heterogeneity of all groups; 2 breast 
cancer patients had BMIs in the normal weight category and 1 patient demonstrated healthy 
glucose handling, which likely contributed to the large standard deviations in the present study.  
Other important limitations include lack of DXA scans in the breast cancer patient group, sub-
optimal measurement tools for assessment of energy expenditure, and not controlling for lean 
tissue mass or physical activity levels when recruiting HM females.  Based on our results, it 
appears as though there is no difference in lean tissue between patients and HM females, 
however since we have shown in Methods (Section 10.5.1 Body Composition) that lean tissue 
calculated from skinfold measurements tends to underestimate true lean tissue mass by roughly 
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2.5 kg, it is difficult to draw accurate conclusions.  It is possible that this error may be more 
pronounced in obese individuals or in breast cancer patients.  Additionally, skinfolds are less 
sensitive than DXA; differences in lean tissue or even fat mass between breast cancer patients 
and HM females might have been apparent if DXA was used.  Therefore, differences in body 
composition between breast cancer patients and HM females potentially may have been 
masked by the relatively low precision of the skinfold measurements. 
It is possible that the questionnaires are not sensitive enough to detect differences 
between patients and HM females. This is particularly supported by the lack of differences 
observed in habitual physical activity between HY females and the other two participant 
groups.  Considering that the HY females had achieved significantly higher VO2peak compared 
to breast cancer patients and HM females, one would expect that physical activity 
questionnaires would align with the differences in VO2peak. Physical activity questionnaires 
rely on subjects’ accuracy, perception and honesty in reporting type, time, duration and 
intensity of physical activity. Moreover, they often provide an overestimation of physical 
activity, particularly in subjects with high percent body fat (Timperio et al. 2003; Buchowski et 
al. 1999), like the patients and HM females in the present study.  Hip-mounted accelerometers 
are objective tools for the measurement of habitual physical activity, and have been validated 
against the doubly labeled water technique for assessing energy expenditure (R = 0.73 (Bouten 
et al. 1996) and R = 0.80 (Westerterp and Bouten 1997)).  HM females may have had greater 
habitual physical activity compared to patients, and this might contribute to healthier glucose 
metabolism.  Accelerometers should be considered for use in future studies for assessing 
habitual physical activity. 
	   96 
TNF-α detection rate is low, particularly when bead array assays are employed 
(Appendix IX).  Detection rates have been reported to be as low as 0% (Dehqanzada et al. 
2007; Dabitao et al. 2011) and, what is particularly disconcerting, these low detection rates 
appear to be unpredictable.  Undetectable TNF-α concentrations were reported in populations 
with widely varying characteristics, including the elderly (Van Munster et al. 2008), breast 
cancer patients (Dehqanzada et al. 2007; Pusztai et al. 2004), HIV-positive males (Dabitao et 
al. 2011), periodontitis patients (Andrukhov et al. 2011) as well as healthy females and males 
(Mussi et al. 1997).  It has been suggested that certain therapeutic drugs and small molecules 
have the potential to induce the production of antibodies against TNF-α and produce 
undetectable serum concentrations (Tarrant 2010).  Drugs with this purported ability have not 
been catalogued, and it remains possible that certain chemotherapy drugs possess this cytokine-
neutralizing effect.  Additionally, it has been suggested that certain unknown properties of anti-
coagulants might enable the detection of serum cytokines. Acid citrate dextrose, citrate and 
lithium heparin are such anticoagulants that may enhance the detection of given cytokines 
(Tarrant 2010).  
Cytokine concentrations were undetectable in several samples, and this may also be due 
to the short half-lives of serum cytokines, of TNF-α in particular.  As outlined in our model 
(Figure 1), cytokines are secreted by adipose and tumour tissue and released into circulation.  If 
cytokine decay rate is high, serum concentrations would constitute an underrepresentation of 
cytokine production in these tissues.  The average half-life of a typical serum protein is 2-3 
weeks (Schultze and Heremans 1966); serum albumin, for example, has a half-life of 20 days.  
Therefore, most serum proteins are quite stable and can be reliably measured, provided diurnal 
and menstrual cycles, or fed/fasted state is controlled for.  Few studies have attempted to 
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characterize the kinetics of serum cytokines, and as such, no reference values for the half-lives 
of the cytokines measured in the present study exist.  Further, the studies that have assessed 
cytokine half-lives have reported widely differing values.  Oliver et al. (1993) observed that 
TNF-α had a half-life of 18.2 min, whereas Waage et al. (1989) reported a half-life of 70 ± 11 
min.  Both of these groups reported that other cytokines measured, including IL-6 and IL-8, 
peaked within 6 hours of an endotoxin challenge, after which time their serum concentrations 
declined rapidly.  The authors alluded to a complex pattern of cytokine release and interaction 
in response to septic shock and it is possible that these effects can be extrapolated to chronic 
inflammation, however no studies have examined this.  Nevertheless, it appears that the 
cytokine response to stress is transient and difficult to capture in serum. 
 
12.6 Future Directions 
 The emphasis of future studies should be on evaluating glucose metabolism in breast 
cancer patients prior to any form of treatment, including surgery and neo-adjuvant 
chemotherapy.  Cancer patients tend to present with impairments in glucose metabolism 
(Freund 1885).  The degree of impairment is positively correlated with tumour size 
(Muscogiuri et al. 2011), and tumour-resection has been shown to restore glucose metabolism 
(Saruc et al. 2009).  However, no studies to date have compared the glucose metabolism of 
breast cancer patients to non-malignant females using an OGTT both pre- and post-tumour 
resection.  Resultantly, the degree to which removal of the primary tumour mass can restore 
glucose metabolism is unknown, as well as the length of time post-tumour resection necessary 
for glucose metabolism to return to the level of a non-malignant female. 
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Glucose metabolism should be evaluated: 1) prior to tumour resection; and 2) 
immediately post-tumour resection.  Ideally, researchers should evaluate glucose metabolism at 
regular intervals prior to initiation of adjuvant chemotherapy or radiotherapy, to help establish 
whether lingering effects of the tumour on glucose clearance exist, as well as whether glucose 
handling returns to the pattern observed in non-malignant controls.  However, it is becoming 
increasingly common to initiate chemotherapy as soon as possible after tumour resection, 
which may render this study design unfeasible.   
Euglycemic hyperinsulinemic clamps would be the ideal technique to include in future 
studies because they would indicate whether abnormalities in glucose metabolism were due to 
reduced glucose uptake in peripheral tissues or impaired suppression of hepatic glucose 
release.  Clamp procedures are long and it may be an excessive burden in a cancer patient 
population.  For this reason, although OGTTs are inferior, they may be a more feasible choice 
in this type of study.  In the present study we presented evidence against inflammation as an 
explanation for impaired glucose metabolism in breast cancer patients.  These results should be 
verified, and a comparison of systemic cytokine levels pre- and post-tumour resection would 
be instrumental in determining whether the lack of differences in systemic cytokines between 
groups in the present study can be attributed to prior removal of the primary tumour mass.   
Animal and cell culture studies should also be conducted to investigate some of the 
mechanisms for impaired glucose metabolism in cancer proposed in this thesis.  One such 
study might evaluate cause and effect by inducing mammary tumours in lean mice or rats.  If 
glucose handling worsens during an intraperitoneal glucose tolerance test after induction of the 
tumour, it would suggest the tumour is the cause of impairments in glucose metabolism (Ahrén 
and Andrén-Sandberg 1993).  A secondary study might evaluate whether removal of tumours 
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in these animals would improve glucose metabolism (Norton et al. 1984).  This series of 
studies should also be repeated in obese animals to observe whether, and to what degree, 
glucose metabolism is worse in obese animals with mammary tumours compared to lean 
animals.  The study conducted by Isaksson et al. in 2003 on the response of skeletal muscle 
from a pancreatic cancer patient to insulin should be repeated in skeletal muscle from breast 
cancer patients.  If the cells are less responsive than expected to physiological concentrations 
of insulin it will confirm that insulin signaling in skeletal muscle of a breast cancer patient is 
dysregulated.  Another interesting experiment would be to co-culture human myocytes with 
breast tumour tissue and observe the growth of myocytes (Larsen and Crowe 2009).  
Impairments in myocyte growth, glucose uptake or responsiveness to insulin might indicate a 
direct effect of the tumour.  It may also be possible to isolate the proteins secreted by the 
tumour that might elicit this response in the myocytes and determine their identity.   
The present study identified breast cancer patients as abdominally obese, dyslipidemic 
and as having metabolic syndrome.  Our study highlighted the importance of exercise and 
nutrition interventions during treatment to prevent anticipated gains in fat mass and counter the 
development of diabetes and cardiovascular disease in survivorship.  Large-scale nutrition and 
exercise intervention studies will reveal whether impairments in glucose metabolism can be 
prevented during treatment trajectory and improve the quality of life of breast cancer survivors.  
Future studies might also examine local fat and muscle biopsies to evaluate local versus 
systemic inflammation.  
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13.0 Conclusions  
The first major conclusion of the present study is that breast cancer patients are at 
increased risk for cardiovascular disease and diabetes at the onset of treatment.  Patients 
presented on average with metabolic syndrome, and as such are at an increased risk of heart 
attack or stroke compared to individuals without metabolic syndrome (Alberti et al. 2006).  
Further, patients presented with abdominal obesity and dyslipidemia, which are independent 
risk factors for cardiovascular disease (Eckel and Krauss 1998) and diabetes (Chan et al. 1994).  
A large body of evidence suggests that breast cancer patients gain fat and lose muscle during 
treatment and in survivorship (Demark-Wahnefried et al. 2001; Demark-Wahnefried et al. 
1997; Demark-Wahnefried et al. 1993).  Fewer studies have examined patients at or near 
diagnosis, however these studies consistently suggest that patients are overweight or obese 
prior to beginning chemotherapy (Amaral et al. 2010; Yaw et al. 2010; Healy et al. 2010).  The 
results of the present study lend additional support to this body of literature.  Importantly, our 
study highlights the need for exercise and nutrition intervention studies to counter the further 
unhealthy changes in body composition that are anticipated during treatment. 
The second major conclusion of the present study is that glucose metabolism is 
impaired in breast cancer patients compared to non-malignant females of the same age and 
BMI.  During an OGTT, serum glucose in breast cancer patients took longer to return to < 6.0 
mM compared to HM and HY females.  Insulin secretion, as indicated by serum c-peptide 
concentrations, was both elevated at fasting and prolonged during the OGTT in patients 
compared to HM females.  Although we hypothesized that this difference in glucose 
metabolism would be related to increased systemic inflammation as a result of the tumour, we 
observed no differences in circulating cytokines between patients and HM females.  Body 
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composition, activity levels and caloric intake, which are known to influence glucose 
metabolism, did not differ between breast cancer patients and HM females.  Alterations to 
glucose metabolism in cancer patients has been observed in other studies (Norton et al. 1984; 
Carter et al. 1975), and it is possible that an unknown factor secreted by the tumour is 
responsible.  Although patients in the present study had previously undergone tumour 
resection, lingering effects of the tumour might persist (Litwin et al. 2008) and might reduce 
glucose uptake in peripheral tissues.   
This is the first study to evaluate body composition, glucose metabolism, inflammation, 
exercise capacity and nutrition in a group of breast cancer patients near the onset of treatment.  
We are also the first to conduct OGTTs in this population and compare the patients to a non-
malignant group of females of the same age and BMI.  Our results therefore offer a unique 
perspective into the physiology and metabolic health of breast cancer patients.  Patients tend to 
develop secondary diseases like cardiovascular disease and diabetes in survivorship (Patnaik et 
al. 2011; Lipscombe et al. 2006), potentially due to unhealthy body composition near diagnosis 
and weight gain during treatment.  Based on our results, we have concluded that a separate 
tumour-related factor might be responsible for differences in glucose metabolism in breast 
cancer patients compared to HM females, and that lingering effects may be observed post-
tumour resection.  Further investigation into this factor may lead to a better understanding of 
its effects on glucose metabolism.  This may translate into more effective exercise and nutrition 
interventions that are targeted to the specific physiology and metabolism of breast cancer 
patients.    
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Appendix II  Health Status Questionnaire 
HEALTH STATUS SCREENING FORM 
STUDY: A nutritional and metabolic evaluation of healthy females 
 
Participant ID: __________________  Date:       
Date of Birth:     
Height:      Weight:    
Has your weight been stable over the last 6 months (Y/N)?     
    
SELF REPORT CHECKLIST: 
Past Health Problems: 
[ ] Epilepsy  
[ ] Emphysema, Pneumonia, Asthma, 
Bronchitis 
[ ] Heart Murmur                    
[ ] High Blood Pressure           
[ ] Disease of the Arteries 
[ ] Congenital Heart Disease    
[ ] High Cholesterol  
[ ] Heart Attack                      
[ ] Heart Operation 
[ ] Cancer 
[ ] Kidney and liver disease      
[ ] Back Injuries 
[ ] Diabetes (diet or insulin)      
[ ] Varicose Veins  
[ ] Heartburn                           
[ ] Enteritis/Colitis/Diverticulitis 
[ ] Ulcers                               
[ ] Bleeding Disorders (including intestinal tract) 
[ ] Diagnosis of any type of infectious disease
 
 
Please explain:          
              
Injuries: 
Do you have any past or present injuries that would prevent you from participating in an exercise study 
(Y/N)?        
If yes, what injuries have you sustained and when did they occur?    
            
            
Present Health: 
125 
When was the date of your last menstrual cycle?     
Are you in pre-menopause (Y/N)?     
If Yes, are you pregnant (Y/N)? ________ Nursing (Y/N)? ________ 
Are you on any oral contraceptives (Y/N)?     
 
If No, when was the last time you took oral contraceptives? ________________ 
 
In the last 2 weeks, have you experienced: 
[ ] Irregular Heart Beat  
[ ] Fatigue 
[ ] Chest Pain                    
[ ] Cough up blood 
[ ] Shortness of Breath       
[ ] Back Pain/Injury 
[ ] Persistent Cough           
[ ] Leg Pain/Injury 
[ ] Wheezing (Asthma)       
[ ] Dizziness 
[ ] Pain; If yes, where?   
126 
Please list any additional current health problems and allergies: 
            
            
             
List medications you are currently taking: 
            
            
             
Current Physical Training Status: 
I consider my physical training status to be: High [  ],   Average [  ],   Low [  ] 
List the types of physical activities that you do on a regular basis:    
           
Smoking:  
 
Never [ ]   Ex-smoker [ ]   Regular [ ]   Average # cigarettes/day          
 
Family Physician Contact Information: 
 
Name:  ___________________________ 
Address: ___________________________ 






Signature of Participant      Date 
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Appendix III Screening and Recruitment of breast cancer patients and HM females 
 
Breast cancer patients 
Beginning February 2009, newly diagnosed breast cancer patients were screened for 
eligibility for the present study by oncologists and clinical trials staff at the GRRCC, and all 
screening sheets were forwarded to this lab. To date, 361 patients have been screened. Of this 
number, 8 were eligible and consented to participate in the study (recruitment rate = 2%). Six 
of the 8 consented patients continued on to complete the 16 week pilot study.  
 
HM females 
Recruitment for HM females began September 2011. I received 222 replies to the 
advertisement for the study. As shown in Figure 1, the majority of replies originated from the 
Graduate Studies Office (GSO) Mailing List. Online advertisements were the second most 
effective method of eliciting response from the community.  
Seventy-five females were screened in the lab. The remaining 147 interested individuals 
were omitted from screening for a variety of reasons including, but not limited to:  
1. time commitment or feasibility  
2. disinterest upon learning details of the study 
3. sex 
4. no response 
 
Twenty-eight females were a match for at least one patient. We identified as many as 8 
matches for PT05, however we were only able to identify 1 match each for PT01 and PT08 
(Figure 2). 
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Appendix IV Comparison of lean tissue estimates (skinfolds) to lean tissue measurements 
(DXA) 













HM01 116.8 55.3 64.6 52.2 47.9 4.3 
HM02 76.8 48.8 37.5 39.3 40.9 -1.6 
HM03 66.0 26.9 17.8 48.6 43.6 5.0 
HM04 84.8 52.8 44.8 39.9 43.6 -3.7 
HM05 81.0 53.9 43.7 37.3 44.3 -7.0 
HM06 72.7 48.6 35.3 37.3 42.4 -5.1 
HM07 62.4 21.9 13.7 48.8 44.6 4.2 
HM08 66.0 42.6 28.1 37.7 33.2 4.5 
HY01 43.3 20.7 9.0 34.0 29.4 4.6 
HY02 51.4 19.2 9.9 40.9 34.8 6.1 
HY03 59.6 27.5 16.4 42.4 38.4 4.0 
HY04 65.9 35.0 23.1 41.8 38.6 3.2 
HY05 59.2 25.6 15.2 44.8 40.1 4.7 
HY06 55.6 23.0 12.8 42.2 37.8 4.4 
HY07 58.7 27.7 16.3 42.4 36.8 5.7 
HY08 75.9 26.1 19.8 54.3 46.8 7.4 
HY09 67.8 31.0 21.0 46.8 47.5 -0.7 
HY10 52.1 27.8 14.5 37.4 36.1 1.2 
PT01 57.4 19.9 11.4 46.0 40.6 5.4 
   Average 42.8 40.4 2.5 
   SD 5.5 5.0 4.1 
Paired t-test for estimated lean tissue mass vs. DXA lean tissue mass: p = 0.018 
  
 Agreement between the skinfolds estimate of lean tissue mass and the DXA 
measurements was also assessed using a Bland-Altman plot (Figure 1) and the method 
described by Bland and Altman (1986).  Bland-Altman plots are used to assess the validity of 
new equipment or techniques compared to a common practice method (Bland and Altman 
1986).  The plot is constructed by plotting the mean of the 2 measurements on the x-axis and 
the difference between these measurements on the y-axis.  Lines are used to indicate the mean 
of the differences as well as ± 2 standard deviations (SD).  If many data points that fall outside 
± 2SD, it suggests that the agreement between the 2 measurement techniques is poor.  Eighteen 
of 19 data points fell within ± 2SD of the mean when we compared the skinfolds estimate of 
lean tissue to the DXA measurements, suggesting that the skinfolds estimate may be similar to 
the DXA measurements.  However, 13 of the 18 data points within ± 2SD were greater than the 
mean.  This may indicate a tendency for the skinfolds estimate to overestimate lean tissue 
mass.  
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Figure 1 Bland-Altman plot to examine agreement between the estimate of lean tissue 
calculated from skinfolds and the measurements of lean tissue taken using DXA.  Solid 
line represents the mean of the differences between the skinfolds and DXA; dashed lines 
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Appendix V 3-day food record 
3-DAY FOOD DIARY 
 
Patient	  ID:____________________________	  	  
	  
Phone	  Number:	  _______________________	  
	  
Record	  Dates:	   ___________	  (DD/MM/YY)	  
	   ___________	  (DD/MM/YY)	  
	   ___________	  (DD/MM/YY)	  
	  
Your	  Most	  Recent	  Treatment	  Date:	  ___________	  (DD/MM/YY)	  
	  
University	  of	  Waterloo	  
Department	  of	  Kinesiology	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INSTRUCTIONS	  FOR	  RECORDING	  	  
DAILY	  FOOD	  INTAKE	  
	  
Your food diary will provide information for studying everything you eat and drink during a 
3-day period. This information includes total calories, types of foods, amount of protein or 
carbohydrates or fats, as well as types of nutrients. It is important to record ALL foods, 
beverages, and supplements – whether it is a full course meal at home or a quick can of pop 
at work. Before you start recording your intake, please read the following instructions and the 
Sample Day.  
 
The 3-Day Food Diary has a separate section for every day (see Day 1, Day 2, Day 3 on top 
each page).  Each day is broken up into 6 eating times: 
	  
1. Morning	  meal	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2.	  Mid-­‐morning	  snack	  
3. Mid-­‐day	  meal	  (lunch)	  	  	  	  	  	  	  	  	  	  	  	  	  4.	  Afternoon	  snack	  
5.	  	  	  Evening	  meal	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  6.	  Evening	  snack	  
	  
Please	  include	  the	  following	  information	  on	  your	  food	  record:	  
	  
1. FOOD	   AND	   BEVERAGE	   ITEMS:	   Enter	   all	   foods	   and	   beverages	   consumed	   at	   the	  
meal	  or	  snack	  time.	   	  Please	  record	  the	  specific	   type	  of	   food	  (for	  example:	  WHOLE	  
WHEAT	   bread,	   FROSTED	   FLAKES	   cereal).	   In	   the	   same	   column,	   record	   all	   items	  
added	   (examples:	   sugar,	   syrup,	   jam,	   butter,	   mayonnaise,	   gravy,	   milk,	   salt).	   For	  
combination	  foods,	  please	  include	  detailed	  information	  on	  each	  item.	  For	  example:	  	  
If	  you	  had	  a	  tuna	  sandwich,	  you	  would	  list	  the	  following	  detailed	  information:	  white	  
bread,	   mayonnaise,	   carrot,	   solid	   white	   tuna,	   salt.	  	  	  	  	  
	  
2. DESCRIPTION	   OF	   ITEM:	   For	   every	   food	   or	   beverage	   item	   listed,	   include	   the	  
following	  (if	  applicable):	  
• Brand:	  MIRACLE	  WHIP	  mayonnaise,	  PIZZA	  HUT	  DEEP	  DISH	  pizza,	  OREO	  cookie	  
• Type	  of	  flavour:	  BLUEBERRY	  muffins,	  STRAWBERRY	  yogurt	  
• Method	  of	  cooking:	  FRIED,	  BAKED,	  BBQ’D	  
• All	  relevant	  information	  on	  food	  label:	  LOW	  FAT	  ranch	  salad	  dressing,	  28%	  
M.F.	  cheddar	  cheese,	  LEAN	  Ground	  Beef	  
• 	  3. UNIT	  OF	  MEASURE:	  For	  every	  item	  consumed,	  enter	  the	  unit	  of	  measure	  you	  are	  using	  
for	  this	  item.	  	  For	  example:	  enter	  the	  word	  “cup”,	  “grams”,	  “piece”,	  “ounce”,	  “teaspoon”,	  or	  
“tablespoon”.	  	  Enter	  a	  unit	  of	  measure	  not	  only	  for	  the	  menu	  item,	  but	  for	  toppings	  or	  
items	  added	  as	  well.	  	  Each	  entry	  must	  have	  its	  own	  unit	  of	  measure.	  	  Use	  measuring	  cups	  
and	  spoons	  whenever	  possible.	  
	  
4. NUMBER	  OF	  UNITS:	  	  In	  this	  area,	  record	  the	  number	  of	  units	  consumed.	  	  Include	  the	  
amount	  of	  the	  food	  or	  beverage	  item	  and	  the	  amount	  of	  any	  topping	  or	  items	  added.	  
	  
5. Fill in the blanks on the bottom of each record.  Indicate the time of your meal or snack and 
where it was eaten (for example: at home, at a restaurant). If you did not eat a meal or snack, 
please place a check mark () in the space provided on the bottom of the page, so that we do 
not think you forgot to record it. 
 
6. Daily check: In the evening, go back over your entries to make sure you have included as 
much detail as possible for each item. At the end of each Day 1,2and 3, there are 2 questions 
that inquire about how the day you recorded compares to your normal diet. Don’t forget to 
answer these questions. 
 
All	  foods	  and	  beverages	  you	  consume	  are	  important	  (including	  water).	  Please	  be	  as	  accurate	  
as	  possible.	  Please	  do	  not	  change	  your	  normal	  eating	  habits	  for	  the	  3	  days	  you	  are	  
recording	  your	  food	  intake.	  Your	  honesty	  is	  crucial	  to	  the	  success	  of	  this	  research	  study.	  
	  
Thank	  you	  for	  your	  participation	  in	  this	  study.	  	  Please	  look	  closely	  at	  the	  Sample	  Day	  before	  
you	  start.	  	  If	  you	  have	  any	  questions,	  please	  phone:	  Dr.	  Marina	  Mourtzakis	  (519-­‐888-­‐
4567	  x38459).	  
Tips:	  
1. Carry	  your	  Food	  Diary	  with	  you	  &	  record	  your	  diet	  soon	  after	  you	  eat	  
2. Please	  record	  foods	  and	  beverages	  (including	  alcohol)	  consumed	  away	  from	  home	  (i.e.	  
at	  the	  mall,	  at	  work,	  at	  a	  restaurant)	  these	  are	  just	  as	  important	  as	  those	  eaten	  at	  home	  
3. Don’t	  forget	  to	  fill	  out	  the	  last	  2	  pages	  on	  supplements	  that	  you	  are	  currently	  taking	  
and	  the	  nutritional	  questionnaire.	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Sample Day 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  UNITS	  
Enter	  all	  foods	  and	  beverages	  consumed.	  	  For	  
combination	  foods,	  please	  include	  detailed	  
information	  on	  each	  item.	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  drink	  
item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  label	  
Enter	  unit	  of	  measure:	  for	  example:	  cup,	  
grams,	  ounce,	  piece,	  teaspoon,	  
tablespoon	  
Enter	  number	  of	  
units	  
Spaghetti with tomato/meat sauce:    
Pasta Spaghetti, cooked Cup 2 
Tomato sauce Hunt’s canned sauce, roasted garlic flavor Cup 1 
Meat balls  Made with extra lean ground beef Number (1 oz/ball) 5 
Parmesan cheese, grated Kraft, 30% Milk Fat (M.F.) Tablespoon 1 
Garlic Bread:    
Italian Bread Toasted Piece (large slice) 3 
Garlic Butter  Teaspoon 3 
Caesar salad:    
Lettuce Romaine Cup 1 
Croutons Safeway brand, garlic flavor Tablespoon 2 
Bacon bits Simulated flavour, No Name Brand Tablespoon 2 
Caesar salad dressing Kraft, Fat free Tablespoon 2 
Milk 1% Cup 1 
Tiramisu Sarah Lee  Slice 1 
Coffee Black Cup 1 
Fill in blanks: Time of meal/snack: 6:00 pm Location meal/snack was consumed:  at home                    
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 1 – Morning Meal	  
Food	  and	  Beverage	  Items	  
	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
	  
Include	  a	  detailed	  description	  of	  each	  
food	  and	  drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  
food/drink	  label	  
Enter	  unit	  of	  measure:	  for	  
example:	  cup,	  grams,	  ounce,	  
piece,	  teaspoon,	  tablespoon	  
Enter	  number	  
of	  units	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 1 – Mid-Morning Snack	  
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
	  
Include	  a	  detailed	  description	  of	  each	  
food	  and	  drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  
food/drink	  label	  
Enter	  unit	  of	  measure:	  for	  
example:	  cup,	  grams,	  ounce,	  
piece,	  teaspoon,	  tablespoon	  
Enter	  number	  
of	  units	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 1 – Mid-day Meal (lunch) 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
	  
Include	  a	  detailed	  description	  of	  each	  
food	  and	  drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  
food/drink	  label	  
Enter	  unit	  of	  measure:	  for	  
example:	  cup,	  grams,	  ounce,	  
piece,	  teaspoon,	  tablespoon	  
Enter	  number	  
of	  units	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 1 – Mid-Afternoon Snack 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
	  
Include	  a	  detailed	  description	  of	  each	  
food	  and	  drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  
food/drink	  label	  
Enter	  unit	  of	  measure:	  for	  
example:	  cup,	  grams,	  ounce,	  
piece,	  teaspoon,	  tablespoon	  
Enter	  number	  
of	  units	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 1 – Evening Meal 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
	  
Include	  a	  detailed	  description	  of	  each	  
food	  and	  drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  
food/drink	  label	  
Enter	  unit	  of	  measure:	  for	  
example:	  cup,	  grams,	  ounce,	  
piece,	  teaspoon,	  tablespoon	  
Enter	  number	  
of	  units	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 1 – Evening Snack 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
	  
Include	  a	  detailed	  description	  of	  each	  
food	  and	  drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  
food/drink	  label	  
Enter	  unit	  of	  measure:	  for	  
example:	  cup,	  grams,	  ounce,	  
piece,	  teaspoon,	  tablespoon	  
Enter	  number	  
of	  units	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	  
	   141 
Day 1 Meals	  
 
Compared to my normal diet, I ate: 
 The same amount as I would usually eat  
 
 More than I would usually eat  
 
 Less than I would usually eat  
 
Please circle how you felt today for each of the symptoms 
below: 
 
0 1 2 3 4 5 6 7 8 9 10 
Best Appetite       Worst Possible Appetite 
 
0 1 2 3 4 5 6 7 8 9 10 
Not nauseated      Worst possible Nausea 
 
0 1 2 3 4 5 6 7 8 9 10 
Not Tired       Worst possible Tiredness
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Day 2 – Morning Meal 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  
drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  
label	  
Enter	  unit	  of	  measure:	  for	  
example:	  cup,	  grams,	  





	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 2 – Mid-Morning Snack 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  
drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  
label	  
Enter	  unit	  of	  measure:	  for	  
example:	  cup,	  grams,	  





	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 2 – Mid-day Meal (lunch) 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  
drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  
label	  
Enter	  unit	  of	  measure:	  for	  
example:	  cup,	  grams,	  





	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 2 – Mid-Afternoon Snack 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  
drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  
label	  
Enter	  unit	  of	  measure:	  for	  
example:	  cup,	  grams,	  





	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 2 – Evening Meal 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  
drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  
label	  
Enter	  unit	  of	  measure:	  for	  
example:	  cup,	  grams,	  





	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 2 – Evening Snack 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  
drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  
label	  
Enter	  unit	  of	  measure:	  for	  
example:	  cup,	  grams,	  





	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 2 Meals	  
 
Compared to my normal diet, I ate: 
 The same amount as I would usually eat  
 
 More than I would usually eat  
 
 Less than I would usually eat  
 
Please circle how you felt today for each of the symptoms below: 
 
0 1 2 3 4 5 6 7 8 9 10 
Best Appetite       Worst Possible Appetite 
 
0 1 2 3 4 5 6 7 8 9 10 
Not nauseated      Worst possible Nausea 
 
0 1 2 3 4 5 6 7 8 9 10 
Not Tired       Worst possible Tiredness 
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Day 3 – Morning Meal 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  
drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  
label	  
Enter	  unit	  of	  measure:	  
for	  example:	  cup,	  grams,	  





	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 3 – Mid-Morning Snack 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  
drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  
label	  
Enter	  unit	  of	  measure:	  
for	  example:	  cup,	  grams,	  





	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 3 – Mid-day Meal (lunch) 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  
drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  
label	  
Enter	  unit	  of	  measure:	  
for	  example:	  cup,	  grams,	  





	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 3 – Mid-Afternoon Snack 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  
drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  
label	  
Enter	  unit	  of	  measure:	  
for	  example:	  cup,	  grams,	  





	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 3 – Evening Meal 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  
drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  
label	  
Enter	  unit	  of	  measure:	  
for	  example:	  cup,	  grams,	  





	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 3 – Evening Snack 
Food	  and	  Beverage	  Items	  
DESCRIPTION	  OF	  ITEM	   UNIT	  OF	  MEASURE	   NO.	  OF	  
UNITS	  
Enter	  all	  foods	  and	  beverages	  
consumed.	  	  For	  combination	  foods,	  
please	  include	  detailed	  information	  
on	  each	  item.	  
Include	  a	  detailed	  description	  of	  each	  food	  and	  
drink	  item	  consumed	  including:	  
- Brand	  name	  
- Flavour	  
- Method	  of	  cooking	  
- All	  other	  relevant	  information	  on	  food/drink	  
label	  
Enter	  unit	  of	  measure:	  
for	  example:	  cup,	  grams,	  





	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
Fill in blanks: Time of meal/snack:______________ Location meal/snack was consumed:____________ 
Please	  CHECK	  ()	  if	  you	  did	  not	  eat	  or	  drink	  at	  this	  meal	  or	  snack	  time:__________	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Day 3 Meals	  
 
Compared to my normal diet, I ate: 
 The same amount as I would usually eat  
 
 More than I would usually eat  
 
 Less than I would usually eat  
 
Please circle how you felt today for each of the symptoms below: 
 
0 1 2 3 4 5 6 7 8 9 10 
Best Appetite       Worst Possible Appetite 
 
0 1 2 3 4 5 6 7 8 9 10 
Not nauseated      Worst possible Nausea 
 
0 1 2 3 4 5 6 7 8 9 10 
Not Tired       Worst possible Tiredness 
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DAYS PILLS WERE 
TAKEN  
(EXAMPLE: DAY 1,2 OR 
3) 
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Patient	  Generated	  Subjective	  Global	  Assessment	  
Patient	  ID:	  






























1. Weight	  	  	  
In	  summary	  of	  my	  current	  and	  recent	  weight:	  
	  
My	  is	  height	  about	  ______	  feet	  /	  inches tall	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (or	  ______	  cm)	  
	  
My	  current	  weight	  is	  about	  ______	  pounds	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (or	  ______	  kg)	  	  	  	  	  	  
 
One month ago I weighed about ______ pounds 
 (or ______ kg) 
	  
Six	  months	  ago	  I	  weighed	  about	  ______	  pounds	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (or	  ______	  kg)	  
	  
During	  the	  past	  two	  weeks	  my	  weight	  has:	  
 	  decreased	  	  
 	  not	  changed	  	  
 	  increased	  	  
	   	  
2.	  Food	  Intake:	  	  	  	  
As	  compared	  to	  my	  normal	  intake,	  I	  would	  rate	  the	  




 	  more	  than	  usual	  	  
 	  less	  than	  usual	  
	  
I	  am	  now	  taking	  food	  of	  the	  following	  TYPE:	  
	  
 	  normal	  food	  	  
 	  normal	  food	  but	  less	  than	  normal	  amount	  	  
 	  little	  solid	  food	  
 	  only	  liquids	  
 	  only	  nutritional	  supplements	  
 	  very	  little	  of	  anything	  
 	  only	  tube	  feedings	  or	  only	  nutrition	  by	  vein	  
	  
	  
	   	  	  
3.	   Symptoms:	  	  I	  have	  had	  the	  following	  problems	  
that	  have	  kept	  me	  from	  eating	  enough	  during	  
the	  past	  two	  weeks	  (check	  all	  that	  apply):	  
 	  no	  problems	  eating	  	  
 	  no	  appetite,	  just	  did	  not	  feel	  like	  eating	  	  
 	  nausea	  	    	  vomiting	  	  
 	  constipation	  	    	  diarrhea	  	  
 	  mouth	  sores	  	    	  dry	  mouth	  	  
 	  things	  taste	  funny	  or	  have	  no	  taste	  
 	  smells	  bother	  me	  	  
 	  problems	  swallowing	  
 	  dental	  problems	  	  
 	  feel	  full	  quickly	  	  
 	  pain;	  where?	  	  __________	  
 	  other*	  	  _________________________	  
4.	  Activities	  and	  Function:	  	  	  
Over	  the	  past	  month,	  I	  would	  generally	  rate	  my	  
ACTIVITY	  as:	  
	  
 	  normal	  with	  no	  limitations	  	  
	  
 	  not	  my	  normal	  self,	  but	  able	  to	  be	  up	  and	  
about	  with	  fairly	  normal	  activities	  
	  
 	  not	  feeling	  up	  to	  most	  things,	  but	  in	  bed	  or	  
chair	  less	  than	  half	  the	  day	  
	  
 	  able	  to	  do	  little	  activity	  and	  spend	  most	  of	  the	  
day	  in	  bed	  or	  chair	  
	  
 	  pretty	  much	  bedridden,	  rarely	  out	  of	  bed	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Appendix VI  TNF-α ELISA protocol 
 In addition to the cytometric bead array assay, serum TNF-α was measured 
using a Quantikine High Sensitivity ELISA kit (R&D Systems Inc.; Minneapolis, MN).  Wells 
of the ELISA plate were pre-coated with mouse monoclonal antibody specific for human TNF-
α.  Following the addition of 50 µL of assay diluent to each well, 200 µL of standard, control 
or sample (undiluted) was added.  The plate was then incubated at room temperature for 3 
hour.  During this incubation period, TNF-α in the standards, controls or samples became 
bound to the antibody coated microwells.  Following the incubation, the plate was washed to 
remove all unbound substances and 200 µL of polyclonal antibody to TNF-α (conjugated to 
alkaline phosphatase) was added to each well and the plate was incubated for 2 hours.  During 
the second incubation period, the immunoconjugate became bound to the TNF-α -antibody 
complex affixed to the wells.  Following the second incubation, the plate was washed again 
and 50 µL of nicotinamide adenine dinucleotide phosphate (NADPH, an alkaline phosphatase 
substrate) was added to each well and the plate was incubated for 1 hour.  During this 
incubation NADPH reacted with the alkaline phosphatase.  50 µL of an amplifier solution 
(INT-violet) was then added to each well so that a purple colour developed in response to the 
alkaline phosphatase activity.  The plate was incubated for 30 minutes after which time 50 µL 
of 1M sulphuric acid was added to each well and the reaction was stopped.  The absorbance of 
each well was read at 650 nm and 490 nm.  Readings at 650 nm were subtracted from the 
readings at 490 nm to correct for optical imperfections in the microplate.  The amount of 
colour following subtraction was directly proportional to the concentration of TNF-α in the 
sample.   
	  
	   159 
Appendix VII Expected concentrations for serum cytokines in breast cancer patients 
 
Table 1. Expected serum concentrations for TNF-α in breast cancer patients 
Study no. Mean ± SD (pg/mL) n Population characteristics Method of assessment Reference 
1 1.47 ± 0.58 40 pre-surgery ELISA Sheen-Chen et al. 1997 
2 1.49 ± 4.40 range: 1 – 27.9 55 
age: 47 yrs 
range: 25 – 77 yrs 
stage I – III 
receiving chemotherapy 
BD CBA Pusztai et al. 2004 
3 15.9 ± 0.9 20 stage IIIb post-surgery/pre-chemotherapy ELISA Berberoglu et al. 2004 
4 21.6 ± 14.5 9 
age: 50 yrs 
range: 38 – 62 yrs 
stage II 
ELISA Jablonska et al. 2001 
5 37.1 ± 16.3 11 
age: 50 yrs 
range: 38 – 62 yrs  
stage III/IV 
ELISA Jablonska et al. 2001 
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Table 2. Expected serum concentrations for IL-6 in breast cancer patients 
Study no. Mean ± SD (pg/mL) n Population characteristics Method of assessment Reference 
1 7.55 ± 33.18 range: 0 – 244.2 55 
age: 47 yrs 
range: 25 – 77 yrs 
stage I – III 
receiving chemotherapy 
BD CBA Pusztai et al. 2004 
2 median: 18.7 range: 6.25 - 30 6 stage IIa ELISA Kozlowski et al. 2003 
3 median: 19.3 rang: 7.8 – 36.4 23 stage IIb ELISA Kozlowski et al. 2003 
4 median: 31.7 range: 6.25 - 100 45 age: 25 – 79 yrs ELISA Kozlowski et al. 2003 
5 median: 40.9 range: 7.8 - 96 12 stage IIIa ELISA Kozlowski et al. 2003 
6 median: 44.1  range: 8.4 - 100 4 stage IIIb ELISA Kozlowski et al. 2003 
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Table 3. Expected serum concentrations for IL-8 in breast cancer patients 
Study no. Mean ± SD (pg/mL) n Population characteristics Method of assessment Reference 
1 median: 2.69 range: 1.36 – 26.34 22 
age: 59.7 yrs 
52% of patients on chemotherapy; 
terminated chemotherapy an average 
of 28.7 months before beginning study 
Bead assay  
(Luminex plate) Dehqanzada et al. (2007) 
2 7.07 ± 5.21 range: 2.3 – 38.5 55 
age: 47 yrs 
range: 25 – 77 yrs 
stage I – III 
receiving chemotherapy 
BD CBA Pusztai et al. 2004 
3 median: 33.6 range: 7.8 – 60 6 stage IIa ELISA Kozlowski et al. 2003 
4 median: 35.2 range: 7.8 – 76 23 stage IIb ELISA Kozlowski et al. 2003 
5 median: 36.3 range: 7.8 – 60 12 stage IIIa ELISA Kozlowski et al. 2003 
6 median: 40.1 range: 7.8 - 76 45 age: 25 – 79 yrs ELISA Kozlowski et al. 2003 
7 median: 48.8 range: 8 – 75 4 stage IIIb ELISA Kozlowski et al. 2003 
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Table 4. Expected serum concentrations for IL-10 in breast cancer patients  
Study no. Mean ± SD (pg/mL) n Population characteristics Method of assessment Reference 
1 median: 1.55 range: 0.67 – 6.30 22 
age: 59.7 yrs 
52% of patients on chemotherapy; 
terminated chemotherapy an average of 
28.7 months before beginning study 
Bead assay  
(Luminex plate) Dehqanzada et al. (2007) 
2 2.30 ± 5.23 range: 0 – 35.4 55 
age: 47 yrs 
range: 25 – 77 yrs 
stage I – III 
receiving chemotherapy 
BD CBA Pusztai et al. 2004 
3 median: 18.9 range: 5.6 – 29 6 stage IIa ELISA Kozlowski et al. 2003 
4 median: 19.6 range: 6.4 – 32 23 stage IIb ELISA Kozlowski et al. 2003 
5 median: 24.7 range: 5.6 – 37 45 age: 25 – 79 yrs ELISA Kozlowski et al. 2003 
6 median: 26 range: 6.9 – 37 4 stage IIIb ELISA Kozlowski et al. 2003 
7 median: 29.9 range: 6.2 – 35 12 stage IIIa ELISA Kozlowski et al. 2003 
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Table 5. Expected serum concentrations for IL-4 in breast cancer patients  
Study no. Mean ± SD (pg/mL) n Population characteristics Method of assessment Reference 
1 median: 7.2 range: 5.64 – 157.74 22 
age: 59.7 yrs 
52% of patients on chemotherapy; 
terminated chemotherapy an average 
of 28.7 months before beginning study 
Bead assay  
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Table 6. Expected serum concentrations for CRP in breast cancer patients 
Study no. Mean ± SD (mg/L) n Population characteristics Method of assessment Reference 
1 4.5 ± 5.8 14 
age: 54.6 ± 8.3 years 
BMI: 30.1 ± 3.6 kg/m2 
Stage I-IIIa 
Had completed chemo at least 3 
months prior to assessment 
Unspecified Campbell et al. 2012 
2 10.1 ± 3.9 5 Stage IIa RANDOX analyser Ravishankaran and Karunanithi 2011 
3 9.2 ± 4.6 8 Stage IIb RANDOX analyser Ravishankaran and Karunanithi 2011 
4 13.8 ± 7.2 15 Stage IIIa RANDOX analyser Ravishankaran and Karunanithi 2011 
5 12.8 ± 9.2 13 Stage IIIb RANDOX analyser Ravishankaran and Karunanithi 2011 
6 21.5 ± 9.9 10 Stage IIIc RANDOX analyser Ravishankaran and Karunanithi 2011 
7 37.5 ± 16.0 8 Stage IV RANDOX analyser Ravishankaran and Karunanithi 2011 
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Appendix VIII Expected concentrations for serum cytokines in non-malignant females 
 
Table 1. Expected serum concentrations for TNF-α in non-malignant females 
Study no. Mean ± SD (pg/mL) n Population characteristics Method of Assessment Reference 
1 0.74 ± 0.09 8 
age: 42 ± 5 yrs 
BMI: 20 kg/m2 
lean 
ELISA Bastard et al. 2000 
2 1.48 ± 0.15 14 
age: 45 ± 4 yrs 
BMI: 40 kg/m2 
obese non-diabetic 
ELISA Bastard et al. 2000 
3 1.68 ± 0.12 7 
age: 58 ± 2 yrs 
BMI: 37 kg/m2 
obese diabetic 
ELISA Bastard et al. 2000 
4 1.93 ± 2.6 range: 0.2 – 14.9 58 
age: 58 ± 6 yrs 
46.7 ± 4.7 % body fat ELISA Ryan et al. 2004 
5 2.25 ± 0.50 37 age: 57 ± 1 yrs 46.8 ± 0.8 % body fat ELISA Ryan et al. 2004 
6 2.44 ± 0.55 37 age: 57 ± 1 yrs 43.5 ± 0.8 % body fat ELISA Ryan et al. 2004 
7 median: 3.5 range: 3 – 25  10 
median age: 28.5 yrs 
age range: 25 – 77 yrs 
21 females, 9 males 
ELISA Mussi et al. 1997 
8 3.5 ± 0.7 40 age: 35 ± 5 yrs BMI: 23.1 ± 1.5 kg/m2 ELISA Mafella et al. 2004 
9 4.3 ± 2.1 48 age: 54 ± 8 yrs range: 48-63 yrs ELISA Cioffi et al. 2002 
10 5.8 ± 1.5 67 age: 36 ± 5 yrs BMI: 37.6 ± 2.1 kg/m2 ELISA Mafella et al. 2004 
11 20.10 ± 4.95 20 age: 20 – 35 yrs BMI: normal/lean ELISA De Lorenzo et al. 2007 
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Table 1 (Cont’d). Expected serum concentrations for TNF-α in non-malignant females 
Study no. Mean ± SD (pg/mL) n Population characteristics Method of Assessment Reference 
12 42.77 ± 10.54 20 age: 20 – 35 yrs BMI: normal but 35% body fat ELISA De Lorenzo et al. 2007 
13 56.37 ± 11.77 20 age: 20 – 35 yrs BMI: 25 – 35 kg/m2 ELISA De Lorenzo et al. 2007 
14 34.3 ± 9.3 8 age: 27 yrs BMI: 26 kg/m2 ELISA Ferguson et al. 2004 
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Table 2. Expected serum concentrations for IL-6 in non-malignant females 
Study no. Mean ± SD (pg/mL) n Population characteristics Method of Assessment Reference 
1 1.59 ± 0.13 37 age: 57 ± 1 yrs 43.5 ± 0.8 % body fat ELISA Ryan et al. 2004 
2 1.7 ± 0.5 67 age: 36 ± 5 yrs BMI: 37.6 ± 2.1 kg/m2 ELISA Mafella et al. 2004 
3 1.89 ± 0.12  37 age: 57 ± 1 yrs 46.8 ± 0.8 % body fat ELISA Ryan et al. 2004 
4 2.29 ± 1.47 range: 0.45 – 10.00 58 
age: 58 ± 6 yrs 
46.7 ± 4.7 % body fat ELISA Ryan et al. 2004 
5 3.9 ± 4.5 184 age: 59 ± 13 yrs BMI: normal ELISA Kip et al. 2004 
6 4.2 ± 0.9 40 age: 35 ± 5 yrs BMI: 23.1 ± 1.5 kg/m2 ELISA Mafella et al. 2004 
7 4.5 ± 4.9 269 age: 58 ± 11 yrs BMI: overweight ELISA Kip et al. 2004 
8 4.7 ± 3.8 327 age: 57 ± 11 yrs BMI: obese ELISA Kip et al. 2004 
9 median: 5.8 IQ range: 1.8 - 14 96 
age: 38 ± 9 yrs 
BMI: 24 ± 4 kg/m2 ELISA Fernandez-Real et al. 2001 
10 5.95 ± 2.28 20 age: 20 – 35 yrs BMI: normal/lean ELISA De Lorenzo et al. 2007 
11 10.9 ± 4.1 48 age: 54 ± 8 yrs range: 48 – 63  ELISA Cioffi et al. 2002 
12 11.42 ± 1.77 20 age: 20 – 35 yrs BMI: normal but 35% body fat ELISA De Lorenzo et al. 2007 
13 13.68 ± 2.29 20 age: 20 – 35 yrs BMI: 25 – 35 kg/m2 ELISA De Lorenzo et al. 2007 
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Table 3. Expected serum concentrations for IL-8 in non-malignant females  
Study no. Mean ± SD (pg/mL) n Population characteristics Method of Assessment Reference 
1 0.9 ± 0.2 20 age: 20 – 35 yrs BMI: normal/lean ELISA De Lorenzo et al. 2007 
2 2.0 ± 0.7 20 age: 20 – 35 yrs BMI: 25 – 35 kg/m2 ELISA De Lorenzo et al. 2007 
3 2.3 ± 0.6 20 age: 20 – 35 yrs BMI: normal but 35% body fat ELISA De Lorenzo et al. 2007 
4 median: 2.57 range: 0.8 – 6.63 13 
age: 18 – 51 
commercially available 
samples purchased (not 
collected by researchers) 
Bead array (Luminex 
plate) Dehqanzada et al. 2007 
5 3.24 ± 1.07  24 age: 36 ± 8 yrs BMI: 23 ± 2 kg/m2 ELISA Straczkowski et al. 2002 
6 3.6 ± 2.2* 50 age: 37 ± 6 yrs BMI: 21 kg/m2 ELISA Kim et al. 2006 
7 4.31 ± 1.43 30 age: 40 ± 11 yrs BMI: 33 ± 3 kg/m2 ELISA Straczkowski et al. 2002 
8 7.2 ± 0.3** range: < 5 - 9 15 
age: 46 – 70 yrs 
7 males, 8 females 
Immulite Assay (Bead 
Assay) Doganay et al. 2002 
9 16.7 ± 22.4* 50 age: 37 ± 6 yrs BMI: 31 kg/m2 ELISA Kim et al. 2006 
10 17.9 ± 0.4** range: 15 - 21 19 
age: 57 – 72 yrs 
9 males, 10 females 
diabetic 
Immulite Assay (Bead 
Assay) Doganay et al. 2002 
* values as high as approximately 50 – 120 pg/mL were noted 
** IL-1beta and IL-6 were below detection limit (5.0 pg/mL) in all samples; IL-8 was detectable in 87% of controls and 89% of 
diabetics; TNF-alpha detectable in 87% of diabetics 
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Table 4. Expected serum concentrations for IL-10 in non-malignant females 
Study no. Mean ± SD (pg/mL) n Population characteristics Method of Assessment Reference 
1 
median: 1.2* 
(25% - 0.7,  
75% 2.9) 
50 age: 36 ± 5 yrs BMI: 23.8 ± 1.2 kg/m2 ELISA Esposito et al. 2003 
2 median: 1.66 range: 0.24 – 2.67 13 
age: 18 – 51 
commercially available 
samples purchased (not 
collected by researchers) 
Bead array 
(Luminex plate) Dehqanzada et al. 2007 
3 
median: 2.45* 
(25% - 1.1,  
75% - 4.45) 
50 age: 37 ± 5 BMI: 35.5 ± 2.9 kg/m2 ELISA Esposito et al. 2003 
4 3.4 ± 0.8 20 age: 20 – 35 yrs BMI: normal/lean ELISA De Lorenzo et al. 2007 
5 3.8 ± 1.3 20 
age: 20 – 35 yrs 
BMI: normal but 35% body 
fat 
ELISA De Lorenzo et al. 2007 
6 4.7 ± 1.9 20 age: 20 – 35 yrs BMI: 25 – 35 kg/m2 ELISA De Lorenzo et al. 2007 
7 
7.89 ± 2.4 
median: 7.75 
range: 3.85 – 12.5 
27 age: 27 ± 5 yrs ELISA Sharma et al. 2007 
8 13.5 ± 8.0 34 age: 32 ± 7 yrs range: 18-45 ELISA Cioffi et al. 2002 
9 16.0 ± 6.6 48 age: 54 ± 8 yrs range: 48 - 64 ELISA Cioffi et al. 2002 
* in this study, IL-10 was lower in individuals with non-obese and obese individuals who had metabolic syndrome 
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Table 5. Expected serum concentrations for IL-4 in non-malignant females 
Study no. Mean ± SD (pg/mL) n Population characteristics Method of Assessment Reference 
1 3.4 ± 0.2 15 age: 55.1 yrs range: 31 – 62 yrs ELISA Famularo et al. 1990 
2 8.26 95%CI: 5.48-12.45 17 
age: 23 ± 2 yrs 
BMI: 21.06 ± 1.92 kg/m2 ELISA Corcos et al. 2004 
3 median: 11.05 range: 6.68 – 15.38 13 
age: 18 – 51 
commercially available 
samples purchased (not 
collected by researchers) 
Bead array (Luminex 
plate) Dehqanzada et al. 2007 
4 16.3 ± 4.5 34 age: 32 ± 7 yrs range: 18 – 45 yrs ELISA Cioffi et al. 2002 
5 16.9 ± 5.6 48 age: 54 ± 8 yrs range: 48 – 63 yrs ELISA Cioffi et al. 2002 
6 17.3 ± 7.2 36 
age: 36 ± 9 yrs 
range: 17 – 55 yrs 
4 males, 32 females  
ELISA Wong et al. 2000 
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Table 6. Expected serum concentrations for CRP in non-malignant females  
Study no. Mean ± SD (pg/mL) n Population characteristics Method of Assessment Reference 
1 0.4 ± 0.1  20 age: 20 – 35 yrs BMI: normal/lean ELISA De Lorenzo et al. 2007 
2 0.8 ± 0.3 20 age: 20 – 35 yrs BMI: normal but 35% body fat ELISA De Lorenzo et al. 2007 
3 1.2 ± 0.3 40 age: 35 ± 5 yrs BMI: 24 ± 2 kg/m2 ELISA Mafella et al. 2004 
4 2.2 ± 0.9 20 age: 21 – 35 yrs BMI: 25 – 35 kg/m2 ELISA De Lorenzo et al. 2007 
5 3.4 ± 0.7 67 age: 37 ± 5 yrs BMI: 38 ± 2 kg/m2  ELISA Mafella et al. 2004 
6 5.3 ± 1.0 37 age: 57 ± 1 yrs 43.5 ± 0.8 % body fat 
Automated 
immunoanalyzer Ryan et al. 2004 
7 5.7 ± 0.6 37 age: 57 ± 1 yrs 46.8 ± 0.8 % body fat 
Automated 
immunoanalyzer Ryan et al. 2004 
8 5.8 ± 11.0  184 age: 59 ± 13 yrs BMI: normal 
High-sensitivity 
Hitachi analyzer Kip et al. 2004 
9 7.01 ± 5.74 range: 0.51 – 35.1 58 
age: 58 ± 6 yrs 
46.7 ± 4.7 % body fat 
Automated 
immunoanalyzer Ryan et al. 2004 
10 8.9 ± 11.8 327 age: 57 ± 11 yrs BMI: obese 
High-sensitivity 
Hitachi analyzer Kip et al. 2004 
11 9.7 ± 20.0 269 age: 58 ± 11 yrs BMI: overweight 
High-sensitivity 
Hitachi analyzer Kip et al. 2004 
	  
	   173 
References 
 
1. Bastard JP, C Jardel, E Bruckert, H Vidal and B Hainque. 2000. “Variations in plasma 
soluble tumour necrosis factor receptors after diet-induced weight loss in obesity.” 
Diabetes Obes Metab 2 (5): 323-5. 
 
2. Cioffi M, K Esposito, MT Vietri, P Gazzerro, A D'Auria, I Ardovino, GA Puca et al. 
2002. “Cytokine pattern in postmenopause.” Maturitas 41 (3): 187–192. 
 
3. Corcos M, O Guilbaud, S Paterniti, F Curt, L Hjalmarsson, M Moussa, J Chambry et al. 
2004. “Correlation between serum levels of interleukin-4 and alexithymia scores in 
healthy female subjects: preliminary findings.” Psychoneuroendocrinology 29 (5): 
686–691. doi:10.1016/S0306-4530(03)00087-8 
 
4. De Lorenzo A, V Del Gobbo, MG Premrov, M Bigioni, F Galvano and L Di Renzo. 
2007. “Normal-weight obese syndrome: early inflammation?” Am J Clin Nutr 85 (1): 
40–45. 
 
5. Dehqanzada Z, C Storrer, M Hueman M, R Foley, K Harris, Y Jama, C Shriver et al. 
2007. “Assessing serum cytokine profiles in breast cancer patients receiving a 
HER2/neu vaccine using Luminex technology.” Oncol Rep 17: 687–694. 
 
6. Doganay S, C Evereklioglu, H Er, Y Türköz, A Sevinc and N Mehmet. 2002. 
“Comparison of serum NO, TNF-α, IL-1β, sIL-2R, IL-6 and IL-8 levels with grades of 
retinopathy in patients with diabetes mellitus.” Eye 16 (2): 163–170. 
 
7. Esposito K. 2003. “Association of Low Interleukin-10 Levels with the Metabolic 
Syndrome in Obese Women.” J Clin Endocrinol Metab 88 (3): 1055–1058. 
doi:10.1210/jc.2002-021437 
 
8. Famularo G, A Procopio R Giacomelli, C Danese, S Sacchetti, MA Perego, Santoni and 
G Tonietti. 1990. “Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera 
and the supernants from patients with progressive systemic sclerosis.” Clin Exp 
Immunol 81 (3): 368-72. 
 
9. Ferguson MA, LJ White, S McCoy, H-W Kim, T Petty and J Wilsey. 2004. “Plasma 
adiponectin response to acute exercise in healthy subjects.” Eur J Appl Physiol 91 (2-
3): 324–329. doi:10.1007/s00421-003-0985-1 
 
10. Fernandez-Real JM, M Vayreda, C Richart, C Gutierrez, M Broch, J Vendrell and W 
Ricart. 2001. “Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in 
apparently healthy men and women.” J Clin Endocrinol Metab 86 (3): 1154–1159. 
 
 
11. Kim C-S, H-S Park, T Kawada, J-H Kim, D Lim, NE Hubbard, B-S Kwon et al. 2006. 
“Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and 
	   174 
associated with obesity-related parameters.” Int J Obesity 30 (9): 1347–1355. 
doi:10.1038/sj.ijo.0803259 
 
12. Kip KE, OC Marroquin, DE Kelley, BD Johnson, SF Kelsey, LJ Shaw, WJ Rogers and 
SE Reis. 2004. “Clinical importance of obesity versus the metabolic syndrome in 
cardiovascular risk in women: A report from the women's ischemia syndrome 
evaluation (WISE) study.” Circulation 109: 706-713. 
 
13. Marfella R, K Esposito, M Siniscalchi, F Cacciapuoti, F Giugliano, D Labriola, M 
Ciotola et al. 2004. “Effect of weight loss on cardiac synchronization and 
proinflammatory cytokines in premenopausal obese women.” Diabetes care 27 (1): 47–
52. 
 
14. Mussi A, C Bonifati, M Carducci, G D'Agosto, F Pimpinelli, D D'Urso, L D'Auria, M 
Fazio and F Ameglio. 1997. “Serum TNF-alpha levels correlate with disease severity 
and are reduced by effective therapy in plaque-type psoriasis.” J Biol Reg Homeos Ag 
11 (3): 115-18. 
 
15. Ryan AS and BJ Nicklas. 2004. “Reductions in plasma cytokine levels with weight loss 
improve insulin sensitivity in overweight and obese postmenopausal women.” Diabetes 
Care 27 (7): 1699-1705. 
 
16. Sharma A, A Satyam and JB Sharma. 2007. “Leptin, IL-10 and Inflammatory Markers 
(TNF-?, IL-6 and IL-8) in Pre-Eclamptic, Normotensive Pregnant and Healthy Non-
Pregnant Women.” Am J Rep Immunol 58 (1): 21–30. doi:10.1111/j.1600-
0897.2007.00486.x 
 
17. Straczkowski M. 2002. “Plasma Interleukin-8 Concentrations Are Increased in Obese 
Subjects and Related to Fat Mass and Tumor Necrosis Factor-alpha System.” J Clin 
Endocrinol Metab 87 (10): 4602–4606. doi:10.1210/jc.2002-020135 
 
18. Wong CK, CY Ho, EK Li and CWK Lam. 2000. “Elevation of proinflammatory 
cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with 
systemic lupus erythematosus.” Lupus 9 (8): 589–593. 
doi:10.1191/096120300678828703 
	   175 
Appendix IX TNF-α detectability in cytometric bead array analysis 
 
Table 1. Studies that failed to detect TNF-α using cytometric bead array analysis  
Study no. Description Reference 
1 TNF-α detectable in 0% of breast cancer patients examined Dehqanzada et al. 2007 
2 TNF-α detectable in 46/53 (87%) of diabetic females Doganay et al. 2002 
3 TNF-α detectable in 10/55 (19%) of breast cancer patients Pusztai et al. 2004 
4 TNF-α detectable in 3/98 (4%) of elderly participants. Participants almost 
entirely females (average age: approx. 84yrs). 
Van Munster et al. 2008 
5 TNF-α not detected in any samples of males  
(n=12: 9 HIV-positive, 3 non-infected). 
Dabitao et al. 2011 
6 TNF-α detectable in 10/30 (33%) healthy controls  Mussi et al. 1997 
7 TNF-α detectable in 8/25 (32%) of healthy controls and 32/37 (86.5%) 
periodontitis patients using BD CBA 
Andrukhov et al. 2011 
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Appendix X American College of Sports Medicine (ACSM) Cardiorespiratory fitness classification for women1 
 VO2max (mL/kg/min) 
Age (yrs) Poor Fair Good Excellent Superior 
20 – 29 ≤ 35 36 – 39 40 – 43 44 – 49 50+ 
30 – 39 ≤ 33 34 – 36 37 – 40 41 – 45 46+ 
40 – 49 ≤ 31 32 – 34 35 – 38 39 – 44 45+ 
50 – 59 ≤ 24 25 – 28 29 – 30 31 – 34 35+ 
60 – 69 ≤ 25 26 – 28 29 – 31 32 – 35 36+ 








	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  Adapted from Table 4.1 in Advanced Fitness Assessment and Exercise Prescription 5th ed. (Heyward, 2006) 
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Appendix XI Power Calculations 
Table 1. Comparison of body composition between breast cancer patients (PT), HM females and HY females (α < 0.05).   
Bolded numbers indicate analyses where power was 80%.  
Variable 
mean ± SD (n) PT vs. HM (paired t-test) 
PT vs. HY 
(t-test) 
HM vs. HY 
(t-test) 
PT HM HY Power 








n needed to 
achieve 
80% power 
BMI (kg/m2) 28.8±6.0 (8) 28.9±6.4 (8) 22.0±2.4 (10) 0.05 30 000 0.843 8 0.843 3 
Weight (kg) 76.8±17.8 (8) 75.9±17.8 (8) 59.0±9.3 (10) 0.052 3100 0.751 10 0.751 10 
Body fat (%) 41.3±10.9 (8) 43.9±12.7 (8) 26.4±4.7 (10) 0.09 145 0.843 8 0.945 6 
Waist 
circumference (cm) 94.6±14.0 (8) 97.4±18.5 (8) 75.1±5.5 (10) 0.072 260 0.977 6 0.977 6 
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Table 2. Comparison of serum glucose during an OGTT between breast cancer patients (PT), HM females and HY females  
(α < 0.05).   
Time 
(min) 
Serum glucose (mM, mean ± SD (n)) 
PT vs. HM  
(paired t-test) 
PT vs. HY  
(t-test) 
HM vs. HY  
(t-test) 
PT HM HY Power  








n needed to 
achieve 
80% power 
-30 5.01 ± 1.28 (8) 4.44 ± 1.18 (8) 4.18 ± 1.16 (10) 0.209 38 0.278 34 0.073 320 
0 5.22 ± 0.97 (8) 4.72 ± 0.91 (8) 4.40 ± 1.18 (10) 0.261 30 0.369 25 0.093 170 
60 8.78 ± 4.10 (7) 6.58 ± 1.64 (8) 5.18 ± 2.72 (10) 0.372 17 0.625 12 0.284 33 
120 7.64 ± 3.39 (7) 5.32 ± 1.26 (8) 4.85 ± 1.27 (10) 0.406 16 0.754 10 0.115 115 
180 4.42 ± 1.13 (7) 3.98 ± 0.99 (8) 4.43 ± 1.88 (10) 0.156 47 0.050 350 000 0.110 125 




Table 3. Comparison of fasting serum glucose to serum glucose during an OGTT for breast cancer patients (t-test; α < 0.05) 
Time (min) Serum glucose (mM, mean ±SD (n)) Power  n needed to achieve  80% power OGTT Average fasting  
60 8.78 ± 4.10 (7) 
5.84 ± 1.09 (8) 
0.557 13 
120 7.64 ± 3.39 (7) 0.252 32 
180 4.42 ± 1.13 (7) 0.676 10 
  
	   180 
Table 4. Comparison of serum insulin during an OGTT between breast cancer patients (PT), HM females and HY females  
(t-test; α < 0.05) 
Time 
(min) 
Serum insulin (µIU/mL, mean ± SD (n)) PT vs. HM  (paired t-test) 
PT vs. HY 
(t-test) 
HM vs. HY 
(t-test) 
PT HM HY Power  








n needed to 
achieve 
80% power 
-30 6.32 ± 3.37 (8) 8.56 ± 5.58 (8) 5.44 ± 2.78 (10) 0.196 45 0.090 185 0.280 34 
0 7.67 ± 5.32 (8) 8.42 ± 5.74 (8) 6.40 ± 3.61 (10) 0.064 410 0.097 160 0.140 85 
60 88.38 ± 59.56 (7) 69.24 ± 42.72 (8) 81.49 ± 71.33 (10) 0.156 60 0.055 1400 0.073 325 
120 83.24 ± 69.82 (7) 44.97 ± 20.27 (8) 39.00 ± 23.31 (10) 0.545 13 0.495 18 0.087 200 
180 15.89 ± 11.04 (7) 14.38 ± 9.05 (8) 10.44 ± 6.77 (10) 0.066 350 0.272 35 0.164 68 
AUC 10171±6193 (7) 7257±3530 (8) 7600±4537 (10) 0.268 24 0.149 70 0.053 2200 
 
 
Table 5. Comparison of fasting serum insulin to serum insulin during an OGTT for breast cancer patients (t-test; α < 0.05).  
Bolded numbers indicate analyses where power was 80%. 
Time (min) 
Serum insulin (µIU/mL, mean ±SD (n)) 
Power  
n needed to 
achieve  
80% power OGTT Average fasting  
60 88.38 ± 59.56 (7) 
6.99 ± 4.27 (8) 
0.798 8 
120 83.24 ± 69.82 (7) 0.973 5 
180 15.89 ± 11.04 (7) 0.755 9 
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Table 6. Comparison of serum c-peptide during an OGTT between breast cancer patients (PT), HM females and HY females  
(t-test; α < 0.05) 
Time 
(min) 
Serum c-peptide (ng/mL, mean ± SD (n)) PT vs. HM (paired t-test) 
PT vs. HY 
(t-test) 
HM vs. HY 
(t-test) 
PT HM HY Power  








n needed to 
achieve 
80% power 
-30 2.63 ± 1.16 (8) 1.86 ± 0.79 (8) 1.47 ± 0.63 (10) 0.549 13 0.723 11 0.197 52 
0 2.56 ± 1.20 (8) 1.91 ± 0.76 (8) 1.78 ± 0.64 (10) 0.387 19 0.489 18 0.066 460 
60 11.54 ± 4.26 (7) 9.08 ± 3.58 (8) 10.58 ± 4.97 (10) 0.279 23 0.068 370 0.101 145 
120 11.90 ± 5.44 (7) 7.60 ± 2.16 (8) 7.44 ± 2.64 (10) 0.662 9 0.684 11 0.052 3600 
180 5.75 ± 3.15 (7) 3.78 ± 1.72 (8) 3.04 ± 1.88 (10) 0.588 11 0.539 15 0.141 82 
AUC 1236 ± 499 (7) 921 ± 336 (8) 1033 ± 393 (10) 0.389 16 0.139 77 0.093 170 
 
 
Table 7. Comparison of fasting serum c-peptide to serum c-peptide during an OGTT for breast cancer patients (t-test; α < 0.05). 
Bolded numbers indicate analyses where power was 80%. 
Time (min) 
Serum c-peptide (ng/mL, mean ±SD (n)) 
Power 
n needed to 
achieve 80% 
power OGTT Average fasting  
60 11.54 ± 4.26 (7) 
2.60 ± 1.18 (8) 
1.000 3 
120 11.90 ± 5.44 (7) 0.999 4 
180 5.75 ± 3.15  (7) 0.733 9 
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Table 8. Comparison of plasma glucagon during an OGTT between breast cancer patients (PT), HM females and HY females  
(t-test; α < 0.05) 
Time 
(min) 
Plasma glucagon (pg/mL, mean ± SD (n)) PT vs. HM (paired t-test) 
PT vs. HY 
(t-test) 
HM vs. HY 
(t-test) 
PT HM HY Power 








n needed to 
achieve 
80% power 
-30 47.34 ± 15.23 (7) 38.91 ± 10.78 (8) 44.27 ± 14.63 (10) 0.325 20 0.069 350 0.144 80 
0 45.53 ± 16.97 (7) 38.91 ± 12.77 (8) 51.38 ± 15.63 (10) 0.167 43 0.107 119 0.434 21 
60 55.61 ± 6.56 (6) 47.48 ± 16.13 (8) 61.73 ± 31.21 (10) 0.291 18 0.094 138 0.233 42 
120 50.86 ± 8.59 (6) 45.69 ± 16.47 (8) 52.73 ± 18.95 (10) 0.130 50 0.057 900 0.130 93 
180 47.24 ± 7.68 (6) 40.97 ± 11.60 (8) 50.42 ± 17.08 (10) 0.252 21 0.074 252 0.268 36 
AUC 1224 ± 2076 (6) 1286 ± 1786 (8) 1374 ± 2612 (10) 0.050 7700 0.052 3900 0.051 9800 
 
Table 9. Comparison of fasting plasma glucagon to plasma glucagon during an OGTT for breast cancer patients (t-test; α < 0.05) 
Time (min) 
Plasma glucagon (pg/mL, mean ±SD (n)) 
Power 
n needed to 
achieve 80% 
power OGTT Average fasting 
60 55.61 ± 6.56 (6) 
46.44 ± 15.72 (7) 
0.387 17 
120 50.86 ± 8.59 (6) 0.101 99 
180 47.24 ± 7.68 (6) 0.052 2500 
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Table 10. Comparison of fasting lipids between breast cancer patients (PT), HM controls and HY controls (t-test; α < 0.05).   
Bolded numbers indicate analyses where power was 80%. 
Variable 
(mean ± SD (n)) PT vs. HM (paired t-test) 
PT vs. HY 
(t-test) 
HM vs. HY 
(t-test) 
PT HM HY Power 














4.12 ± 0.75 (6) 4.47 ± 0.79 (8) 3.74 ± 0.37 (10) 0.149 40 0.279 28 0.824 9 
HDL-C  
(mM) 1.08 ± 0.23 (6) 1.58 ± 0.42 (8) 1.31 ± 0.20 (10) 0.899 6 0.545 13 0.430 21 
LDL-C  
(mM) 2.20 ± 0.36 (6) 2.47 ± 0.57 (8) 2.09 ± 0.45 (10) 0.270 20 0.079 210 0.325 28 
NEFA  
(mM) 0.574 ± 0.220 (8) 0.708±0.288 (8) 0.462±0.214 (10) 0.277 27 0.185 56 0.528 16 
Glycerol  
(µM) 115.7 ± 59.2 (8) 167.1 ± 95.3 (8) 55.7 ± 23.0 (10) 0.388 19 0.843 9 0.979 5 
TAG  
(mM) 1.84 ± 1.17 (6) 0.93 ± 0.27 (8) 0.74 ± 0.33 (10) 0.664 8 0.786 8 0.241 40 
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Table 11. Comparison of glucagon:insulin ratio and insulin sensitivity between breast cancer patients (PT), HM females and HY 
females (t-test; α < 0.05) 
Variable 
(mean ± SD (n)) PT vs. HM (paired t-test) 
PT vs. HY 
(t-test) 
HM vs. HY 
(t-test) 
PT HM HY Power  












Fasting 0.38 ± 0.21(7) 0.29 ± 0.27 (8) 0.43 ± 0.24 (10) 0.128 63 
0.070 350 0.199 55 
60 min 0.04 ± 0.03 (8) 0.04 ± 0.02 (8) 0.05±0.05 (10) 0.201 34 0.476 17 0.101 145 
120 min 0.06 ± 0.04 (8) 0.05 ± 0.03 (8) 0.08±0.06 (10) 0.116 75 0.476 17 0.508 17 
180 min 0.29 ± 0.31 (8) 0.22 ± 0.22 (8) 0.31±0.23 (10) 0.096 103 0.053 2500 0.128 96 
HOMA-IR 1.63 ± 1.53 (7) 1.91 ± 1.69 (8) 1.14±0.60 (10) 0.072 260 0.154 67 0.333 28 
Matsuda 
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Table 12. Comparison of cytokines between breast cancer patients (PT), HM females and HY females (t-test; α < 0.05) 
Cytokine  
(mean ± SD (n)) PT vs. HM (paired t-test) 
PT vs. HY 
(t-test) 
HM vs. HY 
(t-test) 
PT HM HY Power  








n needed to 
achieve 
80% power 
TNF-α (pg/mL) 7.15±4.80 (5) 10.04±3.97 (2) 7.63±1.15 (4) 0.120 17 0.052 2000 0.191 12 
IL-6 (pg/mL) 10.04±2.41 (7) 10.84±2.72 (7) 7.98±1.69 (10) 0.111 80 0.498 16 0.774 9 
IL-8 (pg/mL) 18.26±4.40 (8) 16.49±2.85 (8) 19.54±9.79 (10) 0.409 18 0.065 475 0.139 85 
CRP (mg/L) 7.84 ± 10.97(8) 2.37 ± 2.97(8) 0.21 ± 0.29(10) 0.516 14 0.765 10 0.746 10 
IL-4 (pg/mL) 8.81±1.04 (7) 8.65±1.16 (8) 8.19±1.49 (8) 0.062 375 0.125 82 0.101 130 
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Table 13. Comparison of exercise between breast cancer patients (PT), HM females and HY females (t-test; α < 0.05).   
Bolded numbers indicate analyses where power was 80%. 
Variable 
(mean ± SD (n)) PT vs. HM (paired t-test) 
PT vs. HY 
(t-test) 
HM vs. HY 
(t-test) 
PT HM HY Power 












(mL/kg/min) 27.33±10.90 (6) 30.61±10.86 (8) 43.41±9.95 (10) 0.092 90 0.825 8 0.717 11 
L Forearm 
flexion (lbs) 31±5 (7) 32±6 (8) 31±8 (10) 0.066 290 0.062 575 0.063 575 
R Forearm 
flexion (lbs) 31±6 (7) 33±6 (8) 32±8 (10) 0.116 75 0.097 145 0.059 800 
L Forearm 
extension (lbs) 33±7 (7) 33±8 (8) 28±7 (10) 0.059 500 0.274 32 0.294 32 
R Forearm 
extension (lbs) 33±7 (7) 34±7 (8) 29±7 (10) 0.062 400 0.192 50 0.294 32 
Leg extension 
(lbs) 59±19 (7) 45±8 (8) 32±9 (10) 0.493 13 0.927 6 0.815 9 
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Table 14. Comparison of habitual physical activity between breast cancer patients (PT), HM females and HY females  
(t-test; α < 0.05).  Bolded numbers indicate analyses where power was 80%. 
Variable 
(mean ± SD (n)) PT vs. HM (paired t-test) 
PT vs. HY 
(t-test) 
HM vs. HY 
(t-test) 
PT HM HY Power 








n needed to 
achieve 
80% power 
Work Index 2.03±0.47 (8) 2.76±1.00 (8) 2.29±0.48 (10) 0.658 11 0.189 55 0.237 41 
Sport Index 2.81±1.16 (8) 3.06±0.79 (8) 3.23±0.79 (10) 0.094 128 0.133 90 0.071 350 
Leisure Index 3.00±0.63 (8) 2.92±0.72 (8) 3.45±0.55 (10) 0.846 8 0.318 29 0.417 22 
All activity 
(kcal/wk) 3426±2029 (8) 4073±1799 (8) 3527±2193 (10) 0.133 70 0.051 6300 0.084 215 
All activity 
(f/wk) 21±19 (8) 21±10 (8) 20±9 (10) 0.053 1800 0.052 3500 0.052 3500 
Mod-int activity 
(kcal/wk) 1828±1753 (8) 2527±1421 (8) 2940±1903 (10) 0.188 45 0.232 45 0.081 235 
Mod-int activity 
(f/wk) 8±11 (8) 8±5 (8) 11±6 (10) 0.064 390 0.115 115 0.168 65 
TEE (kcal/d) 2351±490 (8) 2564±429 (8) 2171±570 (10) 0.213 37 0.104 135 0.344 27 
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Table 15. Comparison of nutrition between breast cancer patients (PT), HM females and HY females (t-test; α < 0.05) 
Variable (kcal/d) 
(mean ± SD (n)) PT vs. HM (paired t-test) 
PT vs. HY 
(t-test) 
HM vs. HY 
(t-test) 
PT HM HY Power  








n needed to 
achieve 
80% power 
Caloric intake  1857±422 (7) 1829±431 (8) 1830±409 (9) 0.053 1850 0.052 3800 0.050 2 900 000 
Carbohydrate intake  1000±289 (7) 903±172 (8) 973±283 (9) 0.179 39 0.054 1700 0.094 156 
Protein intake  302±62 (7) 332±105 (8) 311±73 (9) 0.134 58 0.057 870 0.074 290 
Fat intake  565±157 (7) 568±195 (8) 541±136 (9) 0.05 27 000 0.062 545 0.061 600 
Alcohol intake  0±0 (7) 24±55 (8) 6±18 (9) 0.567 11 0.234 37 0.168 61 
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Appendix XII  Individual patient data  
 
Table 1. Individual patient data for age and body composition measurements  
Patient Age (years) Weight (kg) BMI (kg/m2) % body fat Waist circumference (cm) 
1 44 114.5 40.4 55.3 114.7 
2 35 82.2 29.8 49.7 96.0 
3 43 69.0 24.7 47.8 90.8 
4 47 86.3 33.3 42.9 114.6 
5 31 71.8 27.0 41.3 93.0 
6 46 63.2 25.8 40.4 81.7 
7 55 57.4 20.6 19.9 75.8 
8 63 70.4 28.9 33.3 90.0 
Mean 46 76.8 28.8 41.3 94.6 
SD 10 17.8 6.0 10.9 14.0 
 
 
Table 2. Individual patient data for selected OGTT parameters 
















1 5.4 11.5 745 8.0 10951 3.3 1308 
2 6.0 8.2 594 11.2 13174 2.6 1551 
3 5.2 n/a n/a 3.8 n/a 1.6 n/a 
4 7.2 11.9 731 14.4 15612 5.0 1562 
5 4.1 6.0 315 6.1 5608 2.5 966 
6 3.8 4.0 95 2.4 3719 1.5 750 
7 4.7 3.3 223 2.4 3103 1.5 560 
8 4.6 8.7 540 7.5 19027 2.6 1956 
Mean 5.1 7.6 400 8.7 10171 2.6 1236 
SD 1.1 3.4 359 4.3 6193 1.2 499 
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Table 3. Individual patient data for select fasting lipids, cardiovascular fitness and energy intake 
Patient Fasting TAG (mM) Fasting HDL-cholesterol (mM) VO2peak 
Energy intake 
(kcal/d) 
1 1.7 1.1 15.9 1937 
2 n/a n/a 23.8 n/a 
3 n/a n/a 21.1 1933 
4 4.2 0.9 n/a 1837 
5 1.3 1.2 23.7 1098 
6 1.7 0.8 33.0 1936 
7 1.2 1.1 46.5 2402 
8 0.9 1.4 n/a n/a 
Mean 1.8 1.1 27.3 1857 




Table 4. Individual patient data for serum cytokines. * indicates that a value is an outlier, and was excluded from the mean 
calculation. 
Patient TNF-α (pg/mL) IL-6 (pg/mL) IL-8 (pg/mL) IL-10 (pg/mL) IL-4 (pg/mL) CRP (mg/L) 
1 n/a 9.4 18.1 7.7 n/a 3.5 
2 6.4 7.3 13.5 7.5 8.4 0.6 
3 6.4 13.8 16.6 9.9 7.4 26.8 
4 12.5 10.1 26.1 11.0 8.7 4.3 
5 10.5 12.9 15.1 10.2 10.8 1.5 
6 n/a 8.2 15.1 7.1 8.7 1.8 
7 0.0* 8.6 18.1 8.6 8.7 0.2 
8 n/a 20.0* 23.5 8.7 9.2 24.0 
Mean 8.9 10.0 18.3 8.8 8.3 7.8 
SD 3.1 2.4 3.1 1.4 1.9 11.0 
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Appendix XIII  Co-efficients of variation for biochemical assays 
 
 
Table 1. Mean co-efficients of variation (CV) for each metabolic parameter 
Metabolic parameter Number of replicates per assay % CV 
Glucose 3 4.2 
Insulin 2 10.0 
C-peptide 2 9.0 
Glucagon 2 8.9 
Glycerol 3  
NEFA 4  
CRP 2 10.9 
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Appendix XIV  Comparison of medication and supplements taken by patients and HM females 
 
Table 1. Medication taken by patients and HM females (chemotherapeutic drugs excluded) 
Pair Patient HM female 
1 Apo-prochlorazine; Dexamethasone; Granisetron Prozac (fluoxetine); none taken on testing days 
2 Dexamethasone; Granisetron (both drugs taken on OGTT day, which was D3 of chemo) None 
3 
Apo-prochlorazine; Dexamethasone; Granisetron (Kytril); 
Pegfilgrastim (Neulasta); Herceptin (took all drugs on OGTT 
day except Herceptin) 
None 
4 
Novo-venlafaxine XR 150 mg 1x/d (depression); Apo-
paroxetine 20 mg 2x/d (depression); Apo-prochlorazine; 
Granisetron; WBC booster day after chemo; Tylenol 3 as 
needed for bulging discs (L4-5) and arthritis (C3-4) 
None 
5 Apo-prochlorazine; Dexamethasone; Granisetron; Neulasta Seasonale (levonorgestrel and ethinyl estradiol; extended cycle oral contraceptive) 
6 
Adicant Plus 16/12.5 OD; Bisaprolol 10 mg OD; Novo 
Spiroton 25 mg 2 tabs/evening; Pegfilgrastim (Neulasta); 
Dexamethasone; Stemetil PRN; Ondansetron (Zofran); 
(Adicand Plus and Novo-Bisoprolol taken on OGTT day) 
None 
7 Ondansetron; Dexamethasone; Filgrastim (Neupogen) 
Synthyroid, florinef and hydrocortisone daily for 
hypothyroidism and adrenal insufficiency (condition managed 
in this way for 20 years) 
8 Oxycodone in last 1.5 weeks for back pain aggrevated by chemo None 
 
Standard doses:  
 
Apo-prochlorazine – 10 mg as needed 
Dexamethasone – 4 mg 2x daily for D2-3 following chemotherapy 
Granisetron – 1 mg D1-3 of chemotherapy 
WBC booster (pegfilgrastim or filgrastim) – D2 following chemotherapy 
Ondansetron – D1-3 of chemotherapy 
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Table 2. Supplements taken by patients and HM females 
Pair Patient HM female 
1 None Melatonin (all days) 
2 n/a None 
3 None None 
4 None Mutivitamin (Preventive X); VitB; Ca; EPA  (all days) 
5 None None 
6 Omega 3, 6, 9 capsule; multivitamins; multiminerals; lutein; 
lycopene; Ca; VitD  
(days 2 and 3) 
VitD; Ca; Mg; multivitamin; n-3 (all days) 
 
7 Phosphytidyl serine; Ovol 180s (all days) None 
8 
n/a 
EFA oil; caproil; multivitamins; liquid chlorophyll; 
methylcobalamin; Vision Support II; Orthobone; Macasure; 
Strontium (all days) 
 
	  
